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Abstract 
 
Designing and Utilising an in vitro Model to Investigate Cellular Pathways Involved 
in Idiopathic Pulmonary Fibrosis (IPF) and Connective Tissue Disease Associated 
Interstitial Lung Disease (CTD-ILD) 
ILD represents a heterogeneous spectrum of diseases caused by excessive deposition 
of extracellular matrix (ECM) into the interstitial space leading to distortion of the 
lung architecture and impairment of gas exchange.  In this thesis the design of an in 
vitro model is described to test the pathways involved in the fibrotic response.  The 
model was first tested on fibroblast and epithelial cell lines, two cell types that are 
implicated as key players in pulmonary fibrosis, treating cells with the pro-
inflammatory cytokine Transforming Growth Factor-β (TGF-β), ensuring that this 
model was reliable and reproducible.   
Once a model had been established, it was utilised by treating cells with plasma 
from patients with IPF and Systemic Sclerosis Associated ILD (SSc-ILD).  This was 
to assess whether treatment with plasma from patients with fibrotic lung disease 
would induce any changes in these cell lines.  When cells were treated with plasma 
there were no changes in gene expression of the MRC5 fibroblasts but there was an 
increase in proliferation of the fibroblast cells when treated with IPF patient plasma.  
When the A549 epithelial cells were treated with plasma from patients with IPF, 
there was a significant reduction in COL3A1 and FN-EDA.  This was associated 
with a significant downregulation of N-cadherin.  These changes are not those 
expected in EMT.  Conversely treatment of the same cell line with SSc-ILD plasma 
led to a significant increase in gene expression of COL3A1 and FN-EDA.   
Finally, this model was adapted to imitate the constant movement of the lungs by 
stretching the cells in vitro.  Stretch alone caused no significant differences in any of 
the genes associated with fibrosis in either cell type.  However, when used alongside 
TGF-β treatment there was an attenuation of the fibrotic response in COL1A1, FN-
EDA and CCN2 in the fibroblasts and COL1A1 and Slug in the epithelial cells. 
In conclusion, this thesis has produced a novel way to explore some of the key 
pathways involved in fibrosis and the changes that plasma treatment induces on cell 
lines.   
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1 Introduction 
1.1 Lung Anatomy and Physiology  
 
The lungs are the organs responsible for gaseous exchange in the body, functioning 
to oxygenate blood and therefore intricately linked to the cardiovascular system.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 Diagram of the lung anatomy.  This figure shows the right lung is split 
into three lobes (upper, middle and lower) and the left lung is split into two lobes 
(upper and lower).  There is branching of the airways, with the central trachea 
splitting into the right and left main bronchus, and dividing into the smaller bronchi 
and bronchioles.  It is highly vascularised to allow efficient gas exchange.  Image 
courtesy of shuttershack. 
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Deoxygenated blood is carried to the lungs from the pulmonary artery which arises 
from the right side of the heart.  Once oxygenated, this returns to the left atrium of 
the heart via four pulmonary veins where it passes to the left ventricle to be pumped 
through the aorta and then circulates around the body (1).  
During breathing the diaphragm, innervated by the phrenic nerve, contracts and 
flattens.  At rest, the diaphragm contracts just small amounts but during exercise it 
can contract much further allowing for much deeper inspiration.  The external 
intercostal muscles also contract, moving the ribs forwards and upwards, increasing 
the size of the chest cavity further (2).  This reduces the pressure in the thoracic 
cavity thus drawing air through the mouth and down the trachea, which divides into 
the right and left main bronchi.  These divide into smaller bronchi and bronchioles 
that continue to divide into smaller and smaller branches until they end in the 
terminal airways, called alveoli.   
The alveoli have thinly lined walls and a vast network of capillaries to allow gaseous 
diffusion to occur efficiently.  This allows for easy gas exchange with diffusion of 
oxygen into the blood and carbon dioxide back into the lungs to be exhaled.  The 
walls of the alveoli mainly consist of flattened type I alveolar epithelial cells.  Type 
II alveolar epithelial cells are interspersed between them and act to secrete 
surfactant, a fluid which lowers the surface tension within the alveoli, allowing them 
to open easily (2).  Pulmonary macrophages act as resident phagocytes, having an 
immunological role. 
Between the alveolar epithelium and the capillary endothelial layer is the pulmonary 
interstitium.  This contains fibroblastic cells which secrete extracellular matrix 
(ECM) providing structure for the lungs.  
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1.2 Definition and Classification of Interstitial Lung 
Disease (ILD) 
 
ILD is an encompassing term used to describe any process damaging the pulmonary 
parenchymal tissues.  There is excessive deposition of ECM in the interstitial space, 
as described in Figure 1-2, which leads to distortion of the lung architecture and 
impairment of gas exchange.  Clinically, patients with ILD usually present with a 
dry cough and increasing dyspnoea.  If treatment is not commenced, or treatment is 
commenced but is non-therapeutic, the disease can progress, eventually leading to 
respiratory insufficiency and death. 
Figure 1-2 gives a basic pictorial description of the pulmonary parenchyma, with the 
epithelial cell layer and endothelial cell layer being separated by the two basement 
membranes and the pulmonary interstitium.  In ILD, there is increased production 
and deposition of ECM in the pulmonary interstitium, increasing the distance that 
gasses need to transfuse across for oxygenation of the blood. 
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1.3 The Clinical Considerations of Interstitial Lung 
Disease (ILD) 
 
It is important to note that not all ILDs are the same.  The ILD spectrum is a 
heterogeneous group of conditions (over 200) caused by inflammation and fibrosis 
of the lung.  Recent literature has attempted to subgroup and categorise the ILD 
cases as represented in Figure 1-3 (3). However, the largest group in this 
classification is the idiopathic group, which are not linked by pathological 
mechanisms.  The idiopathic and Connective Tissue Disease (CTD)-associated 
groups will be discussed in more detail below. 
Figure 1-2  Diagram of the pulmonary parenchyma.  The above diagram depicts 
the epithelial cell layer that comprises the alveolar sacs.  Gaseous exchange occurs 
across these layers, with diffusion of oxygen from the lungs through the pulmonary 
interstitium and the endothelial cell layer to be absorbed by red blood cells.  
Usually the layers for diffusion are very thin, making this process incredibly 
efficient.  If excess matrix is secreted into the interstitial space, the layers that gases 
need to diffuse across thicken making gas exchange less efficient.  It also distorts 
the architecture of the lung and results in increased breathlessness for the patient.  
Epithelial cell layer 
Basement membrane 
Pulmonary interstitium 
and fibroblasts  
 Basement membrane 
Endothelial cell layer O2 
CO2 
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Figure 1-3  A classification of ILD into groups and subgroups.  Given the large number of individual lung diseases that the term ILD encompasses this 
thesis focuses on the idiopathic and CTD-ILD subgroups.  Reference adapted from Ryerson CJ, Collard HR.  Update on the diagnosis and classification of 
ILD.  Curr Opin Pulm Med 2013; 19: 453-9. 
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1.3.1 Diagnosing ILD 
 
Subgrouping patients with ILD requires consideration of the patient’s history and 
clinical examination findings. The treating chest physician would be assessing for a 
clear occupational or environmental exposure such as asbestosis or subtle features of 
an underlying CTD. In some cases, a precipitating cause is not found or is not 
immediately apparent and the patient is given an idiopathic subgroup label.  The 
term “idiopathic” describes any disease or condition in which the underlying cause 
is unknown. Investigations for patients with ILD include pulmonary function tests 
(PFTs), which often show a restrictive pattern and reduced gas transfer, High 
Resolution Computed Tomography (HRCT) and, if required, a lung biopsy.  In 
many cases a lung biopsy is not performed as it carries a relatively high mortality for 
a diagnostic procedure (cited as 3.6% in one meta-analysis) (4) and patients may be 
too frail or have lung function that is too poor for the procedure to occur safely.   
 
1.3.2 HRCT Appearances in ILD 
 
Difficulties acquiring lung tissue to diagnose ILD have meant that HRCT is an 
important tool in diagnosing and classifying ILD.  There are a number of distinct 
radiological patterns recognised.  Usual Interstitial Pneumonia (UIP) is characterised 
by a reticular pattern with honeycombing and a relative lack of ground glass change. 
It predominantly affects the bases of the lungs.  Lobar volume loss and distortion of 
the lung architecture may often be seen in advanced disease (5).  This pattern is a 
classic feature of IPF but can also be seen in a number of CTDs particularly 
rheumatoid arthritis (RA) and occasionally in systemic sclerosis (SSc) (6, 7).  The 
Non-Specific Interstitial Pneumonia (NSIP) pattern is characterised by ground-glass 
attenuation typically present at the periphery and the bases of the lungs.  Patients 
may be further sub-grouped into those with predominantly fibrotic changes (fibrotic 
NSIP) and those with inflammatory change and more ground-glass attenuation 
(cellular NSIP).  This may occur without an identifiable underlying cause and makes 
18 
 
up one of the idiopathic subgroups (7).  It is also the most commonly seen pattern in 
SSc, occurring in 80% of patients, as well as occurring in other CTDs such as 
myositis-associated ILD (8, 9).  Ground-glass shadowing is suggestive of 
inflammatory change and suggests a potentially reversible pathology that may 
respond to immunosuppressive treatment.  However, work in SSc shows that this 
appearance also represents fine intra-lobular fibrosis with inconsistent improvements 
with immunosuppressive treatment (10, 11). 
Organising Pneumonia is another recognised HRCT pattern.  In idiopathic disease it 
is called Cryptogenic Organising Pneumonia (COP), however, it is also a recognised 
pattern occurring in a number of CTDs, including myositis-associated ILD (9).  It is 
characterised by patchy bilateral consolidation and tends to respond well to steroids 
and immunosuppression whether or not an underlying CTD is discovered.   
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Although HRCT is recognised as a useful tool in the diagnosis and management of 
ILD there are a number of limitations with the technology.  As discussed above, 
patterns do not indicate a particular diagnosis but give a differential of possible 
causes (eg, a UIP pattern can occur in idiopathic disease, multiple CTDs and 
asbestosis).  Identifying patterns can be difficult because two or more typical 
characteristics may be present in one HRCT scan (e.g. honeycombing with extensive 
ground-glass shadowing) and there is recognised inter-observer variation even 
between specialist radiologists (5, 12).  HRCT is also associated with a large 
radiation dose for patients making frequent follow-up scans more difficult.  This 
suggests that although HRCT is valuable it is not infallible, and therefore other 
biomarkers in ILD would be helpful to secure a correct diagnosis, allow for 
monitoring of the disease and give clues regarding the underlying pathogenesis of 
the disorder. 
(d) (c) 
(a) (b) 
Honeycombing 
Traction 
bronchiectasis 
Reticular 
pattern 
Blood 
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Heart 
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shadowing 
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Figure 1-4  HRCT appearances in ILD.  (a) Normal lung appearance.  (b) Typical 
pattern of Usual Interstitial Pneumonia (UIP) with a reticular pattern and 
honeycombing predominantly affecting the bases and periphery of the lung.  (c) A 
representative example of a Non-Specific Interstitial Pneumonia (NSIP) pattern.  This 
shows ground-glass shadowing with reticular opacity typically affecting the periphery 
and bases of the lungs.  (d) Typical HRCT pattern with organising pneumonia and 
evidence of patchy bilateral consolidation. 
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1.3.3 Idiopathic Pulmonary Fibrosis (IPF) 
 
IPF is defined as a specific form of chronic, progressive fibrosing interstitial 
pneumonia, with fibrosis limited to the lungs (11).  It tends to affect older males and 
the prevalence is higher in smokers (13).  It is the most common form of idiopathic 
ILD which is progressive and lethal, with death occurring within a median time of 3 
years from diagnosis (14).  It was historically treated with high-dose steroids and 
immunosuppression in the form of azathioprine, although trials have shown this did 
not improve mortality (15).  It therefore suggests that inflammation does not have a 
significant role in this disease.  Newer antifibrotic drugs, such as Pirfenidone and 
Nintedinib, are now available and may have a role in slowing progression of the 
disease (16-18).  Given the different therapeutic options available in ILD it is 
imperative that a correct diagnosis is made in every case to ensure that patients 
receive the correct treatment. 
IPF is characterised by a UIP pattern on HRCT.  According to American Thoracic 
Society / European Respiratory Society (ATS / ERS) criteria published in 2011 (11), 
IPF should be diagnosed in a multi-disciplinary setting and patients must meet the 
following criteria; 
(a) Exclusion of any other cause of ILD. 
(b) The presence of a UIP pattern on HRCT.   
(c) Or specific combinations of HRCT appearances and / or the presence of 
surgical lung biopsy findings that are discussed in a multidisciplinary team 
(MDT) setting.   
To diagnose “definite IPF”, the patient can have a UIP pattern on HRCT which has 
been shown to be diagnostically accurate for IPF, particularly when made by a 
specialist ILD centre (19).  If patients have a HRCT appearance that lacks 
honeycombing and appears like fibrotic NSIP then ideally a surgical lung biopsy 
should be performed.  If this shows features consistent with UIP the patient is 
diagnosed with definite IPF.  Unfortunately, given that surgical lung biopsy is an 
invasive procedure with a substantial morbidity associated with it and that many 
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patients are elderly with poor lung function at presentation, surgical lung biopsy can 
only be performed in a small number of patients.  However, patients may be 
diagnosed with “probable IPF” if they are older in age group and after MDT 
discussion (11).  
 
1.3.4 ILD as a complication of CTD 
 
As can be seen in Figure 1-3, ILD is a common complication of many CTDs 
including systemic sclerosis (SSc), rheumatoid arthritis (RA) and the idiopathic 
inflammatory myopathies (IIM), polymyositis (PM) and dermatomyositis (DM). 
Whereas morbidity and mortality from CTD complications other than ILD appear to 
be improving with therapeutic advances, this is not so with ILD, which remains a 
significant clinical problem (20).  These conditions have a number of clinical 
features and hallmark characteristics discussed in detail below. 
   
1.3.4.1 Idiopathic Inflammatory Myopathies (IIM) 
 
IIM can be subdivided into several distinct groups, the most common of which 
include PM, DM, inclusion-body myositis (IBM), myositis-CTD overlap and 
juvenile dermatomyositis (JDM).  They have in common the presence of moderate 
to severe muscle weakness and muscle inflammation (21).   
IIMs have a strong association with ILD.  Like many of the other CTDs, the IIM are 
associated with the presence of autoantibodies and these can predict the likelihood 
of developing ILD.  This will be discussed in detail in section 1.3.4.4.  ILD can 
present prior to the onset of muscle symptoms or late during the course of the 
disease.  ILD is an important manifestation of the disease and its presence has a 
major impact on mortality (22).  IIM-ILD can present with a variety of HRCT 
appearances including NSIP, organising pneumonia or UIP (23).  However, 
myositis-associated ILD tends to respond well to immunosuppression (24).  
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1.3.4.2 Systemic Sclerosis (SSc) 
 
SSc is characterised by a generalised vascular abnormality and fibroblast 
dysfunction leading to extensive fibrosis of the skin and internal organs (25).  
Women are much more frequently affected than men (26).  Many organs can be 
affected including the skin, gastrointestinal tract and kidneys (26).  In the lungs, SSc 
is associated with pulmonary arterial hypertension (PAH) and the development of 
ILD.  The prevalence of ILD in SSc is estimated between 25-90%, depending upon 
the definition of ILD used (27, 28).  Pulmonary complications are the leading cause 
of mortality in SSc, with pulmonary fibrosis being responsible for 20-30% of deaths 
(20, 29). 
SSc can be broadly classified into three subsets; (a) Diffuse cutaneous systemic 
sclerosis (dcSSc), associated with skin thickening above the elbows and severe 
fibrosis of multiple internal organs.  It has a higher prevalence of severe ILD.   (b) 
Limited cutaneous systemic sclerosis (lcSSc) associated with skin thickening limited 
to the hands, face, feet and forearms.  These patients tend to suffer with isolated 
PAH but less severe ILD.  (c) Systemic sclerosis sine scleroderma (ssSSc), where 
patients experience internal organ involvement without skin thickening (30).  This 
subset is more difficult to diagnose given the lack of overt clinical signs. 
 
1.3.4.3 Rheumatoid Arthritis (RA) 
 
RA is a chronic, systemic inflammatory disease primarily affecting the joints.  It 
affects around 1% of the population and is a leading cause of disability.  However, 
the disease can affect a number of extra-articular sites including the eyes and lungs.  
ILD, identified on HRCT, occurs in roughly 20% of patients with RA (31).  Risk 
factors for its development include older age, raised erythrocyte sedimentation rate 
(ESR) and higher Health Assessment Questionnaire (HAQ) score, a score rated by 
patients which gives an idea of the amount of disability suffered due to the condition 
(32).  The presence of anti-CCP antibodies is also an independent risk factor for 
developing ILD (33).  Interestingly, in RA-ILD there is a higher prevalence of UIP 
pattern disease unlike in other CTDs where the pattern is much less prevalent.  In 
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RA-ILD the UIP pattern is associated with a much poorer survival (3.2 years) than 
those with other HRCT patterns (6.6 years) (6).  The UIP pattern and poor survival 
is much more similar to IPF than other CTDs and it does not appear to respond to 
immunosuppression.  Trials are currently being undertaken to assess if RA-ILD will 
respond to Pirfenidone and Nintedinib, drugs used to slow fibrotic progression in 
IPF. 
 
1.3.4.4 Autoantibodies 
 
CTDs are characterised by the presence of circulating autoantibodies.  These can act 
as biomarkers and give a good prediction for the phenotypic features of disease that 
a patient may exhibit.  In myositis there are a growing number of myositis-specific 
and myositis-associated autoantibodies (MSA/MAA) that are detectable.  Several 
MSA strongly associated with ILD include the antisynthetase autoantibodies.  These 
target one of several amino-acyl-transfer RNA synthetases (Table 1-1).  MSA are 
usually mutually exclusive.  The presence of one of these antibodies is associated 
with the antisynthetase syndrome (ASS) characterised by the presence of myositis, 
ILD, Raynaud’s phenomenon, mechanic’s hands, fever and an inflammatory 
arthritis.  The most common antibody in this group is anti-Jo-1.  This autoantibody 
is directed against histidyl-tRNA synthetase and is routinely detectable in clinical 
practice.  The other antisynthetase antibodies are much rarer and the ability to test 
for them is usually only available in specialised centres.   
Interestingly, certain antisynthetase antibodies are more strongly associated with 
ILD than with myositis.  Roughly 70% of patients with anti-Jo-1 antibody will 
develop ILD (22).  However, in the case of anti-PL-7 or anti-PL-12 almost 100% of 
patients will develop ILD, and often in the absence of myositis (34, 35).  This could 
be described as an “amyopathic” form of disease, where patients have features such 
as rash or ILD but lack muscle involvement. These antibodies could be better 
described as “CTD-ILD specific” autoantibodies, or “ILD-specific autoantibodies” 
(ISA), as myositis may be an absent feature. 
When anti-Jo-1 levels are measured they correlate with creatine kinase (CK) levels 
as well as other measures of myositis activity.  This suggests that anti-Jo-1 levels 
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could be a potential biomarker for disease activity.  The possibility also arises that 
anti-Jo-1 antibodies are involved in the pathogenesis of disease and further work is 
needed to assess if this is the case (36). 
The anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) is 
another MSA.  This occurs in association with clinically amyopathic 
dermatomyositis (CADM) and is associated with a rapidly progressive and indeed 
fulminant ILD, particularly in patients of Japanese ethnicity.  In Caucasian patients 
the antibody is associated with muscle involvement, in the presence of a typical DM 
skin rash and an ILD that, although often severe, tends to respond to 
immunosuppression (37). 
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Myositis Specific 
Antibody (MSA) 
Prevalence 
in 
Myositis 
Clinical Associations Likelihood of 
developing ILD 
Anti-synthetases and 
their target protein: 
- Jo-1 (histidyl) 
 
15-20% 
Associated with 
antisynthetase syndrome, 
and characterised by the 
presence of: 
- Myositis (PM or DM) 
- Arthritis 
- ILD  
- Raynaud’s 
- Fevers 
- Mechanic’s hands 
 
~ 70% develop ILD 
(22)  
- PL-12 (alanyl) < 5% 
 
~ 90% develop 
ILD, myositis often 
mild (35) 
- PL-7 
(threonyl) 
 
< 5% ~90% develop ILD, 
often prior to 
myositis (34) 
- Anti-KS 
(asparaginyl) 
< 5% ~ 90% develop 
ILD, myositis rare 
(38) 
- Anti-OJ 
(isoleucyl) 
< 5% Up to 100% 
develop ILD (39) 
- Anti-EJ 
(glycyl) 
<5% Up to 100% 
develop ILD (40) 
- Anti-Zo 
(phenylalanyl) 
<1 % ILD-associated (41) 
- Anti-Ha 
(tyrosyl) 
<1% No literature 
Anti-MDA5 7% (37) Associated with 
clinically amyopathic 
DM (CADM) 
Rapidly progressive 
ILD, especially in 
Japanese and Chinese 
patients 
50 - 70% develop 
rapidly progressive 
ILD in 
Japanese/Chinese 
ethnicity  (42) 
~ 50% in Caucasian 
(43) 
 
Table 1-1 MSA and their association with ILD.  Prevalence data has been adapted 
from reference below, with ILD data from the cited references in the table.  Several 
antisynthetase antibodies are associated with ILD in the absence of myositis (44). 
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There are also several MSA that are not specified in Table 1-1 that are less 
frequently associated with ILD.  These include anti-SRP, anti-Mi-2, anti-TIF1-
gamma, anti-NXP2 and anti-SAE.  They are associated with other features of the 
myositis disease spectrum including skin rash and malignancy. 
 
1.3.4.5 Myositis Associated Autoantibodies (MAA) 
 
MAA are antibodies that are associated with myositis but with features of overlap 
disorders, i.e. the patient may have sclerodactyly associated with SSc.  Table 1-2 
describes the association of MAA with ILD.   
Myositis 
Associated 
Autoantibodies 
(MAA) 
Prevalence of 
Antibody 
Disease 
Associations 
Likelihood of 
developing ILD 
Anti-PM-Scl  Occurs in up to 
17% of patients 
with overlap 
myositis (45) 
3-6% of patients 
with SSc (46) 
Associated with 
scleromyositis 
~50% of patients will 
develop ILD (45, 47) 
Anti-Ku 
(myositis) 
Occurs in 13% of 
patients with 
overlap myositis 
(45) 
Associated with 
myositis overlap 
syndrome 
~30% of patients will 
develop ILD (45) 
Anti-U1RNP  5 – 35% of patients 
presenting with SSc 
or overlap 
syndromes (46) 
Associated with 
mixed connective 
tissue disease 
(MCTD) 
~35% show HRCT 
abnormalities 
associated with ILD, 
~20% classified as 
severe (48) 
Anti-Ro-52/60 ~40% of IIM 
patients have anti-
Ro-52/60 alongside 
their MSA or MAA 
(47)  
Frequently occur 
with an MSA, 
especially with the 
anti-syntheases, or 
with various 
MAAs. 
~40% of patients 
develop ILD, 
however it is unlikely 
that these antibodies 
are responsible for 
the ILD risk, which is 
instead due to the 
MSA/MAA detected. 
(47) 
 
Table 1-2  MAA and their association with ILD.  Table is compiled from the cited 
references. 
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1.3.4.6 SSc-Specific Antibodies 
 
SSc is also associated with a number of disease-specific autoantibodies.  Like the 
IIM, the particular antibody that an SSc patient has can aid in predicting the subset 
of disease and the clinical phenotype that the patient exhibits. Table 1-3 gives a 
summary of the antibodies in SSc and their association with ILD.  
 
SSc-
associated 
antibody 
Prevalence of 
Antibody 
Disease Associations Likelihood of 
developing ILD 
Anti-topo-
isomerase 
(Scl70) 
~30% of SSc 
patients (49)  
Diffuse SSc (50) ~ 60% of patients 
develop ILD (51) 
Anti-Th/To ~5% of SSc 
patients (50) 
Limited SSc (52) ~50% of patients 
develop ILD (53) 
Anti-U3 RNP ~8% of patients 
with SSc (54) 
Occurs in SSc. 
Associated with 
skeletal muscle 
involvement and PAH 
(55)  
~40% of patients have 
ILD (55) 
Anti-U11/U12 
RNP 
~3% of patients 
with SSc (56) 
Occurs in SSc ~80% of patients 
develop ILD which is 
often severe (56) 
Anti-
RuvBL1/2 
1-2% of SSc 
patients (57) 
Associated with 
myositis overlap and 
diffuse skin thickening 
(57)  
Over 50% of patients 
will develop ILD (57) 
Anti-EIF2B ~1% of patients 
with SSc / SSc 
overlap (58) 
Associated with SSc / 
SSc overlap syndrome  
Up to 100% of patients 
will develop ILD (58) 
 
Table 1-3  SSc-Associated Autoantibodies and their association with ILD.  Table is 
compiled from cited references. 
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Anti-topoisomerase antibody is associated with dcSSc (59).  It is associated with a 
higher frequency of lung fibrosis, with over 60% of patients who have the antibody 
developing ILD (51, 60, 61), and is an independent predictor for the development of 
ILD in SSc (51).  Interestingly, a study that monitored anti-topoisomerase levels 
over time identified a sub-group of patients who became antibody negative over the 
course of the disease.  They experienced less progressive ILD and had better 
survival rates than patients who remained antibody positive (62).  This has led to 
further investigation to assess if the presence of autoantibodies has any mechanism 
in the pathogenesis of fibrosis.  It is thought that antibodies may be involved in the 
activation of immune cells or may amplify the immune response and much work is 
being undertaken in this field to assess the exact pathway by which the disease 
process occurs and if antibodies have a direct pathogenic role (63).  
 
1.3.5 Diagnostic Uncertainty in ILD 
 
A thorough clinical history and examination will often enable clinicians to assign 
individual patients into the correct ILD diagnostic subgroup. For example, patients 
with a clear history of occupational exposure to asbestos or use of typical 
medications such as nitrofurantoin or amiodarone may be easy to classify.  Other 
patients may have clear evidence of an underlying CTD on physical examination.  
Where subgroup diagnostic labelling remains difficult, diagnostic assignments 
should be undertaken by tertiary multidisciplinary teams (3). Occasionally, 
distinguishing between idiopathic and CTD-ILD subgroup cases may prove difficult, 
and several factors contribute to such difficulties:   
• CTD symptoms and signs may be absent or subtle, so easily missed in a busy 
respiratory clinic.  For example, in the antisynthetase syndrome the expected 
CTD features other than ILD (i.e. Raynaud’s phenomenon, myositis, mechanic’s 
hands, DM rash and inflammatory arthritis) may be absent at ILD onset (35).  
Furthermore ILD patients may only volunteer CTD symptoms if directly asked, 
and chest physicians may not enquire regarding subtle symptoms (64).   
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• CTD symptoms and signs other than ILD may never develop once the 
immunosuppression used to treat ILD has commenced. 
 
• As previously discussed, the HRCT appearances in ILD cases labelled as 
idiopathic also occur in CTD-ILD (5).  Thus, while HRCT is an important tool in 
ILD diagnosis, it may not always accurately distinguish between subgroups.  
There are various HRCT patterns in CTD-ILD that vary in frequency depending 
upon the underlying CTD.  For example, SSc-ILD tends to present with an NSIP 
pattern (65).  In contrast, RA-ILD has a much higher prevalence of a UIP pattern 
(6, 7). 
 
• Not all investigations are available to the treating physician.  For example, a 
large number of patients are precluded from undergoing a lung biopsy as they 
are too frail or do not have the respiratory reserve.  Also, comprehensive 
serology is not available in every NHS hospital. 
 
 
Assigning every individual ILD patient into the correct ILD diagnostic subgroup has 
become crucial based on recent mechanistic insights and drug developments. 
Treatment strategies now differ considerably between ILD subsets, so making a 
correct diagnosis is vitally important to ensure optimal treatment choices. For 
instance, patients with SSc-ILD will often respond to prednisolone and 
cyclophosphamide even if their HRCT shows a UIP pattern (66). However, if this 
pattern is associated with IPF steroids are harmful and so contra-indicated (Raghu, 
2012). These differing treatment outcomes make it vital that a correct ILD subgroup 
diagnosis is achieved in every case. Accumulating research suggests that use of 
comprehensive CTD-serology is likely to represent a vital tool in this respect (67). 
This serological classification has now been identified as having an important role in 
diagnosing and managing patients with ILD and has been included in the recently 
published ATS / ERS guidelines for the management of ILD (68). This guideline 
recognises that there is a “serological domain” required when diagnosing patients 
with idiopathic ILD and suggests the category “interstitial pneumonia with 
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autoimmune features” for patients who have certain features suggesting an 
autoimmune process but the patient does not meet criteria for a diagnostic label of a 
CTD. 
This leads to the clinical question of whether patients who are diagnosed with IPF 
actually have an underlying CTD that can be disclosed by comprehensive serology.  
It is important to ascertain if patients are being misdiagnosed thereby receiving 
incorrect treatments.  This quantification of diagnostic error in IPF has not been 
studied in a UK population previously.  Previous studies have been performed but 
these have been in East Asian populations and have included all idiopathic ILD 
subgroups without distinguishing IPF.  These are discussed in more detail in chapter 
4 but suggest the diagnostic error may be between 6.6 – 38% in patients with 
idiopathic ILD (69, 70).  The first part of this thesis assesses the level of diagnostic 
error within a UK population of patients diagnosed with IPF and what proportion 
actually have an underlying CTD when serum is analysed using 
immunoprecipitation.  It is important that this work is undertaken prior to any 
mechanistic work to ensure that the IPF population being examined is as 
homogeneous as possible. 
 
1.4 Mechanistic Research 
 
As for any disease, the effectiveness of ILD therapies will be dictated by their 
specificity, i.e. how well they target the pathological mechanisms causing the 
parenchymal injury. A major stricture currently limiting the effectiveness of ILD 
treatments is that their underlying pathologies are so poorly understood.  Gaining 
mechanistic insights would therefore clearly be of benefit.  
A number of animal models of pulmonary fibrosis have been developed to try to 
better understand mechanisms of disease.  As the underlying cause of ILD is 
unknown it is difficult to develop a model that directly mimics the disease process.  
One model of IPF uses inhaled bleomycin to induce a fibrotic response in rodents.  
This medication is used as a treatment for cancer in humans but has the side effect of 
31 
 
causing lung fibrosis.  The inhaled drug causes an initial inflammatory response 
which can be measured in broncho-alveolar lavage (BAL) fluid.  By day 14, this 
response subsides and an increase in production and deposition of collagen in the 
interstitial space occurs (71).  The advantages of this model include a fibrotic 
process that targets the lungs without other systemic effects.  It also produces a 
picture of pulmonary fibrosis with histology similar to that seen in IPF.  
Unfortunately, this model also has limitations as there appears to be an initial 
inflammatory response that has not been seen in patients with IPF. This model has 
been adapted by giving mice smaller, repetitive doses of bleomycin to represent the 
chronic injury thought to occur in IPF (72).  Another established model, used to 
investigate the molecular pathways occurring in IPF, is to expose mice to doses of 
radiation.  This appears to cause changes in the lungs similar to those occurring in 
IPF and has been used in several molecular studies described later in this chapter 
(73).   
Genetic mouse models have also been developed that overexpress key molecules 
involved in fibrosis such as Transforming Growth Factor-β (TGF-β) (74).  This is to 
better understand the pathways involved in the fibrotic process.  Unfortunately, 
these models also have their drawbacks as genetic analyses in IPF have shown the 
condition is likely due to a complex interplay of multiple factors.  However, certain 
genetic defects such as MUC5B increase susceptibility in individuals.  
Unfortunately, a perfect model with which to study ILD does not exist. 
     
1.4.1 The Extracellular Matrix (ECM) 
 
It is hypothesised that CTD-ILD is preceded by inflammation, which if suppressed 
appropriately may prevent parenchymal fibrosis and scarring (75). This does not 
apply in all ILD subtypes, as in IPF fibrosis does not appear to be preceded by 
inflammation. Irrespective of whether fibrosis is preceded by inflammation, fibrotic 
damage follows activation of the myofibroblast which leads to excessive amounts of 
ECM production in the interstitial space.  The production of ECM is a dynamic 
process that is continually remodelled and the balance between production and 
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degradation is tightly regulated.  The ECM has multiple versatile functions including 
binding to growth factor signalling molecules, influencing cell migration and it can 
also change a number of behaviours based on the stiffness of the underlying matrix 
(76).  The ECM is made up of two main classes of macromolecules; proteoglycans 
and fibrous proteins including collagens, elastins and fibronectin (77).  There are a 
number of different collagens in the body, however collagen type I and collagen 
type III are the most abundant in the ECM of the lung.  Collagen type I is composed 
of two alpha 1 chains and one alpha 2 chain, which are the products of two genes 
COL1A1 and COL1A2, located on chromosome 17 and 7 respectively.  Each chain 
consists of 1050 amino acids.  Once formed, these peptides are then transported into 
the rough endoplasmic reticulum where they are modified by a number of different 
reactions and then wound into a triple helix structure before being secreted into the 
extracellular space.  Extracellular enzymes, the procollagen peptidases and a 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), remove 
the N-terminal and C-terminal propeptides at the end of the collagen molecule.  This 
then allows them to polymerise in the extracellular space forming fibrillary 
structures (78).  These undergo cross-linking catalysed by enzymes belonging to the 
lysyl oxidase family.  There is evidence to suggest that it is these hydroxyallysine 
cross-links that lead to the irreversibility of fibrosis and prevent the degradation of 
collagen by members of the Matrix Metalloproteinase (MMP) family (79). 
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Figure 1-5  The collagen type 1 molecule.  Collagen type 1 consists of two α 1 
chains and one α 2 chain which are wound into a triple helix structure before being 
secreted into the extracellular space.   
 
Fibronectin (FN) is a glycoprotein that is secreted into the ECM. It is produced by 
hepatocytes in a soluble form (called plasma fibronectin).  It is also produced in an 
insoluble form by a number of cell types including mesenchymal and epithelial 
cells, where it constitutes part of the ECM and is termed cellular fibronectin. It has 
several functions but in the ECM acts as a cell adhesion molecule by joining to 
collagen.  It can also act as a ligand for several integrin receptors.  Despite being 
produced from a single gene it undergoes post-translational splicing and can exist as 
several isoforms, with at least 20 different subtypes recognised in humans (80).  The 
insoluble form may be spliced into extra type III domains A and B (FN-EDA and 
FN-EDB respectively).  FN-EDA appears to play a crucial role in the development 
of pulmonary fibrosis.  Early work showed FN-EDA to be present in the fibroblastic 
foci in biopsy specimens from patients with IPF (81).  Further work using a murine 
model showed that genetically modified mice, that are null for the FN-EDA splice 
variant, and then treated with intratracheal bleomycin fail to develop pulmonary 
α1 Chain α1 Chain α2 Chain 
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pro-peptide 
Cleavage Site Cleavage Site 
Mature Collagen 
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fibrosis 21 days after treatment. This was compared to wild-type mice who have 
significant fibrotic change (82).  The surprising part of this paper was that this did 
not improve mortality in these mice, as FN-EDA null mice had a higher mortality 
rate due to a more severe and prolonged inflammatory response after bleomycin.  
They hypothesised this may be due to a lack of ability to activate TGF-β and its 
paradoxical anti-inflammatory properties.  The same authors also cultured primary 
fibroblasts from patients with IPF undergoing lung biopsy and found that these 
patients also produced more α-Smooth Muscle Actin (α-SMA) and FN-EDA than 
control specimens from patients undergoing lung biopsies for non-fibrotic 
conditions (82).  For these reasons the genes that are assessed later in this work 
include COL1A1 and COL3A1 as well as FN-EDA, a splice variant of the FN gene. 
These molecules appear to play a crucial role in the formation of the ECM as well as 
feedback mechanisms in propagating fibrosis.   
The proteoglycan molecules also play an important role in the ECM.  These are 
proteins that have glycosylated side chains.  Several members are in the small 
leucine-rich proteoglycan family (SLRP) and include decorin, biglycan and 
fibromodulin.  Others, for example versican, are much larger molecules.  They can 
have an effect upon signalling molecules within the matrix such as fibroblast growth 
factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth 
factor (VEGF) (83).  At 14 days post-inhaled bleomycin in mice there was a 
significant increase in these proteoglycan molecules including versican, heparin 
sulphate proteoglycan (HSPG), biglycan and fibromodulin (84).  Lung specimens 
from patients with IPF also show an increase in glycosaminoglycan proteins 
compared to those from healthy control subjects (85). 
There are a number of molecules that interact to keep the balance between ECM 
formation and degradation tightly regulated, these are members of the Matrix 
Metalloproteinase (MMP) family and tissue inhibitor of metalloproteinases 
(TIMPs).  MMPs are expressed by a number of different cell types including 
fibroblasts, epithelial and endothelial cells (86).  The MMPs have been highly 
studied in IPF and other fibrotic diseases as they have a role in the degradation of 
collagen.  This has yielded some very interesting results as many MMPs are 
upregulated in IPF which appears paradoxical.  For example, MMP-3 mRNA and 
protein is increased in the lungs of people with IPF and mice that lack MMP-3 are 
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protected against fibrosis when they are administered intratracheal bleomycin (87).  
Similarly, MMP-7 null mice are also protected in this model (88).  MMPs may have 
both antifibrotic and pro-fibrotic roles, depending on the cell type that secretes them 
or during the initiation or propagation of fibrosis.  In the extracellular space, MMPs 
are tightly regulated by TIMPs, which bind to the active site of MMPs making them 
less active.    
 
 
1.4.2 The Role of Transforming Growth Factor-beta (TGF-β) and 
Other Signalling Pathways in Pulmonary Fibrosis 
 
There are a number of important cytokines that act upon the ECM, ensuring that 
homeostasis is maintained.  The TGF-β superfamily consists of the TGF-βs, bone 
morphogenetic proteins (BMPs) and activins (89).  There are 3 recognised isoforms 
of TGF-β referred to as TGF-β1, TGF-β2 and TGF-β3.  The experiments performed 
in this thesis assessed the effects of TGF-β1 and this will be referred to when TGF-β 
is used unless specified.  TGF-β has a critical role in inflammation, as discovered 
when TGF-β null mice were genetically produced.  Some mice did survive to term, 
although there appeared to be considerable intrauterine loss as much fewer mice 
were born than expected.  These mice grew normally for 2 weeks but died at 3-4 
weeks due to an excessive inflammatory response in many organs including the 
heart and lungs (90).  The TGF-β pathway, as shown in Figure 1-6 (91), is a well-
recognised signalling pathway implicated in fibrosis.  It also has effects on 
apoptosis, migration and EMT.  TGF-β is secreted and held in a latent form by 
bonding with a latency-associated protein (LAP) and the latent-TGF-β-binding 
protein (LTBP) (92).  It is activated by a variety of molecules including plasmin, 
MMP-2, MMP-9, thrombospondin-1 and integrins.  Each appears to interact with 
LAP to form an active molecule.  This then allows the dissociation of TGF-β, 
allowing it to bind to its receptor on the cell surface. 
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Activation of the Smad cascade is one way that TGF-β can act.  This pathway is 
activated when the dissociated TGF-β binds to the TGF-β type II receptor on the cell 
surface.  This leads to recruitment and phosphorylation of the TGF-β type I receptor.  
A Smad 2 / Smad 3 complex (also referred to as the R-Smad complex) is bound to 
the TGF-β type I receptor along with Smad anchor receptor activation (SARA).  
This in turn phosphorylates the R-Smad complex and it is released into the 
cytoplasm to form a complex with Smad 4.  This permits the complex to enter the 
nucleus where it can bind to promoters and regulate gene transcription, as shown in 
Figure 1-6 (91).  Smad 7 acts as an inhibitory Smad and blocks phosphorylation of 
the R-Smad complex, inhibiting signalling and consequently gene transcription (93).  
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Figure 1-6 Summary of TGF-β signalling.  The Smad pathway occurs when active TGF-β 
binds to the TGF-β type II receptor which recruits and phosphorylates the TGF-β type I 
receptor.  Smad 2 and 3 are then phosphorylated and released, where they bind to Smad 4 
and are able to enter the nucleus and cause gene transcription.  TGF-β also has effects 
through non-canonical signalling.   
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Figure 1-7  Summary of non-canonical TGF-β signalling.  The interactions that this 
pathway has are not fully understood and this diagram is a simplified representation 
of the complex interplay of factors involved in many of the roles that TGF-β has 
including Epithelial-Mesenchymal Transition (EMT), apoptosis and cell growth 
arrest.  
 
TGF-β signalling not only occurs via the Smad pathway but also by a number of 
non-canonical signalling pathways including the MAP Kinase pathways, Rho-like 
GTPase pathways and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways, as 
represented in Figure 1-7 (94).  Many studies have been performed to assess the role 
of each of these pathways in fibrosis.  It is unclear what each pathway does in turn 
as they appear to strongly interact, both with other non-canonical pathways and the 
Smad pathway above and is dependent upon the cell type.  However, it can be seen 
that these pathways have multiple crucial cellular effects.  It has also been shown 
that when TGF-β is used to stimulate cells into producing COL1A2, this effect 
occurs through the Smad and non-Smad signalling pathway (95).  
 
Non-canonical 
pathway
Par 6
Smurf1
RhoA
EMT
PI3K
Akt
mTor
Apoptosis, EMT 
and Growth 
Arrest
Ras
Raf
Mek
Erk
Snail
EMT
Tak / Tab / Traf 6
MKK4
Jnk
Apoptosis and 
EMT
MKK3/6
P38
Apoptosis and 
EMT
39 
 
1.4.3 Platelet Derived Growth Factors 
 
There are other signalling molecules that appear to play a crucial role in fibrosis.  
One such molecule is Platelet Derived Growth Factor (PDGF) and its receptors 
(PDGFR).  The PDGFs are four possible subunits (A-D) that act upon two possible 
PDGFRs (α and β). The PDGFRs are transmembrane proteins that belong to the 
tyrosine kinase family.  Binding to the receptor activates a number of intracellular 
signalling pathways including the PI3K / AKT pathway and the MAP Kinase 
pathways, described in more detail above.  Its activation appears to play a 
fundamental role in cell proliferation, cell growth, differentiation and migration  
(96).  The importance of PDGF in fibrosis was assessed when rats were exposed to 
asbestos, inducing the onset of pulmonary fibrosis.  Within 5 hours there was a 
significant increase in the mRNA production of PDGFRα, however this was not a 
prolonged response and tapered back to baseline levels over the time course of up to 
8 days (97).  Expression of the PDGF-A gene is also increased in the bleomycin-
induced mouse model of pulmonary fibrosis (98). 
An inhibitor of PDGFR signalling, crenolanib, was used to examine its effect in 
fibrosis.  Mice were challenged with angiotensin II, which causes effects similar to 
those seen in SSc in both the skin and heart.  Treatment with crenolanib reduced 
fibrosis, confirmed by a reduction of picrosirius red staining in histology specimens, 
a surrogate marker for collagen formation (99).  In another study to assess the effect 
of inhibiting PDGFR signalling, mice were irradiated to induce pulmonary fibrosis.  
Treatment with PDGFR tyrosine kinase inhibitors attenuated the fibrotic response 
with an improvement in mouse survival (100).  The importance of these molecules 
in fibrosis are shown by the use of the drug nintedinib in IPF (17).  This is a potent 
inhibitor of the tyrosine kinases and appears to slow disease progression in IPF.  
This confirms the critical role that this molecule has in perpetuating fibrosis. 
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1.4.4 The Production of the Myofibroblast and its Role in Fibrosis 
 
Stimulation of fibroblasts with TGF-β causes proliferation and activation of the cell, 
leading to the secretion of ECM proteins. Some of these fibroblasts become 
synthetic cells, known as a myofibroblast.  It is the myofibroblast that is the key cell 
in fibrosis, responsible for increasing the production of collagens, fibronectin and 
other ECM components.  The hallmark of this cell type is its expression of α-SMA 
which gives it contractile properties.  It has an active role in wound healing, where 
its migratory and contractile properties are required.  Myofibroblasts are driven by 
myocardin related transcription factors (MRTF) (101).  MRTFs are transcriptional 
co-activators.  They are formed in the cytoplasm of cells and translocate to the 
nucleus in mechanical stress or growth factor stimulation.  Here they bind with 
serum response factor (SRF) to cause gene transcription, in particular, transcription 
of α-SMA. 
There are a number of studies that have been published that give evidence for the 
SRF / MRTF pathway playing a key role in fibrosis.  Genetically modified mice that 
have a knockout for the MRTF-A gene were protected from bleomycin-induced lung 
fibrosis suggesting that this is a key molecule in this process (102).  It has also been 
found that MRTF-A is more widely expressed in the skin of patients with diffuse 
SSc than in healthy control skin.  When these dermal fibroblasts are isolated and 
cultured they produce more collagen, α-SMA and CCN2.  These cells were treated 
with CCG-1423, originally described as a Rho inhibitor and blocks the SRF / MRTF 
pathway. By inhibiting this pathway in vitro there was a reduction in the expression 
of these genes (103).  
Sisson et al treated cells and mice with a different SRF / MRTF pathway inhibitor 
(CCG-203971) which again acts to block nuclear localisation of MRTF preventing 
its downstream effects.  When performed in vitro this intervention prevented 
differentiation to the myofibroblast, with a reduction in α-SMA and decreased 
expression of fibronectin (104).  The authors also examined the effects of this drug 
in vivo using the bleomycin-induced lung fibrosis mouse model.  They found that it 
significantly reduced the lung collagen content after injury, observed using 
picrosirius red staining.   
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1.4.5 Epithelial-Mesenchymal Transition (EMT) 
 
Although some myofibroblasts appear to derive from activated fibroblasts this does 
not account for all of these cells.  It seems that there are many cell types that can 
become mesenchymal and thus contribute to the fibrotic process and add to the 
myofibroblast pool. Indeed, TGF-β is also responsible for a process called epithelial-
mesenchymal transition (EMT) where epithelial cells transdifferentiate into cells of 
mesenchymal type and secrete ECM contributing to the profibrotic process.  EMT 
was initially described in embryology but is now recognised as occurring in adult 
cells (105).  EMT is characterised by loss of the junctions between cells, loss of 
apical-basal polarity and associated changes in the cell cytoskeleton.  Several 
transcription factors including Snail Family Transcriptional Repressor 1 (Snail, 
SNAI1), Snail Family Transcriptional Repressor 2 (Slug, SNAI2), Twist and Zinc-
finger-E-box-binding (ZEB) control the regulation of the genes that lead to EMT 
(106). Snail and Slug reduce the expression of E-cadherins, claudins and occludins.  
This destabilises the tight cell-cell adherence between epithelial cells and reduces its 
barrier function.  There is a corresponding increase in N-cadherin, fibronectin and 
collagen.  N-cadherin is expressed by mesenchymal cells and gives weaker cell 
adhesion.  This allows cells to migrate more easily.  The cells also re-organise their 
actin cytoskeleton, increasing contractility and motility (107).  It is accepted that 
EMT can be induced in various epithelial cell lines by stimuli such as TGF-β.  This 
leads to an increase in collagen type I and III and a corresponding reduction in 
expression of E-cadherin (108).  However, interestingly, even when EMT is 
stimulated in vitro and there is an upregulation of COL1A1 mRNA, the amount of 
collagen type 1 protein produced and deposited was significantly less than that of 
fibroblasts (109).  Although it is recognised that these processes occur in vitro the 
contribution that EMT makes in animal models of fibrosis and human fibrotic 
diseases is more controversial.   
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EMT was first described in vivo in 2002 in an animal model of renal fibrosis where 
over a third of the fibroblast population was thought to have arisen through EMT 
(110).  Using this theory, it was suggested that similar mechanisms may occur in 
ILD.  Studies have shown that EMT, including that occurring from type II alveolar 
epithelial cells, contribute up to 50% of the myofibroblast population (111) (72).  
However, these models used the marker SP100A4, also known as fibroblast-specific 
protein-1, as a fibroblast specific marker.  However, this protein is also found in 
macrophages, neutrophils and endothelial cells so is not “fibroblast specific” and 
this error may have led to an overestimation of the contribution that EMT plays 
(106), (112). 
 
1.4.6 Endothelial-Mesenchymal Transition (Endo-MT) 
 
More recent studies suggest that several other cell types may contribute as 
precursors of the myofibroblast.  Endothelial cells can transform into a 
mesenchymal cell type, acquiring the ability to express α-SMA and collagen, via a 
process called endothelial-mesenchymal transition (Endo-MT). Endothelial cells 
respond in a similar way to epithelial cells when treated with TGF-β in vitro.  There 
is a reduction in expression of cell junction proteins that cause adherence between 
cells including vascular endothelial (VE)-cadherin and CD31.  Similarly, endothelial 
cells have been shown to contribute to the myofibroblast pool in bleomycin-induced 
pulmonary fibrosis (113). Other evidence supportive of Endo-MT occurring in ILD 
comes from biopsy specimens of patients with SSc-ILD.  These revealed that cells 
expressing the endothelial cell specific marker CD31 also expressed high levels of 
mesenchymal-specific genes such as collagen type I and fibronectin suggestive that 
endothelial cells were gaining a mesenchymal phenotype (114). 
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1.4.7 Evidence for Other Precursors of the Myofibroblast 
 
Fate mapping strategies have been used to assess the contribution that lung pericytes 
have in fibrosis.  Pericytes are mesenchymal cells that share a basement membrane 
with endothelial cells.  Hung et al suggested that almost 70% of the cells in the lung 
that were α-SMA positive derived from pericytes after bleomycin treatment (115).   
A final cell type implicated in fibrosis are fibrocytes.  Fibrocytes are mesenchymal 
cell progenitors that are found in the bone marrow.  They can also differentiate into 
fibroblasts and myofibroblasts once they reach a specific organ.  Cell lineage tracing 
has suggested that fibrocytes may contribute up to 15% of the myofibroblast 
population in a model of kidney fibrosis (110) and lung biopsy samples from 
patients with IPF have shown that fibrocytes contribute to fibroblastic foci (116).  A 
summary of these processes is shown in Figure 1-8 below (101). 
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Figure 1-8  A representation of the development of the myofibroblast.  The myofibroblast may derive from a number of cell types.  It may be 
from active fibroblasts resident in the particular tissue, from endo-MT, EMT and from circulating fibrocytes produced by bone marrow.  Endo-
MT; endothelial -mesenchymal transition, EMT; epithelial-mesenchymal transition.   
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As discussed, it appears that processes such as EMT and Endo-MT are driven by the 
canonical and non-canonical pathways driven by TGF-β signalling.  These signalling 
pathways also have an impact on downstream mediators of fibrosis.  A particular 
molecule of interest in fibrosis is CCN2 which belongs to a family of proteins that 
appear to interact and have a variety of effects discussed in more detail below. 
 
1.4.8 The CCN Family 
 
The CCN family are a group of multifunctional proteins of which there are 6 
members.  Each protein has a similar structure and contains 5 exons that code for 
similar regions depicted below in Figure 1-9 (117). 
 
 
Figure 1-9  Diagram of the shared structure of the CCN family of proteins.  Each has 
5 exons as depicted above.   
 
 
 
 
46 
 
As a group they have a role in cell adhesion, migration and signalling due to their 
connection to the ECM (117).  They have a role in angiogenesis which is important 
for tissue development and wound healing.  They also act in regulating cell 
proliferation.  The proteins appear to have differing roles in fibrosis with some, for 
example CCN2, having pro-fibrotic effects, and CCN3 appearing to have a negative 
regulatory role. 
 
1.4.8.1 CCN1 
 
The first member of the CCN family can also be referred to as cysteine-rich protein 
61 (Cyr61). Functions include cell adhesion, migration, differentiation and 
angiogenesis (118).  Mice that lack the CCN1 gene die in utero due to defects in 
cardiovascular development (Mo FE, 2006). 
The role of CCN1 in fibrosis is controversial with studies showing opposing effects.  
Work produced by Jun and colleagues showed that CCN1 is highly expressed in 
healing skin wounds.  In these wounds cellular senescence is important to restrict 
fibrosis once the wound has healed.  It appears that CCN1 is required for the cellular 
senescence process acting through integrin-mediated receptors suggesting an 
antifibrotic effect (118).  Further work in vivo verified this result showing similar 
evidence for cellular senescence in murine models of myocardial and liver fibrosis 
(119, 120).  Kim et al used an established model of liver fibrosis, administering 
carbon tetrachloride to the animal to provoke injury eventually leading to hepatic 
fibrosis.  These mice showed an upregulation of CCN1, which was thought to trigger 
cellular senescence.  By administering purified CCN1 protein to mice with 
established hepatic fibrosis, the authors showed a regression of the fibrotic tissue 
within the liver and a reduction in mRNA of collagen. 
However, this antifibrotic role has not been confirmed in further studies.  A 
previously accepted murine model of renal fibrosis was used to identify the role of 
CCN1 in kidney injury. These mice undergo surgery to cause unilateral urethral 
obstruction, which causes fibrosis in the obstructed kidney.  This injury led to an 
increase in production of the CCN1 protein at day 1 which remained elevated until 
day 10 after injury.  Interestingly, the authors blocked the effects of CCN1 using an 
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antibody which reduced the initial fibrotic response, however this could not be 
sustained (121).  CCN1 expression is also increased in the lungs of mice exposed to 
bleomycin and this increase occurs during the initial inflammatory stage (122).  The 
same authors also found that the overexpression of CCN1 using adenovirus-mediated 
gene transfer directly to the lungs induced lung injury in mice by causing a 
neutrophilic alveolitis measured in broncho-alveolar lavage (BAL) fluid (122).  
Evidence from these studies suggests that CCN1 may be upregulated in acute lung 
injury and have a pro-inflammatory response, which is clearly contradictory to 
previous work.  One reason for this discrepancy may be that CCN1 has a different 
role depending on the tissue that it is expressed in. 
In human lung tissue from patients with IPF, CCN1 mRNA and protein levels were 
elevated.  This was in association with increased levels of pro-fibrotic genes such as 
collagen, FN and α-SMA (123).  The effect that CCN1 was inducing was further 
investigated by culturing these fibroblasts ex vivo and using RNA-interference to 
knockdown CCN1 expression.  This reduced the constitutive expression of these pro-
fibrotic genes again suggesting CCN1 may play a pro-fibrotic role in lung fibrosis.  
Similar effects have been shown in models of myocardial fibrosis (120). 
 
1.4.8.2 CCN2 
 
This protein was previously referred to as Connective Tissue Growth Factor (CTGF).  
It has a pivotal role in embryogenesis as CCN2 knock-out mice die shortly after birth 
due to severely malformed ribcages (124).  It has roles in angiogenesis, tissue repair 
and fibrosis where it appears to act as a downstream mediator of TGF-β.  Much work 
has been undertaken showing evidence that CCN2 plays a key role in propagating 
fibrosis. When CCN2 was given to mice in isolation it did not induce fibrosis and 
when TGF-β was given alone there was an initial fibrotic effect in the skin but it did 
not lead to a sustained response.  However, when both molecules were administered 
in combination there was a sustained fibrotic response, suggesting an interaction 
between the two molecules for propagation of fibrosis (125).  There also appear to be 
other regulators of CCN2 expression including hypoxia and mechanical stretch (126, 
127).   
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Studies have shown that CCN2 is overexpressed in fibroblasts isolated from skin 
biopsy specimens of patients with SSc (128).  There is also a correlation between the 
level of CCN2 in the circulating plasma of patients with SSc and disease severity 
(129). 
Murine models have also been used to assess the role that CCN2 has in fibrosis.  
Mice were genetically modified to lack expression of CCN2 within skin fibroblasts.  
When they were administered subcutaneous bleomycin to induce a fibrotic response, 
the mice who lacked CCN2 were protected from developing skin fibrosis (130).  To 
assess whether CCN2 has a similar pro-fibrotic role in lung fibrosis, mice were 
exposed to inhaled bleomycin in vivo.  This led to an increase in levels of CCN2 
mRNA which preceded an increase in COL1A2 (95).   
These mouse model experiments led to an interest in developing a drug to inhibit 
CCN2 in patients with fibrotic diseases.  The above study by Ponticos et al treated 
mice with a specific anti-CCN2 antibody (FG-3019) after treatment with bleomycin.  
Histological sections 7 and 14 days after treatment showed that less type I collagen 
and α-SMA was produced in the lungs of animals treated with the antibody.  In a 
similar way, a monoclonal antibody to CCN2 was given to mice being administered 
angiotensin II, which is a known inducer of skin fibrosis (99).  Mice treated with the 
drug showed a significant reduction in skin thickness and collagen production when 
compared to untreated mice 14 days after treatment.  In fact, the above drug has been 
used in phase 2 clinical trials of patients with IPF (131).  This was well tolerated and 
showed some promising results, with 30% of treated subjects showing an increase in 
Forced Vital Capacity (FVC) from baseline.  
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1.4.8.3 CCN3 
 
CCN3 is also referred to as nephroblastoma overexpressed gene (NOV) and is 
known to play a role in embryogenesis, inflammation and tissue repair (132).  CCN3 
knockout mice survive in utero but may show cardiac and skeletal abnormalities, 
muscle atrophy and cataracts (133).   
Riser et al used TGF-β to stimulate the upregulation of CCN2 and type I collagen in 
vitro using mesangial cells from rat glomeruli, and then showed that concomitant 
treatment with CCN3 inhibited this effect.  They investigated this further by showing 
a lack of change in the downstream phosphorylation of Smad, suggesting the effect 
of CCN3 was not a direct, blocking effect on TGF-β (134).  Overexpression of 
CCN3, by insertion of a CCN3 vector in fibroblasts, leads to similar reductions of 
CCN2 and type I collagen (135).  This was suggestive that CCN3 has an antifibrotic 
effect. 
CCN3 effects have also been investigated in vivo using the unilateral ureteral 
obstructive model of renal fibrosis where there was an increase in protein expression 
after injury, both in the obstructed kidney and in the circulating plasma.  However, in 
CCN3 null mice where this increase could not occur, there was a reduction in fibrosis 
(132).  Again, this result appears contradictory to previous work, where CCN3 
appears antifibrotic.  To date the effects of CCN3 in a murine model of pulmonary 
fibrosis have not been investigated.  
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1.4.8.4 CCN4 
 
CCN4 is also referred to as WNT1-inducible signalling protein (WISP-1).  Treatment 
of epithelial cells with CCN4 leads to EMT with an increase in α-SMA positive cells 
(136).  In the carbon tetrachloride murine model of liver fibrosis, it was shown that 
blockade of CCN4 using an antibody reduced the amount of collagen in the liver, 
suggesting that CCN4 acts as a pro-fibrotic mediator (137).  
In type II epithelial cells isolated from lungs of mice treated with bleomycin there is 
an increase in CCN4 expression.  If mice were treated with CCN4 antibody prior to 
receiving bleomycin there was a reduction in fibrosis, again suggesting a pro-fibrotic 
role of CCN4.  This increase was also present in type II epithelial cells isolated from 
biopsy specimens from patients with IPF (136).  
  
1.4.8.5 CCN5 
 
CCN5, also referred to as WNT2-inducible signalling protein (WISP-2), is unique 
within the CCN family as it does not have a C-terminal domain.  This domain is 
important as in other CCN proteins it has been found to bind to integrins, other 
matrix molecules and important signalling molecules such as Notch 1 (117).  CCN5 
appears to have a critical role in embryogenesis as CCN5 null mice do not survive in 
utero and its expression is widespread early in embryonic development (138). 
When CCN5 was overexpressed in primary human lung fibroblasts cultured from 
patients with IPF there was reduced expression of CCN2, α-SMA and type 1 
collagen.  This suggests that CCN5 has anti-fibrotic effects (139). 
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1.4.9 Fibroblast Surface Markers and their Role in Fibrosis 
1.4.9.1 Thy-1 
 
Thy-1 is a glycophosphatidylinositol anchored cell surface protein, found on the 
surface of fibroblasts as well as many other cells and tissues in the body including 
neurons and T-lymphocytes.  There is a variety of evidence to suggest that thy-1 has 
a role in lung fibrosis.  Thy-1 null mice administered bleomycin experienced more 
severe lung fibrosis, with a greater accumulation of collagen, than their wild type 
counterparts (140).  Biopsy specimens from patients with IPF found that 
myofibroblasts within the fibroblastic foci also appear to be thy-1 negative.  In 
contrast, in healthy lungs the majority of fibroblasts are thy-1 positive (140).  This is 
suggestive that thy-1 expression has a protective role in fibrosis. 
 
 
 
Having recognised the multitude of cell types and transformations which could 
contribute to lung fibrosis, and given that it is recognised that elevated serum levels 
of TGF-β are detectable in ILD patients (141), it was wondered whether ILD patient 
plasma could cause changes in fibroblasts or epithelial cells towards that of a 
myofibroblast phenotype. This appears of considerable importance, as it could give 
clues as to what may be happening in the lungs of ILD patients, and by which 
pathway fibrosis is affecting the lung. It is clear that this may be different depending 
upon the underlying cause, i.e. in IPF which is predominantly fibrotic or CTD-ILD 
which is more strongly associated with inflammation.  By recognising the pathways 
that drive the fibrotic response it will aid the development of future therapeutic 
targets for a more personalised medicine approach for ILD patients.  Currently there 
are only two drugs, pirfenidone and nintedanib, that have been shown to have any 
impact upon the relentless progression of IPF.  However, these drugs only appear to 
slow progression of the disease and do not stop the ongoing fibrosis.  CTD-ILD 
appears to respond to steroids and immunosuppressive agents suggesting a different 
underlying aetiology.  If the mechanisms of the disease are better understood then 
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affecting part of the pathway driving the fibrotic response may allow termination of 
disease progression.  This work strives to recognise any key molecules involved in 
fibrosis when lung cell types are treated with ILD plasma.   
The key aims of the work that is presented in the next few chapters include: 
1) To identify the proportion of patients diagnosed with IPF who have a 
recognised antibody associated with CTD-ILD in their serum.  This will 
ascertain whether patients are being incorrectly diagnosed with IPF, thereby 
receiving incorrect treatment that may not be beneficial.  It will also show 
whether the IPF population used in later chapters has a number of patients 
with covert CTD-ILD, affecting any comparisons that can be made. 
2) To design an in vitro model of fibrosis that can measure changes in fibrotic 
markers.  Two cell types have been chosen, fibroblasts and epithelial cells, as 
previous literature has implicated these cell types as key cells in the fibrotic 
response.  
3) To use this model by treating cell lines with plasma from patients with 
fibrotic lung diseases.  Two diseases were chosen, IPF (a predominantly 
fibrotic disease that affects the lungs) and SSc-ILD (a disease that has an 
inflammatory component and responds to immunosuppression).   
4) To adapt the in vitro model by using stretch to imitate the constant movement 
of the lungs and to assess what impact this movement has upon the fibrotic 
response in the lungs. 
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2 Materials and Methods 
2.1 Recruitment of ILD Patients to Enable Clinical 
Research 
2.1.1 United Kingdom – Biomarkers in Interstitial Lung Disease 
(UK-BILD) Study 
 
As ILD is relatively rare it was necessary to set up a UK-wide collaborative network 
designed to enable recruitment of a sufficient number of cases to permit research into 
disease mechanisms.  The UK-BILD study was thus established to allow this 
research to be undertaken. It is now an established large-scale, national collaboration 
involving 38 centres across the UK, a list of which is given in Appendix 1.  It was 
designed as a cross-sectional study recruiting patients across the spectrum of ILD 
subgroups.  This multicentre, collaborative approach allows sufficient numbers of 
patients to be recruited, particularly in rarer disease subtypes, to allow statistically 
meaningful within and between subgroup comparisons to be made.  
  
2.1.2 Ethical Approval 
 
In order to recruit into UK-BILD, ethical approval was sought from the Research 
Ethics Committee (REC).  An ethical application was made and called; “Identifying 
disease susceptibility genes and autoantibodies associated with the development and 
clinical characteristics of interstitial lung disease (ILD) in patients with and without 
proven connective tissue diseases (CTDs)”.  This received favourable ethical opinion 
on the 11th March 2011, Research Ethics Committee (REC) reference number 
11/H1010/4 (see Appendix 3 for REC approval form), later also referred to as the 
“UK-BILD study”.  Following its ethical approval, the study received endorsement 
for portfolio support (UK-Clinical Research Network (UKCRN) ID: 15775) and is 
now supported by UKCRN nurses at the 38 individual recruitment centres.   
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2.1.3 Recruitment of Centres and Patients into UK-BILD 
 
Patients with a definite diagnosis of ILD were recruited into UK-BILD in a cross-
sectional manner.  Patients were identified as being eligible for study enrolment by 
research teams at ILD or Rheumatology centres.  To be eligible for the study patients 
must be 18 years or older at time of ILD diagnosis and have evidence of ILD on their 
HRCT scans. Pulmonary function testing must show evidence of restriction (reduced 
vital capacity, often with an increased forced expiratory volume in 1 second / forced 
vital capacity (FEV1/FVC) ratio) and impaired gas exchange.  Those with a 
diagnosis of IPF must have met criteria for this diagnosis based on the 2011/13 
ATS/ERS guidelines.  The disease duration should be longer than 3 months.  The 
exclusion criteria included drug-induced ILD and those unable or unwilling to give 
consent for study inclusion. 
Key clinical data was completed on a two-page proforma, an example of which is 
included in appendix 2, and sent via secured NHS email to be recorded on a 
centralised database.   
One EDTA tube and one serum gel tube (10ml blood per tube) were taken from 
patients and sent to the Centre for Integrated Genomic Medical Research (CIGMR) 
at the University of Manchester.  Once samples were received, they were separated 
by centrifugation into plasma (stored for mechanistic research), serum (stored for 
serotyping by immunoprecipitation) and DNA samples (stored for future genotyping 
projects), labelled using the laboratory information management tracking system and 
stored at -80°C for future use.  Each centre has required Research and Development 
(R&D) approval through its individual site prior to commencing recruitment.  The 
first patient was collected on 7th January 2015.  There are now 38 centres recruiting 
patients with ILD.  Appendix 1 shows the centres that are currently recruiting 
patients.  As of the 16th May 2017, this study has recruited over 2624 patients of 
many different ILD subgroups, a breakdown of which is shown in chapter 3.   
Data was collected as part of the study including patient demographics (age, gender 
and ethnicity), smoking history, the date of ILD onset, any CTD or respiratory 
symptoms and signs and a history of previous or current malignancy in a cross-
sectional manner.  The data collection sheet is shown in Appendix 2. 
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Smoking data was collected on patients to determine if they were current smokers, 
previous smokers or never smokers.  To determine if they were heavy smokers a 
pack year calculation was performed.  This is calculated by (number of cigarettes 
smoked per day / 20) multiplied by the number of years smoked.  Patients were 
subdivided into heavy smokers (greater than 40 pack year history), moderate 
smokers (20-40 pack year history) or light smokers (less than 20 pack year history). 
Patients with a diagnosis of IPF were separated into 3 distinct categories.  The first 
two categories of IPF are termed “definite IPF”.  The first category includes patients 
who have a characteristic appearance on HRCT with a reticular pattern, 
honeycombing and a lack of ground glass change (ie, a definite UIP pattern) and 
these patients do not require a histological specimen for confirmation of their 
diagnosis.  The second category is for patients who lack honeycombing and have a 
scan appearance more consistent with fibrotic NSIP but undergo diagnostic lung 
biopsy which confirms a UIP pattern.  The third category is termed “probable IPF”, 
where the patient has a HRCT pattern similar to the second category (fibrotic NSIP) 
but is unable to undergo surgical lung biopsy, most likely due to poor lung function 
or underlying co-morbidity.  However, if these patients are of an older age group, 
discussed in an MDT clinical setting and another cause is not recognised they can be 
diagnosed with probable IPF.  These diagnostic guidelines have recently been 
updated (142). 
Physicians recruiting patients to the study were required to identify specific CTD and 
respiratory symptoms and signs when examining patients.  CTD symptoms included 
Raynaud’s phenomenon, arthralgia and myalgia.  Signs included sclerodactyly, 
calcinosis, Mechanic’s hands, periungal erythema and telangiectasia.  Many of these 
signs, if present, may be subtle and were included on the form as a prompt for 
physicians to specifically look for these.  Respiratory signs included clubbing, 
crackles and evidence of pulmonary hypertension, diagnosed according to either 
echocardiographic or right heart catheter criteria. 
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2.1.4 Recruitment of Healthy Control Subjects    
 
Healthy control subject plasma was obtained through the Myositis Research Tissue 
Bank (MRTB) and their samples were requested via the MRTB Steering Committee.  
The Bank received favourable ethical opinion on the 10th November 2015, REC 
reference number 15/NW/0826.  There was limited data available regarding these 
patients however they were recruited to a tissue bank for use as healthy control 
subjects and their age and gender had been recorded. 
 
2.2 Serotyping of IPF Patients using Immunoprecipitation 
 
Immunoprecipitation is the gold standard technique for the detection of 
autoantibodies in patients’ sera.  The aim is to purify specific proteins from a cell 
extract, human plasma or serum samples.  Usually it involves an antibody to 
recognise the protein of interest but in this scenario it is the antibody itself that is of 
interest.  For this reason, human serum is incubated alongside protein A beads that 
are immunoglobulin-binding proteins that can bind to any autoantibodies present in 
the patient serum.  The sample is then washed to remove any unbound proteins.  This 
mixture is then incubated with the radiolabelled cell extract to form a complex.  
These are washed again to remove any unbound protein.  Elution occurs to de-couple 
the antigen, and the remaining proteins are then ran on a sodium dodecyl sulphate 
(SDS)-polyacrylamide gel to separate the protein by molecular weight.  
Autoradiography is then undertaken and analysed to assess for the presence of 
particular bands associated with particular autoantibodies.  This process is depicted 
in Figure 2-1. 
 
 
 
 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This technique was performed in a specialised laboratory with a high specificity and 
sensitivity.  This was not performed by myself but was undertaken by Dr Zoe 
Betteridge at the National Immunoprecipitation Laboratory, University of Bath.  It 
has been described previously in work performed by the group (143). 
Radiolabelled 
cell extract 
Protein A Antibody present in 
patient serum 
Human serum 
Proteins separated 
according to size 
Figure 2-1  Simplified description of technique used in immunoprecipitation 
procedure.  Human serum was incubated alongside protein A beads that bind to any 
autoantibodies present in the serum.  This mixture was then incubated with 
radiolabelled cell extract.  Proteins were separated according to molecular weight and 
autoradiography was used to detect the presence of bands which may correlate with a 
corresponding autoantibody. 
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Briefly, 10ul patient sera was mixed with 2mg protein-A-sepharose beads in IPP 
buffer. This allows for binding of the autoantibodies present in the sera.  K562 cells 
were labelled with [35S]-methionine, a radioactive material, and then lysed.  Beads 
were washed in IPP buffer before being added to the radioactive cell extract.  
Samples were mixed at 4°C for 2 hours.  Beads were washed in IPP buffer with a 
final wash in Tris buffered saline (TBS) buffer.  They were then re-suspended in 
sodium dodecyl sulphate (SDS), heated and separated by molecular weight on a 9% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE).  They are then analysed by 
auto-radiography to give a band at certain molecular weights.  An example gel is 
shown below, some lanes are used as positive controls, in which samples from 
patients with recognised autoantibodies are run alongside the IPF samples for quality 
control purposes.  It should be noted that autoantibodies are usually mutually 
exclusive and the positive controls used in the gel below were using mixed patient 
sera. 
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     Lane no.     1   2    3   4   5    6   7    8   9  10 11  12  13 
 
 
Figure 2-2  Example of immunoprecipitation gel kindly provided by Dr Zoe 
Betteridge.  Lane 1 is provided as a negative control.  Positive controls are shown in 
lane 3 (U1, Jo-1, NXP-2 and RNAPol II), lane 6 (Ro-60, La, PM-Scl), lane 7 (Anti-
Mitochondrial Antibody (AMA)) and lane 9 (PL-7, PL-12 and Zo). Lanes 2, 4, 5, 8, 
11, 12 and 13 were from various patients recruited through the UK-BILD study.  All 
lanes show strong unknown bands at various molecular weights, with lane 2 showing 
RNAPol II and lane 8 showing AMA. 
 
 
 
 
 
52kDa
 
80kDa 
110kDa 
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2.3 Cell Culture 
2.3.1 General Cell Culture Materials 
 
Cell culture was performed for both MRC5 fibroblast cells, a human foetal fibroblast 
cell line and A549 epithelial cells, a human cancerous lung epithelial cell line.  The 
following materials were used in all cell culture work undertaken; 
Plastics 
• T75 cell culture flask, Cellstar, Sigma-Aldrich, Dorset, UK 
• Centrifuge tube (15ml), Cellstar, Sigma-Aldrich, Dorset, UK 
Reagents 
• Dulbecco’s phosphate buffered saline (PBS), Sigma-Aldrich, Dorset, UK 
• Penicillin-streptomycin (100x), Sigma-Aldrich, Dorset, UK 
• Trypsin-EDTA Solution (10x), Sigma-Aldrich, Dorset, UK 
• Fetal Bovine Serum (FBS), qualified, EU-approved, South America origin 
(500ml), Thermo Fisher Scientific, Paisley, UK 
• TCH Defined Serum Replacement, 50X concentrate, MP Biomedicals, 
Leicester, UK 
• Dimethyl Sulphoxide (DMSO) Hybri-Max, Sigma-Aldrich, Dorset, UK 
• Trypan Blue Solution, Sigma-Aldrich, Dorset, UK 
Cytokine 
• Recombinant Human TGF-β1, Lot#0713AF354, Peprotech, London, UK.   
Equipment 
• Heraeus Multifuge X1 Centrifuge, Thermo Fisher Scientific, Runcorn, UK 
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Materials for MRC5 Fibroblasts 
 
• MRC5 cell line, Sigma-Aldrich, Dorset, UK 
• Minimum Essential Medium (MEM) (1x) with Earle’s salts and L-glutamine, 
Gibco by Life Technologies, Thermo Fisher, Runcorn, UK 
• Minimum Essential Media Non-Essential Amino Acids (100x), Gibco by Life 
Technologies, Thermo Fisher, Runcorn, UK 
 
Medium used for culture of MRC5 cells 
 
Serum 
supplemented 
medium 
Minimum 
Essential 
Medium 
(MEM) (1x) 
with Earle’s 
salts and L-
glutamine 
 
1% Minimum 
Essential 
Media Non-
Essential 
Amino Acids 
(100x) 
 
1% Penicillin-
streptomycin 
(100x) 
 
10% Fetal 
Bovine Serum 
(FBS) 
 
Serum free 
medium 
Minimum 
Essential 
Medium 
(MEM) (1x) 
with Earle’s 
salts and L-
glutamine 
 
1% Minimum 
Essential 
Media Non-
Essential 
Amino Acids 
(100x) 
 
1% Penicillin-
streptomycin 
(100x) 
 
 
Serum 
replacement 
medium 
Minimum 
Essential 
Medium 
(MEM) (1x) 
with Earle’s 
salts and L-
glutamine 
 
1% Minimum 
Essential 
Media Non-
Essential 
Amino Acids 
(100x) 
 
1% Penicillin-
streptomycin 
(100x) 
 
2% TCH 
Defined Serum 
Replacement, 
50X 
concentrate 
 
 
Table 2-1 Medium used for culture of MRC5 cells. 
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Materials for A549 Epithelial Cells 
• A549 cell line, ATCC, CCL-185, Middlesex, UK 
• F-12K Kaighn’s modification of Ham’s F-12 with L-glutamine, sterile 
filtered medium, ATCC, Middlesex, UK 
 
Medium used for culture of A549 cells 
 
Serum 
supplemented 
medium 
F-12K Kaighn’s 
modification of 
Ham’s F-12 with 
L-glutamine 
 
1% Penicillin-
streptomycin 
(100x) 
 
10% Fetal Bovine 
Serum (FBS) 
 
Serum free 
medium 
F-12K Kaighn’s 
modification of 
Ham’s F-12 with 
L-glutamine 
 
1% Penicillin-
streptomycin 
(100x) 
 
 
Serum 
replacement 
medium 
F-12K Kaighn’s 
modification of 
Ham’s F-12 with 
L-glutamine 
 
1% Penicillin-
streptomycin 
(100x) 
 
2% TCH Defined 
Serum 
Replacement, 50X 
concentrate 
 
 
Table 2-2 Medium used for culture of A549 cells. 
 
2.3.2 General Cell Culture Methods 
 
Cell lines (either MRC5 or A549) were cultured in T-75 flasks (Sigma-Aldrich, UK) 
along with 10ml of their respective serum supplemented medium (described above). 
The flasks were placed in a standard 5% CO2 incubator at a temperature of 37°C. 
Cells were split once they reached 80% confluence.  The used culture medium was 
discarded and cells washed twice with PBS (Sigma-Aldrich, UK).  Trypsin (Sigma-
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Aldrich, UK) was added and the flask placed in the incubator at 37°C for 5 minutes 
until cells were removed from the bottom of the flask.  Serum supplemented medium 
(5ml) was added to the flask, the mixture placed in a 15ml centrifuge tube and spun 
at 1000xg for 5 minutes.  The excess medium was then removed and the remaining 
cell pellet was re-suspended in 1ml medium. For all described experiments a cell 
count was performed using a haemocytometer.  To undertake this 10ul of the re-
suspended cell pellet, 10ul trypan blue (Sigma-Aldrich, UK) and the appropriate 
dilution were mixed in a sterile Eppendorf.  Using this mixture, 10ul was placed on 
the haemocytometer and a count undertaken.   
 
2.3.2.1 Cell Culture Experiment Assessing the Effect of TGF-β 
 
Cells (MRC5 cells, passage 11-13 or A549 cells, passage 22) were plated at a density 
of 1x105 cells per well in a 6 well plate and cultured for 24 hours.  Cells were given 
2ml per well of serum supplemented medium.  After 24 hours this medium was 
replaced with serum free medium (described in Table 2-1 and Table 2-2).  MRC5 
cells were serum starved for 16 hours and A549 cells were serum starved for 8 hours. 
The medium was then replaced with serum supplemented medium (2ml) and cells 
treated with TGF-β (Peprotech, UK) of varying concentrations.  The MRC5 cells 
were treated with 0.5ng/ml, 1ng/ml and 2ng/ml TGF-β alongside untreated control 
wells.  The A549 cells were treated with TGF-β 1.5ng/ml or 3ng/ml alongside 
untreated control wells.  The conditioned medium was removed, placed in sterile 
Eppendorf tubes and stored at -80°C for use in western blot experiments. RNA was 
extracted, see section 2.7 for method, at 24, 48, 72 and 96 hours respectively.   
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2.3.2.2 Cell Culture Experiment Assessing the Effect of TGF-β but Using 
Serum Supplementation Instead of Serum Starvation 
 
To reduce the impact of serum starvation, the above experiment was repeated using a 
similar method.  However, medium was not replaced with serum free medium but by 
serum replacement medium containing 2% TCH (MP Biomedicals, UK), as 
described in Table 2-1 and Table 2-2.  TCH ensures that cells are kept in a consistent 
growth environment but are free from growth factors and steroid hormones, ensuring 
that these molecules found in FBS do not impact upon cells.  After 16 hours, cells 
were treated with TGF-β (0.5ng/ml, 1ng/ml and 2ng/ml in the MRC5 cells or 
1.5ng/ml and 3ng/ml in the A549 cells) alongside untreated, control wells.  RNA was 
extracted at 48 hours only. 
 
2.3.2.3 Cell Culture Experiment Assessing the Effect of Patient Plasma 
 
Cells (MRC5 cells, passage 12-20 or A549 cells, passage 16-24) were plated at a 
density of 1x105 cells per well in a 6 well plate for 24 hours with each well receiving 
2ml of serum supplemented medium.  After 24 hours this medium was removed, 
discarded and cells were washed with warmed PBS and replaced with 1.2ml serum 
replacement medium.  After 16 hours cells were treated with 100ul patient or healthy 
control plasma and RNA extracted at 24, 48 and 72 hours respectively. 
 
2.3.2.4 MRC5 Stretch experiment with TGF-β or Patient Plasma 
 
2.3.2.4.1 Extra Materials Required 
 
• Bioflex 6 well culture plates, Flexcell International Corporation, Burlington, 
North Carolina, USA 
• Flexcell Strain Unit, FX-4000, Flexcell International Corporation, Burlington, 
North Carolina, USA 
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MRC5 cells (passage 14-17) were seeded onto bioflex 6 well plates (Flexcell, 
Burlington, USA) at a density of 2.5x105 and covered with 2ml serum supplemented 
medium per well.  Once cells were fully confluent, the medium was removed, the 
cells washed with warmed PBS and the medium replaced with serum replacement 
medium overnight.  After 16 hours, cells were left untreated, treated with stretch 
only, treated with TGF-β only (2ng/ml) or treated with a combination of TGF-β 
(2ng/ml) and stretch.  Stretch was applied at 6.66% in pulsed sine wave intervals at 1 
Hertz (Hz).  After 24 hours, RNA was extracted using the method described in 
section 2.7. 
In a similar experiment to assess the impact of stretch and patient plasma, cells were 
kept in the same conditions and then treated with 100ul IPF patient plasma or 100ul 
healthy control plasma respectively.  One plate was stretched while the other was 
kept in the same incubator but without stretch applied.  Again, cells were stretched at 
6.66% in pulsed sine wave intervals at 1 Hz for 24 hours.  RNA was extracted using 
the protocol described in section 2.7. 
 
2.3.2.5 A549 Stretch Experiment with TGF-β 
 
2.3.2.5.1 Extra Materials Required 
 
• Silicon stretch chambers, custom made 
• Laminin from Engelbreth-Holm-Swarm murine sarcoma (basement 
membrane), Sigma-Aldrich, Dorset, UK 
• Heraeus Multifuge X1 Centrifuge, Thermo Fisher Scientific, Runcorn, UK 
 
Laminin (4ug/ml) was placed on stretch chambers and incubated at 37°C for 2 hours 
to coat the chamber and allow for cell attachment and growth.  A549 cells (passage 
19-23) were plated at a density of 1x106 and left to grow in 4ml serum supplemented 
medium until confluent.  The cells were washed with PBS and the medium replaced 
with serum supplemented medium overnight.  Cells were then split into 4 groups 
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with the experiment repeated in duplicate; (a) untreated with no stretch; (b) treated 
with TGF-β (1.5ng/ml) with no stretch; (c) untreated with stretch; (d) treated with 
TGF-β (1.5ng/ml) and stretch.  Stretch was set to 6.6% at 1 Hz.  RNA was extracted 
at 24 hours as per methods described in section 2.7. 
This experiment was performed in a similar manner using patient plasma.  Once cells 
were grown in serum supplemented medium, 150ul patient plasma or healthy control 
plasma was added to each chamber and cells either stretched or left in the same 
incubator without stretch for 24 hours.  RNA was then extracted using methods 
previously described. 
 
2.4 Immunocytochemistry 
2.4.1 Immunocytochemistry Materials 
 
• Phosphate Buffered Saline tablet, Sigma-Aldrich, Dorset, UK 
• 0.01% Phosphate Buffered Saline and Tween (PBST) prepared as described 
in Appendix 4 
• Neutral Buffered Formalin (NBF) 10%, Leica Biosystems, Milton Keynes, 
UK 
• Goat serum, Vector Laboratories, Burlingame, California, USA 
• Vectashield Hard Set Mounting medium with dapi, Vector Laboratories, 
Burlingame, California, USA 
• Glass cover slip, 22x22mm, Scientific Laboratory Supplies Ltd, Manchester, 
UK 
• Nikon eclipse Ti confocal microscope, Amsterdam, Netherlands 
• Phalloidin, A12379, Alexa Fluor, Life Technologies, USA 
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Primary Antibodies Used for Immunocytochemistry 
Protein Company Product Code Antibody Type Dilution 
Collagen 1 Abcam ab34710 Rabbit 
polyclonal 
1/500 
α-SMA Abcam ab5694 Rabbit 
polyclonal 
1/250 
Thy-1 Abcam ab133350 Rabbit 
monoclonal 
1/250 
 
Table 2-3  Primary Antibodies for Immunocytochemistry 
 
Secondary Antibodies Used for Immunocytochemistry 
Antibody Company Product code Dilution 
532 goat anti-
rabbit IgG 
Alexa fluor, Life 
Technologies 
A-11009 1/1000 
 
Table 2-4  Secondary Antibodies for Immunocytochemistry 
 
2.4.2 Immunocytochemistry Methods 
 
Cells were plated at a density of 1x105 in 6 well plates or 2.5x104 in 12 well plates, 
cultured and treated with TGF-β or patient plasma as described previously.  The 
addition of a glass cover slip was placed in the bottom of each well.  This was to 
allow optimum views when using the microscope for staining.  After 48 hours cells 
were washed carefully with PBS.  Cells were fixed by adding 1ml NBF (Leica 
Biosystems, Milton Keynes, UK) per well in a fume hood and incubating for 15 
minutes at room temperature.  The NBF was removed and the cells washed twice 
with 0.01% PBST to permeabilise the membrane.   
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Phalloidin (Life Technologies, USA) was diluted in 1.5ml methanol and made to a 
dilution of 1 in 40 with PBST, added to each well and incubated under light-sensitive 
conditions for a further 40 minutes at room temperature.  The phalloidin was 
removed by three 5-minute washes with PBST.   
A blocking solution of 5% goat serum (diluted with PBST) was then added to each 
well (1ml per well) and the plate left to incubate at room temperature for 2 hours.  
The primary antibody (made to the dilution specified above) was made in 5% goat 
serum diluted with PBST and added to each well.  This was left overnight at 4°C.  
The antibody was removed by three 5-minute washes with PBST.   
The secondary antibody, made to the dilution specified above, was added to each 
well (750ul per well).  This was incubated at room temperature for 2 hours.  Again, 
the antibody was removed and the cells given a short wash with PBST.  The glass 
cover slip was removed from each well and added to glass slides using hard set 
mountant along with Dapi staining.  Cells were then imaged using a confocal 
microscope (Nikon eclipse Ti, Netherlands).  When not in use, slides were stored at 
4°C. 
 
2.5 Cell Proliferation Assay  
2.5.1 Cell Proliferation Assay Materials 
 
• Cell culture materials as documented above 
• Alamar Blue Cell Viability Reagent, Invitrogen, Paisley, UK 
• Fluostar Optima Microplate reader, BMG Labtech, Ortenberg, Germany 
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2.5.2 Cell Proliferation Assay Methods 
 
Initially, a standard curve was produced for both the MRC5 fibroblasts and the A549 
epithelial cells respectively.  To undertake this, cells were plated at increasing 
densities and left to settle for 2 hours.  Alamar blue reagent (10%) (Invitrogen, 
Paisley, UK) was then added to each well and the plate kept under light sensitive 
conditions at 37°C for 3 hours prior to measurement of fluorescence.   
To calculate proliferation, cells were plated at 6250 cells per well in a 96 well plate 
along with 150ul of serum replacement medium.  After 24 hours, cells were washed 
with PBS and changed to serum supplemented medium overnight.  Cells were then 
treated with TGF-β (concentrations as previously described) or patient plasma 
(6.25ul per well).  Alamar blue (10%) was then added to wells after 24, 48, 72 and 96 
hours respectively and left for 3 hours under light sensitive conditions until 
measurement of fluorescence. 
 
2.6 PCNA Staining for Cell Proliferation 
 
2.6.1 PCNA Staining for Cell Proliferation Materials 
 
• Cell culture materials as per section 2.3 
• PBS tablet, Sigma-Aldrich, Dorset, UK 
• 0.01% PBST prepared as described in Appendix 4 
• Analytical reagent grade methanol, Fisher Chemical, Fisher Scientific, 
Leicestershire, UK 
• Goat serum, Vector Laboratories, Burlingame, California, USA 
• Bovine serum albumin (BSA) lyophilized powder, Sigma-Aldrich, Dorset, 
UK 
• Glycine for electrophoresis, Sigma-Aldrich, Dorset, UK 
• Anti-PCNA antibody, ab18197, Rabbit polyclonal, dilution 
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• Alexa Fluor 532 goat anti-rabbit IgG, molecular probes by life technologies, 
Oregon, USA 
• Vectashield hard set mounting medium with dapi, Vector Laboratories, 
Burlingame, California, USA 
• Glass cover slip, 22x22mm, Scientific Laboratory Supplies Ltd, Manchester, 
UK 
• Nikon eclipse Ti confocal microscope, Amsterdam, Netherlands 
 
2.6.2 PCNA Staining for Cell Proliferation Methods Performed for 
Cells Treated with TGF-β or Patient Plasma 
 
Cells were plated at a density of 5x104 in 12 well plates and cultured in conditions 
previously described (see section 2.3.2).  The MRC5 cells were treated with 1ng/ml 
or 2ng/ml TGF-β alongside untreated, control wells respectively.  A549 cells were 
treated with 1.5ng/ml or 3ng/ml TGF-β.  After 48 hours 1ml 100% methanol was 
added to each well and incubated at room temperature for 5 minutes until cells were 
fixed.  Cells were washed and incubated in 1% BSA, 10% normal goat serum, 0.3M 
glycine in 0.1% PBST for 1 hour to permeabilise the cells and block non-specific 
protein-protein interactions.  Cells were then diluted with the Anti-PCNA antibody, 
diluted 1/1000, at 4°C overnight.  Cells were washed with PBS and the secondary 
antibody (Alexa Fluor 532 goat anti-rabbit IgG, diluted 1 in 1000) was added for 2 
hours.  This was then removed by two 5-minute washes.  The cover slip was then 
removed and placed onto slides using mountant containing dapi. 
The experiment was repeated as described above except each well was treated with 
50ul patient or healthy control plasma respectively. 
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2.7 RNA Extraction, cDNA synthesis and Quantitative 
Polymerase Chain Reaction (qPCR) 
2.7.1 RNA Extraction Materials 
 
• Trizol reagent, Ref 155096-018, Thermo Fisher, Runcorn, UK 
• Chloroform, Ref C2432, Sigma-Aldrich, Dorset, UK 
• Isopropanol 99.5% pure, Acros organics, Thermo Fisher Scientific, Runcorn, 
UK 
• Molecular grade ethanol, Sigma-Aldrich, Dorset, UK 
• Diethylpyrocarbonate (DEPC)-Treated water, nuclease free, Ambion, Thermo 
Fisher Scientific, Runcorn, UK 
• GeneJET RNA cleanup and concentration Micro kit, Ref K0842, Thermo 
Scientific, Runcorn, UK 
• 25cm cell scraper, Sarstedt, Leicester, UK 
• Eppendorf centrifuge 5417R, Eppendorf, Stevenage, UK 
• Nanodrop 2000 spectrophotometer, Thermo Scientific, Runcorn, UK 
 
2.7.2 RNA Extraction Methods 
 
Cells were cultured and treated as previously described (see section 2.3.2).  To 
extract RNA, cells were washed with 1ml warmed PBS.  Once washed, 500ul of 
Trizol (Thermo-Fisher, Runcorn, UK) was added to each well and incubated at room 
temperature for 5 minutes.  The cells were then scraped and the mixture added to a 
sterile 1.5ml Eppendorf tube.  Chloroform (200ul) was added to each Eppendorf and 
the mixture shaken vigorously for 15 seconds.  The tube was then left to stand for 15 
minutes before being placed in the centrifuge and spun at 12,000xg for 15 minutes at 
a temperature of 4°C.  This separated the mixture into three distinct phases.  The 
upper colourless phase, containing the RNA, was removed by careful pipetting to 
ensure that it was not contaminated from the other layers, and placed into a sterile 
1.5ml Eppendorf.  To precipitate the RNA, 500ul isopropanol (Acros organics, 
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Runcorn, UK) was then added and the sample was briefly vortexed before being left 
to stand for 10 minutes at room temperature.  The Eppendorf was placed in the 
centrifuge and spun at 12,000xg for 10 minutes at 4°C.  Residual liquid was removed 
from the Eppendorf tube leaving a small cell pellet at the bottom of the tube.  To 
wash the RNA pellet, 500ul of 75% ethanol (Signa-Aldrich, Dorset, UK) was added 
to the pellet and spun at 12,000xg for 5 minutes at 4°C.  Again, the residual liquid 
was removed leaving the RNA pellet at the bottom of the tube. This was left to air 
dry for 5 minutes and 200ul DEPC-treated water (Thermo-Fisher, Runcorn, UK) was 
added.  An RNA clean-up kit (Thermo-Fisher, Runcorn, UK) was then used, 
following the instructions provided by the company, to produce a 10ul sample of 
RNA.  The nanodrop (Thermo-Fisher, Runcorn, UK) was used to quantify the 
amount of RNA as well as to measure the sample purity.   
 
2.7.3 cDNA Synthesis Materials 
 
• High-Capacity cDNA Reverse Transcription Kit, Ref 4368814, Life 
Technologies, Thermo Fisher, Runcorn, UK 
• Biorad T100 Thermal Cycler, Bio-rad Laboratories, Watford, UK 
• 0.2ml Flat Cap PCR Tube, Star lab, Milton Keynes, UK 
 
2.7.4 cDNA Synthesis Methods 
 
For each sample, 1ug cDNA was made, using the RNA extracted as described 
previously.  Quantities of RNA necessary for this concentration were calculated from 
nanodrop values.  The above cDNA kit was used as per manufacturer instructions.  
In brief, 2ul reverse transcription buffer, 0.8ul deoxyribonucleotide triphosphate 
(dNTP), 2ul random primers, 1ul multiscribe reverse transcriptase and 1ug RNA 
were added for each sample.  The thermocycler was programmed under the 
following conditions; 10 minutes at 25°C, 2 hours at 37°C, 5 minutes at 85°C and 
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continuous hold at 4°C.  The product, 20ul of cDNA, was diluted 1 in 20 and stored 
at -20°C prior to use. 
 
2.7.5 Design of Primers 
 
qPCR primers used were as follows.  A detailed description of primer testing is given 
in section 4.1. 
Primer Primer Sequence Temp Reference and 
Product Size 
RPLPO 
(Forward) 
3’-CACTGAGATCAGGGACATGTTG-5’ 60.3 NM_001002.
3 
77 bp 
RPLPO 
(Reverse) 
3’-CTTCACATGGGGCAATGG-5’ 56.0  
Collagen 
1a1 
(Forward) 
3’-GGACACAGAGGTTTCAGTGGT-5’ 59.8 NM_000088 
185 bp 
Collagen 
1a1 
(Reverse) 
3’-GCACCATCATTTCCACGAGC-5’ 59.4  
Collagen 
3a1 
(Forward) 
3’-GAAAGATGGCCCAAGGGGTC-5’ 61.4 NM_000090 
103 bp 
Collagen 
3a1 
(Reverse) 
3’-TATACCTGGAAGTCCGGGGG-5’ 61.4  
Fibronectin 
Extra 
Domain A 
(Forward) 
3’-TCCAAGCGGAGAGAGT-5’ 51.7 (144) 
360 bp 
Fibronectin 
Extra 
Domain A 
(Reverse) 
3’-GTGGGTGTGACCTGAG-5’ 54.3  
Slug 
(Forward) 
3’-CGCCTCCAAAAAGCCAAAC-5’ 56.7 (145) 
149 bp 
Slug 
(Reverse) 
3’-CGGTAGTCCACACAGTGATG-5’ 59.4  
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Snail 
(Forward) 
3’-ACCCCAATCGGAAGCCTAACT-5’ 59.8 (146) 
75 bp 
Snail 
(Reverse) 
3’-GGTCGTAGGGCTGCTGGAA-5’ 61.0  
E-cadherin 
(Forward) 
3’-TCATGAGTGTCCCCCGGTAT-5’ 59.4 (147) 
E-cadherin 
(Reverse) 
3’-GTCAGTATCAGCCGCTTCAGAT-5’ 60.3  
N-cadherin 
(Forward) 
3’-CCACAG CTCCACCATATGACT-5’ 59.8 (145) 
133 bp 
N-cadherin 
(Reverse) 
3’-CCCCAGTCGTTCAGGTAATC-5’ 59.4  
CCN1 
(Forward) 
3’-
GTGACGAGGATAGTATCAAGGACC-5’ 
62.7 NM_001554.
4 
198 bp 
CCN1 
(Reverse) 
3’-ATTTCTGGCCTTGTAAAGGGTTG-5’ 58.9  
CCN2 
(Forward) 
3’-GCTTACCGACTGGAAGACACG-5’ 61.8 NM_001901.
2 
233 bp 
CCN2 
(Reverse) 
3’-CGGATGCACTTTTTGCCCTT-5’ 57.3  
CCN3 
(Forward) 
3’-CACGGCGGTAGAGGGAGATA-5’ 61.4 NM_002514.
3 
251 bp 
CCN3 
(Reverse) 
3’-GGGTAAGGCCTCCCAGTGAA-5’ 61.4  
CCN4 
(Forward) 
3’-AAGAGAGCCGCCTCTGCAACTT-5’ 62.1 NM_003882.
3 
105 bp 
CCN4 
(Reverse) 
3’-TCATGGATGCCTCTGGCTGGTA-5’ 62.1  
PDGFR-α 
(Forward) 
3’-TGGGAGGGTGGTCTGGATGAG-5’ 63.7 (148) 
174 bp 
PDGFR-α 
(Reverse) 
3’-GATGAAGGTGGAACTGCGGGAAC-
5’ 
64.2  
MRTF-A 
(Forward) 
3’-TCCACCCCCACACTCATTAAG-5’ 59.8 NM_020831.
4 
67 bp 
MRTF-A 
(Reverse) 
3’-TCTTGCTGCGCTGTGACTTC-5’ 59.4  
Thy-1 
(Forward) 
3’-CCTGACCCGTGAGACAAAGAAG-5’ 62.1 (149) 
130 bp 
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Thy-1 
(Reverse) 
3’-
GCTAGTGAAGGCGGATAAGTAGAG-5’ 
62.7  
 
Table 2-5 List of primers used for qPCR.  If primers had previously been used a 
reference is given in column 4.  Ideal annealing temperatures are given in column 3, 
however the annealing temperature used in all experiments was 60°C. 
 
2.7.6 Quantitative PCR (qPCR) Materials 
 
• qPCR strip tubes and caps 0.1ml, Ref 981103, Qiagen, Manchester, UK 
• SensiMix SYBR Hi-ROX Kit (SYBR green), Ref QT605-02, Bioline, 
London, UK  
• Rotor Gene 6000 72 well plate qPCR machine, Corbett Life Science, Qiagen, 
Manchester, UK 
 
2.7.7 qPCR Methods 
 
A master mix containing SYBR green (10ul per sample), forward primer (0.6ul per 
sample), reverse primer (0.6ul per sample) and water (6.8ul per sample) was made.  
Diluted cDNA (2ul) was added to each well alongside the master mix (18ul).  qPCR 
was set up and performed using Rotor Gene 6000, 72 well plate quantitative PCR 
machine.   
A single hold step at 95°C for 10 minutes was commenced.  This was then followed 
by 40 cycles of 95°C for 10 seconds, 60°C for 15 seconds and 72°C for 20 seconds.  
A melt step was added to ensure single product formation.   
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2.7.8 Statistical Analysis for qPCR 
 
To calculate the fold change of particular genes of interest, the average CT value of 
the housekeeping gene (RPLPO) was subtracted from the average CT value of the 
experimental gene of interest giving a delta CT value (ΔCT). The ΔCT of the control 
cells was then subtracted from the ΔCT value of the TGF-β treated cells giving a 
delta-delta CT (ΔΔCT) value.  Given that calculations were logarithm base 2, the 
value of 2^(-ΔΔCT) was used to calculate a fold change.  Values were transferred to 
Prism software for calculation of significance using a two-way anova with 
Bonferroni post-test. 
When cells were treated with human plasma a fold change was not calculated so that 
variation between individual patients could be assessed.  Again, ΔCT values were 
calculated by subtracting the mean CT value of the housekeeping gene (RPLPO) 
with the mean CT value of the gene of interest for that individual patient or control 
sample.   An average ΔCT value was calculated for the control samples and all 
values plotted in relation to the mean value of this healthy control group.  Again 
values are in logarithm base 2.  Prism software was used to calculate significance 
using an unpaired two-tailed t-test. 
 
2.8 Agarose Gel 
2.8.1 Agarose Gel Materials 
 
• cDNA sample that had undergone qPCR as described above 
• 2% agarose gel, prepared as described in Appendix 4 
• Safe View Nucleic Acid Stain, NBS Biologicals, Cambridgeshire, UK 
• TAE buffer prepared as described in Appendix 4 
• 100 base pair ladder, New England Biolabs, Hertfordshire, UK 
• Biorad Chemidoc, Biorad laboratories limited, Hertfordshire, UK 
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2.8.2 Agarose Gel Methods 
 
To test that each primer produced just a single product a 2% agarose gel was made.  
The above contents were mixed in a sterile bottle and heated in the microwave to 
ensure the agarose had fully dissolved in the TAE.  Safe view nucleic acid stain (2ul) 
was then added to the solution to allow visualisation of the product.  The gel was 
poured into the appropriate casing and left for 30 minutes until fully set. The comb 
was removed and the gel immersed into 1% TAE buffer.  20ul of sample was loaded 
into each well and a reference ladder (New England Biolabs, Hertfordshire, UK) was 
added to the end well in each case.  The sample was ran through the gel at 70-90 
vaults until appropriately separated and then imaged using the chemidoc system 
(Biorad laboratories, Hertfordshire, UK). 
 
2.9 Western Blot 
2.9.1 Western Blot Materials 
 
2.9.1.1 Trichloroacetic Acid Protein Precipitation Materials 
 
• Trichloroacetic acid (TCA), Sigma-Aldrich, Dorset, UK 
• Urea-lysis buffer, prepared as described in Appendix 4 
 
2.9.1.2 Gel Preparation and Gel Electrophoresis  
 
• Protogel 30% (w/v) acrylamide: 0.8% (w/v) Bis-Acryl-amide stock solution, 
Geneflow, Staffordshire, UK  
• 4X Protogel resolving buffer 1.5M Tris-Hcl, 0.4% SDS, pH8.8, Geneflow, 
Staffordshire, UK 
• Protogel stacking buffer 0.5M Tris-HCl, 4% SDS, pH 6.8, Geneflow, 
Staffordshire, UK 
• Ammonium persulphate (10%) 
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• Tetramethylethylenediamine (TEMED), Sigma-Aldrich, Runcorn, UK 
• Ultrapure 10X Tris/Glycine/SDS running buffer, diluted to 1X, Geneflow, 
Staffordshire, UK 
• Protein loading buffer blue (2x), National Diagnostics, Nottingham, UK 
• Precision Plus Protein Dual Color standards ladder, BioRad, Hertfordshire, 
UK 
2.9.1.3 Transfer 
 
• Transfer Buffer prepared as described in Appendix 4 
• Whatman chromatography paper, Sigma-Aldrich, Dorset, UK 
• Amersham Protran premium 0.45um nitrocellulose blotting membrane, GE 
Healthcare Life Sciences, Buckinghamshire, UK 
 
2.9.1.4 Blocking and Antibody Incubation 
 
• Tris Buffered Saline (TBS) prepared as described in Appendix 4 
• Tris Buffered Saline with Tween (TBST) prepared as described in Appendix 
4 
• Ponceau S, Sigma-Aldrich, Dorset, UK 
• Marvel skimmed milk powder, Premier Foods, St Albans, UK 
 
Primary Antibodies Used for Western Blot 
 
Company Protein Product 
Code 
Antibody Type Dilution 
Abcam Collagen 1 ab34710 Rabbit polyclonal 1 in 1000 
Sigma-
Aldrich 
Fibronectin F3648 Rabbit polyclonal 1 in 1000 
 
Table 2-6  Primary Antibodies used in Western Blot with company, product code 
and dilution specified. 
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Secondary Antibodies Used for Western Blot  
 
Company Antibody Product Code Dilution 
Dako Swine anti-rabbit P0217 1 in 5000 
 
Table 2-7  Secondary Antibodies used in Western Blot with company, product code 
and dilution specified. 
 
2.9.1.5 Imaging 
 
• Super Signal West Dura Extended Duration Substrate, Thermo Scientific, 
Rockford, USA 
 
2.9.1.6 Equipment 
 
• Eppendorf centrifuge 5417R, Eppendorf, Stevenage, UK 
• Geneflow electrophoresis gel tank, Geneflow Limited, Staffordshire, UK 
• BioRad criterion blotter for transfer, BioRad, Hertfordshire, UK 
• Biorad Chemidoc, Biorad laboratories limited, Hertfordshire, UK 
 
2.9.1.7 Sample 
 
• Protein samples prepared by mixing 5ul protein sample, 5ul distilled water 
and 10ul of 2 x loading buffer. 
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2.9.2 Western Blot Methods 
 
2.9.2.1 Trichloroacetic Acid Protein Precipitation 
 
Conditioned medium (400ul) from each well was treated with 5% TCA (Sigma-
Aldrich, Dorset, UK), vortexed and placed at 4°C overnight.  Eppendorfs were then 
centrifuged for 30 minutes at 13,000 rpm at 4°C.  Supernatant was removed.  
Samples were centrifuged for a further 10 minutes at 13,000 rpm at 4°C to remove 
residual TCA.  Protein pellets were then re-suspended in urea-lysis buffer (20ul).  
Samples were stored at -80°C until required for western blot. 
 
2.9.2.2 Western Blot Gel Preparation and Gel Electrophoresis 
 
An 8% acrylamide resolving gel was prepared using 2.7ml 30% acrylamide, 2.5ml 
resolving buffer, 4.72ml distilled water, 200ul 10% ammonium persulphate (APS) 
and 20ul TEMED.  The lower resolving gel was allowed to set for roughly 30 
minutes at room temperature.  A small amount of ethanol was added along the top of 
each gel to remove any bubbles.  This was poured away prior to adding the stacking 
gel.   
A 4% stacking gel was prepared using 1.3ml 30% acrylamide, 2.5ml stacking buffer, 
6.1ml distilled water, 100ul ammonium persulphate and 25ul TEMED.  Combs were 
added for the formation of wells and the gel was allowed to set prior to use. 
Gels were immersed in 1 x running buffer. Samples (prepared as described above) 
were added to each well.  A ladder (5ul) was added to the end well of each sample 
for reference.  Samples were ran through the gel at 80V for 30 minutes, and this 
speed was increased to 100V until the proteins were separated. 
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2.9.2.3 Western Blot Transfer 
 
Proteins were transferred onto nitrocellulose membranes using the wet transfer 
method.  Items were soaked in transfer buffer before being stacked into a cassette in 
the order below.  The criterion blotter tank was filled with transfer buffer, the 
cassette was inserted and a charge ran at 250mA for 2 hours to transfer the protein to 
the nitrocellulose membrane. 
 
 
 
 
 
 
 
 
 
2.9.2.4 Western Blot Blocking and Antibody Incubation  
 
A Ponceau S stain (Sigma-Aldrich, Dorset, UK) was used to stain each blot and an 
image recorded for normalisation of the sample.  The stain was removed after rinsing 
with TBST. 
A 3% milk solution (40ml) was then used as a blocking agent for 1 hour.  The 
membrane was washed 3 times for 10 minutes each using TBST.  The primary 
antibody was added and incubated at 4°C on a rocker overnight.  The primary 
antibody was removed by washing the membrane 3 times for 10 minutes each at 
room temperature.  The secondary antibody was added for 2 hours and incubated at 
room temperature.  This was then removed by further washing of the membrane with 
TBST.   
 
 
 
 
 
 
Sponge 
Sponge 
3 chromatography 
paper 
3 chromatography 
paper 
Acrylamide gel 
Nitrocellulose 
membrane 
 
Figure 2-3 Diagram of the gel and membrane sandwich showing the order in 
which materials were stacked to facilitate the transfer. 
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2.9.2.5 Western Blot Imaging and Analysis  
 
The gel was imaged by washing the membrane with horse radish peroxidase (HRP) 
solution.  The Biorad Chemidoc was used to image the membrane.  Analysis was 
performed using Image J software to measure densitometry of the protein bands.  
Loading was normalised against ponceau staining.  
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3 Immunoprecipitation to Assess for Covert CTD-
ILD in Patients Diagnosed with IPF 
 
In this chapter the proportion of patients diagnosed with IPF that actually have an 
underlying CTD disclosed by serology was assessed.  Comprehensive serology was 
undertaken by immunoprecipitation, seen as the “gold-standard technique” for 
antibody interrogation and discovery, and is discussed in more detail in the materials 
and methods section.  Whether patients are assigned an “idiopathic” label but 
actually have an underlying CTD has been analysed in previous studies.  However, 
these were not performed in a UK population and patients had the diagnosis 
“Idiopathic Interstitial Pneumonia (IIP)” which includes any HRCT pattern 
consistent with “idiopathic” disease whereas this chapter specifically assesses 
patients assigned an IPF diagnosis.  The importance of distinguishing between IPF 
and other idiopathic diagnoses is now vital due to new treatment options and drug 
discovery in IPF.  Patients with a cellular NSIP or an organising pneumonia pattern 
are treated with steroids and therefore have treatment that would be given for an 
underlying CTD.  However, with an IPF diagnosis steroid treatment has been shown 
to shorten life expectancy and patients should instead be treated with newer, anti-
fibrotic medications such as pirfenidone and nintedanib (15).  It is, therefore, vital 
that the issue of diagnostic error in IPF in UK hospitals is assessed and quantified. 
As previously mentioned there have been other studies to assess the role of serology 
in diagnosing patients with ILD.  A study published by Song et al retrospectively 
analysed patients diagnosed with IIP in a Korean hospital, who had undergone line-
blot immunoassay able to detect 11 myositis autoantibodies.  The authors found that 
38% of patients had a recognised MSA or MAA present (70).  Unfortunately, the 
authors did not discuss HRCT patterns of these patients, nor if their serology results 
led to a change in clinical management.  Similarly, when serology was assessed in a 
Japanese population, 6.6% of patients had evidence of an antisynthetase antibody.  It 
should be noted that, although none of the latter patients had evidence of a UIP 
pattern on HRCT, 2 patients who underwent a lung biopsy had a UIP pattern 
histologically, allowing for the possibility of a diagnosis of IPF (69).  The authors 
used the immunoprecipitation procedure but were only detecting six antisynthetase 
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antibodies and were not assessing for the rarer synthetases or other CTD antibodies, 
making this study less comprehensive for detecting antibodies.   
Another Japanese study followed 168 patients with a diagnosis of IIP.  Using an 
enzyme-linked immunosorbent assay (ELISA) system, 10.7% of patients were 
positive for antisynthetase antibodies.  These authors did collect data regarding the 
HRCT pattern of each group, and 5.6% of patients assigned an IPF diagnosis had an 
antisynthetase and 12.1% of patients with an HRCT pattern other than UIP had an 
antisynthetase antibody present (150).  To our knowledge no study has analysed 
patients with a diagnosis of IPF made in a UK centre and undertaken 
immunoprecipitation to assess for the presence of a CTD-associated antibody.  It is 
vital to ascertain the degree of diagnostic error to assess whether patients assigned an 
IPF diagnosis are being treated appropriately in the UK. 
 
3.1 Case Recruitment and Accrual 
 
As mentioned in the previous chapter, patients with ILD were recruited into the UK-
BILD study.  This is a multi-centre collaboration involving 38 UK sites.  Figure 3-1 
gives a breakdown of patients recruited into the study by ILD sub-group.  It should 
be noted that recruitment of IPF patients was suspended as it was ascertained that 
enough participants had been recruited for any future genetic research within 1 year 
of opening.  According to the histogram showing accrual, it would appear that 
sarcoid is almost as prevalent as IPF, but this is misleading as IPF cases had reached 
this number within 1 year of recruitment and then further case recruitment was 
suspended, allowing other subgroups to appear more prevalent in relation. 
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Figure 3-1  Recruitment of patients into the UK-BILD study separated into ILD 
subgroups.  There have been 2624 patients recruited into the study, with IPF the most 
prevalent form of ILD. 
As can be seen in Figure 3-1 even with 38 centres recruiting there are still very few 
cases collected into some of the rarer forms of ILD, such as Acute Interstitial 
Pneumonia (AIP).  It is therefore essential that multi-centre collaboration continues 
to allow for investigation into some of these rarer subgroups. 
 
3.2 Autoantibody Results 
 
Autoantibody testing by immunoprecipitation was performed by Dr Zoe Betteridge a 
postdoctoral scientist located at the University of Bath.  The procedure was 
undertaken on 249 patients diagnosed with IPF and recruited into UK-BILD.  
Immunoprecipitation was performed using the materials and methods as described in 
section 2.2.   
0
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The procedure produces a gel, which is analysed by autoradiography and this gives 
bands at certain molecular weights which may correlate with a recognised 
autoantibody.  An example is given in the materials and methods section and a 
further example is given below; 
 
 
Figure 3-2 Further example of an immunoprecipitation gel kindly provided by Dr 
Zoe Betteridge.  The above example shows positive controls in lane 1 (anti-Ku and 
anti-Mi-2), lane 2 (anti-MDA5), lane 3 (anti-SAE and anti-RNAPI / III), lane 4 (anti-
U3 and anti-TIF1), lane 5 (anti-SRP and anti-topoisomerase), lane 10 (anti-OJ) and 
lane 11 (anti-EJ).  The other lanes show various patients from the UK-BILD study.  
Lane 6 shows an unknown strong band at 54 kDa, it shows weak bands at 68, 70 and 
105 kDa.  Lane 7 shows strong bands present at 28, 31 and 54 kDa, it shows weak 
bands at 30 and 120 kDa.  Lane 8 shows strong bands present at 54, 65 and 90 kDa 
and weaker bands at 64, 120 and 200 kDa.  Lane 9 shows strong bands present at 54 
kDa.  Weaker bands were present at 30, 31, 66, 68, 105 and 150 kDa.  Thereby lanes 
6-9 all had the same strong, unknown band present at 54kDa, discussed in more 
detail below.  Lane 12 shows a strong band at 95 kDa and weaker bands at 130, 150 
and 170 kDa.  Lane 13 shows a strong unknown band at 65 kDa and a weaker band 
present at 140 kDa. 
  
            Lane no.      1     2    3    4    5    6    7    8    9   10  11  12  13    
240kDa 
54kDa 
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Patients were therefore divided into those with no strong bands present on 
immunoprecipitation, those with strong bands present but not corresponding to a 
recognised CTD-associated autoantibody, those that had a recognised MSA / MAA 
present and patients who had a strong band present at 54 kDa.  The results are shown 
in the table below; 
 
Immunoprecipitation Result Number of patients 
No strong bands present on immunoprecipitation  146 (58.6%) 
Strong bands present on immunoprecipitation but not 
corresponding with a recognised CTD-associated antibody 
91 (36.5%) 
MSA / MAA positive result 4 (1.6%) 
54 kDa band present 7 (2.8%) 
 
Table 3-1  Results of Immunoprecipitation.  Table showing patients assigned a 
diagnosis of IPF and whether a recognised antibody was shown in their sera.  One 
patient was excluded from analysis due to reasons described below. 
 
Of the 249 patients tested, 4 (1.6%) had a recognised MSA or MAA present in their 
sera.  One patient had an anti-mitochondrial antibody present which was associated 
with confirmed primary biliary cirrhosis, but the antibody is not associated with ILD, 
so this patient was taken out of the analysis.  The other antibodies present included 
anti-OJ, anti-PM-Scl, anti-ku and anti-RNA Pol II, with one patient in each group 
respectively.  There were also 7 (2.8%) patients who had an unknown but very strong 
identical band present at 54 kDa, represented separately in row 4 of Table 3-1.  It is 
difficult to undertake subgroup comparisons given the small numbers of patients who 
had evidence of a recognised MSA / MAA or a new band found at 54kDa.  Any p 
values would not be meaningful given that the group sizes are so uneven and that 
there were so few patients with an antibody present.   
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A further 91 IPF patients (36.5%) had strong unknown bands on 
immunoprecipitation, but which did not correspond to any known CTD autoantigen.  
These were analysed separately to the 146 (58.6%) patients diagnosed with IPF who 
did not have strong bands present when examined by immunoprecipitation.  The data 
is not published, but from the experience of the National Immunoprecipitation 
Laboratory at the University of Bath only ~ 20% of healthy control patients have 
bands present on immunoprecipitation but these are generally weak and non-specific.  
They estimate that less than 10% of these healthy subjects would be expected to have 
strong bands present.  This suggests that there is a larger prevalence of strong bands 
in patients with IPF, suggestive of a currently unelucidated immunological 
component to the disease.  The group has therefore been separated to assess if there 
are any distinguishing characteristics in these patients. 
 
3.3 Patient Demographics  
 
Demographic data was collected on the UK-BILD proforma and included 
information regarding age, gender and ethnicity.  Initially the demographic data of 
the patients was compared to assess if there was a significant difference between age 
or gender of the four groups.  All UK-BILD patients in the study were Caucasian to 
allow for any future genetic testing to occur once it could be assured that all patients 
were antibody negative.  It can be seen from Table 3-2 that predominantly more 
males are affected at 70 years old.  This did not differ between those who were 
antibody negative with no strong bands on immunoprecipitation, those with strong 
bands present, those who had an underlying MSA / MAA or those with the 54kDa 
band.  This is similar to demographic data previously published that also suggest that 
IPF is more prevalent in older, male patients (11).  These subtle clues are important 
for clinicians to rule out an underlying CTD, for example a younger patient would be 
less likely to have IPF and many CTDs (e.g. SSc) have a higher prevalence in female 
patients. 
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Demographic 
information 
No strong 
bands (n=146) 
Unknown 
strong bands 
(n=91) 
MSA / MAA 
positive result  
(n=4) 
54 kDa Band 
(n=7) 
Gender Male 117 
(80.1%) 
Female 29 
(19.9%) 
 
Male 64 
(70.3%) 
Female 27 
(29.7%) 
Male 3 (75%) 
Female 1 
(25%) 
Male 5 
(71.4%) 
Female 2 
(28.6%) 
Age Median age: 74 
years 
Age range: 50-
94 years 
Median age: 
72 years 
Age range: 50-
89 years 
Median age: 
70 years 
Age range: 58-
76 years 
Median age: 
71 years 
Age range: 63-
83 years 
Ethnicity Caucasian 146 
(100%) 
Caucasian 91 
(100%) 
Caucasian 4 
(100%) 
Caucasian 7 
(100%) 
 
Table 3-2  Patient demographic data showing proportion of males, age when 
recruited to the study and ethnicity. 
 
3.4 Smoking Data 
 
Data was collected within the UK-BILD study regarding smoking history.  It was 
recorded whether patients were past, current or never smokers and the pack year 
history was recorded to give an idea of heavy smoking. 
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Smoking 
history 
Pack Year 
History 
No strong 
bands 
(n=146) 
Unknown 
strong 
bands 
(n=91) 
MSA / 
MAA 
positive 
result (n=4) 
54kDa 
Band 
(n=7) 
Current 
smoker 
 1 (0.7%) 3 (3.3%) 0 (0%) 2 
(28.6%) 
<20 pack 
years 
1 (0.7%) 2 (2.2%) 0 (0%) 0 (0%) 
>20 but <40 
pack years 
0 (0%) 0 (0%) 0 (0%) 1 
(14.3%) 
>40 pack 
years 
0 (0%) 1 (1.1%) 0 (0%) 1 
(14.3%) 
Ex-smoker  110 
(75.3%) 
63 (69.2%) 3 (75%) 3 
(42.9%) 
<20 pack 
years 
48 (32.9%) 30 (33%) 2 (50%) 3 
(42.9%) 
>20 but <40 
pack years 
40 (27.4%) 24 (26.4%) 1 (25%) 0 (0%) 
>40 pack 
years 
21 (14.4%) 9 (9.9%) 0 (0%) 0 (0%) 
Unknown 1 (0.7%) 0 (0%) 0 (0%) 0 (0%) 
Never 
smoker 
 36 (24.7%) 25 (27.5%) 1 (25%) 2 
(28.6%) 
 
Table 3-3  Patient demographic data showing differences in smoking history 
between patients with IPF who had no strong bands, the presence of unknown strong 
bands on immunoprecipitation, those with an MSA / MAA present and those with an 
unknown band at 54kDa. 
 
Interestingly, the majority of patients with IPF were previous smokers.  However, 
there was a significant proportion of patients who have never smoked.  There did not 
appear to be any appreciable difference in smoking history between the three groups 
of patients although it is difficult to draw firm conclusions based on the limited 
number of patients in the MSA / MAA positive or 54kDa groups. 
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3.5 IPF Diagnostic Subgroup 
 
Patients were divided by IPF diagnostic subgroup, separated according to HRCT 
appearances and the availability of lung histology as discussed in the introduction 
(section 1.3.3).  The proportion of patients from each category is shown in the table 
below. 
 
IPF Subgroup No strong 
bands (n=146) 
Unknown 
strong bands 
(n=91) 
 
MSA / MAA 
positive result 
(n=4) 
54 kDa 
band (n=7) 
Definite UIP 
 
90 (61.6%) 67 (73.6%) 3 (75%) 4 (57.1%) 
Definite 
Fibrotic NSIP 
17 (11.6%) 7 (7.7%) 1 (25%) 0 (0%) 
Probable 
Fibrotic NSIP 
39 (26.7%) 17 (18.7%) 0 (0%) 3 (42.9%) 
 
Table 3-4  Patients separated according to IPF diagnostic subgroup. 
 
It is possible that more patients who are found to have an underlying CTD would be 
in the probable category.  These patients have less obvious changes on HRCT with a 
fibrotic NSIP pattern distinguished by a lack of honeycombing, and cannot undergo 
lung biopsy due to underlying co-morbidities.  However, more antibody positive 
patients had a definite UIP pattern on HRCT and were not from the less robust 
diagnostic categories.  It is already known that patients can have a UIP pattern with 
CTD-ILD, and this can lead to diagnostic error.  However, it should be considered 
that these are very small numbers of patients and overall the diagnosis of IPF is very 
definite.  
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3.6 Specificity of CTD Features 
 
Clinicians were asked to record information regarding the presence of symptoms of 
an underlying CTD in all patients recruited to the UK-BILD study.   
 
CTD Feature No strong 
bands (n=146) 
Strong 
bands 
(n=91) 
 
MSA / MAA 
positive result 
(n=4) 
54 kDa band 
(n=7) 
Raynaud’s 
phenomenon 
4 (2.7%) 0 (0%)  0 (0%) 0 (0%) 
Arthritis 3 (2.1%) 1 (1.1%) 0 (0%) 0 (0%) 
Sclerodactyly 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Calcinosis 0 (0%) 0 (0%)  0 (0%) 0 (0%) 
Raised CK 1 (0.7%) 0 (0%) 0 (0%) 0 (0%) 
Mechanics hands 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Myalgias 0 (0%) 0 (0%)  0 (0%) 0 (0%) 
Periungal 
erythema 
11 (7.5%) 9 (9.9%) 0 (0%) 1 (14.3%) 
Telangiectasia 1 (0.7%) 0 (0%) 0 (0%) 0 (0%) 
 
Table 3-5  Prevalence of CTD features in patients assigned a diagnosis of IPF before 
immunoprecipitation had been undertaken.  Groups are divided into those without 
strong bands on immunoprecipitation, those with strong bands present although of no 
known antibody, those with recognised MSA / MAA present and those with an 
unknown band present at 54kDa. 
 
As would be expected, patients assigned a diagnosis of IPF had very few CTD 
features present.  Interestingly, those patients with an MSA or MAA present also did 
not have any CTD features, including any subtle abnormalities such as mechanic’s 
hands or symptoms common in the general population such as myalgia.  Features 
such as periungal erythema (7.5%), Raynaud’s phenomenon (2.7%) and arthritis 
(2.1%) were present in the group that were completely negative on 
immunoprecipitation, presumably meaning they were not specific for an underlying 
CTD.  It should be noted that one limitation of assessing for these features is that 
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recruitment was conducted at individual centres and clinicians may have various 
expertise in assessing for subtle signs. 
 
3.7 Specificity of Respiratory Features 
 
In a similar manner, clinicians were asked to record the presence of respiratory 
features in patients recruited to the study.  These respiratory features are shown in 
Table 3-6 below. 
Respiratory 
Feature 
No strong 
bands (n=146) 
 
Strong 
bands 
(n=91) 
 
MSA / MAA 
positive 
result (n=4) 
54 kDa band 
(n=7) 
Clubbing 47 (32.2%) 
 
30 (33%) 3 (75%) 2 (28.6%) 
Pulmonary Arterial 
Hypertension (PAH) 
- Echo Criteria 
- Right heart 
catheter criteria 
5 (3.4%) 
 
5 (3.4%) 
0 
1 (1.1%) 
 
0 
1 (1.1%) 
0 
 
0 
0 
0 
 
0 
0 
 
Table 3-6  Prevalence of respiratory features in patients with a diagnosis of IPF. 
Groups divided into those who lack strong bands on immunoprecipitation, those with 
strong bands present although no known antibody, those with recognised MSA / 
MAA present and those with an unknown band present at 54kDa.  
 
Clubbing is present in a significant number of patients with IPF but this was also 
present in patients with an MSA or MAA present, suggesting the presence of 
clubbing did not accurately exclude an underlying CTD.  A small number of patients 
who were antibody negative had PAH.  In IPF, PAH is usually associated with very 
severe, end-stage disease (151).  PAH was not present in patients with an underlying 
MSA / MAA or with the 54kDa band present, however, such small numbers of 
patients were examined in these groups that it is under powered to assess the 
significance.  
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3.8 Association with Malignancy 
 
Participating centres were required to document whether patients had a current or 
previous history of malignancy.  The results are shown in the table below and have 
been divided into skin, haematological and solid organ tumours.   
 
Type of 
Malignancy 
No strong 
bands (n=146) 
 
Strong bands 
(n=91) 
MSA / MAA 
positive 
result (n=4) 
54 kDa band 
(n=7) 
Skin 4 (2.7%) 
Basal Cell 
Carcinoma (2) 
Squamous Cell 
Carcinoma (2) 
2 (2.2%) 
Basal Cell 
Carcinoma (1) 
Squamous 
Cell 
Carcinoma (1) 
0 0 
Haematological 2 (1.4%) 
Chronic 
Lymphocytic 
Leukaemia (1) 
Leukaemia 
(unspecified) / 
Non-Hodgkin’s 
Lymphoma (1) 
1 (1.1%) 
Non-
Hodgkin’s 
Lymphoma 
(1) 
0 0 
Solid Organ 10 (6.8%) 
Prostate (2) 
Breast + Renal 
(1) 
Breast (1) 
Bladder (2) 
Colon (3) 
Laryngeal (1) 
2 (2.2%) 
Colon (1) 
Tongue (1) 
0 0 
 
Table 3-7  Prevalence of skin, haematological and solid organ malignancies in 
patients with a diagnosis of IPF. Groups divided into those who lack strong bands on 
immunoprecipitation, those with strong bands present although no known antibody, 
those with recognised MSA / MAA present and those with an unknown band present 
at 54kDa. 
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The prevalence of malignancy in this cohort was 8.4%, however the average age of 
the patients was 73 years old and many of those were previous smokers.  A range of 
malignancies was noted with no noticeable pattern emerging. 
 
Time since 
malignancy 
diagnosed 
(years) 
No strong 
bands (n=146) 
Malignancy 
Diagnosis 
(n=16 – 2 
patients with 
multiple 
malignancies) 
Strong bands 
(n=91) 
Malignancy 
Diagnosis 
(n=5) 
MSA / MAA 
positive result 
(n=4) 
Malignancy 
Diagnosis 
(n=0) 
Unknown 
bands at 54 
kDa (n=7) 
Malignancy 
Diagnosis 
(n=0) 
Less than 1 
year 
0 0 0 0 
1-5 years 4 2 0 0 
6-10 years 4 2 0 0 
More than 10 
years 
9 1 0 0 
Unknown 1 0 0 0 
 
Table 3-8  Number of years since a malignancy diagnosis depending on IPF 
subgroup. For patients with multiple diagnoses of malignancy each has been counted 
separately, hence the numbers do not tally to the total number of patients as one 
patient had both breast and renal cancer and another had an unspecified diagnosis of 
leukaemia followed by a separate diagnosis of Non-Hodgkin’s Lymphoma.   
  
As noted in Table 3-8 above many of the malignancy diagnoses are historic and this 
would be expected in an older population.  The group did not appear to be linked to 
any recent diagnoses of malignancy, with no patients being diagnosed in the 
preceding year.  It should be noted that this was a cross-sectional study and therefore 
it did not follow patients to assess if they develop a subsequent malignancy. 
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3.9 MSA / MAA Positive Group 
 
As such a small number of MSA and MAA were found it is easier to discuss the 
implications of each antibody in turn.   
Anti-OJ is an MSA and one of the 8 recognised antisynthetase antibodies, directed 
against anti-isoleucyl-tRNA synthetase.  Anti-OJ positive patients may present with a 
negative Antinuclear Antibody (ANA) as the synthetase antigen is cytoplasmic rather 
than nuclear.  It is one of the rarer antisynthetase antibodies, found in less than 5% of 
patients with IIM and an MSA present. However, it can be found in patients who 
present with ILD alone and so the frequency may be higher than predicted (39, 40).  
As it is such a rare antibody most of the available data is based on retrospective 
observations of small patient cohorts.  One study found that 63% of patients with the 
antibody presented with ILD alone, with just 13% and 25% of patients having a 
classical DM rash or PM signs respectively (40).   During the follow up period, 
100% of patients developed ILD.  Another study of 7 patients with the antibody 
similarly showed that 100% of the patients had ILD whereas just 4 patients 
developed muscle weakness, suggesting it is more strongly associated with ILD than 
with myositis (39).  The estimated 5-year survival of patients with anti-OJ antibodies 
is estimated at 60% in a study where pulmonary fibrosis accounted for 50% of all 
deaths in patients with ASS (152). 
Anti-PMScl was present in the serum of 1 patient.  This antibody occurs in myositis-
scleroderma overlap disease and is a recognised MAA.  Hep-2 screening on patients 
with this antibody usually shows a homogeneous nucleolar staining pattern (153).  In 
a meta-analysis that included 116 patients with anti-PMScl antibodies, 76% of 
patients had evidence of sclerodactyly and 74% had Raynaud’s phenomenon 
showing its clear association as an overlap antibody.  It also has a strong association 
with ILD, with 38% of patients having documented evidence of ILD (45). 
The presence of another MAA was discovered in 1 patient, which was the anti-ku 
antibody.  This is found in a variety of CTD diagnoses including SSc, SLE, RA and 
UCTD (154).  Hep-2 screening on patients with anti-ku shows dense, fine speckled 
staining of the nucleus, with nucleoli staining possible (153).  The presence of the 
antibody is specific for an autoimmune disease.  One study retrospectively examined 
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30 patients with the antibody.  It was strongly associated with arthralgia which was 
reported in almost 80% of patients and Raynaud’s phenomenon in just over half of 
the patients.  Nearly 40% of patients had myositis and the same proportion had 
evidence of ILD on HRCT scan.  Of these, 3 patients had a UIP pattern present 
suggesting that the diagnosis could be mistaken for IPF (155). 
The final antibody detected by immunoprecipitation was anti-RNAP II.  There are 3 
antibodies directed against the RNA polymerases, labelled RNAP I, II and III 
respectively.  The anti-RNAP antibodies are found in around 20% of patients with 
SSc (61, 156).  Anti-RNAP I and III frequently occur together, are found in patients 
with SSc and those with the antibody have a higher frequency of SSc renal crisis. 
Anti-RNAP II antibodies may be found in SSc as well as occurring in SLE and 
UCTD.  They are often found alongside other autoantibodies including Anti-RNAP I 
and III and anti-topoisomerase (157).  As anti-RNAP autoantibodies are not 
frequently found in isolation, it is difficult to assess their association with ILD.  
However, when associated with anti-topoisomerase antibody 55-75% of patients 
developed ILD and 50% of patients developed ILD when it was associated with 
Anti-RNAP I and III (156). 
 
3.10  Discussion 
 
This chapter highlights the fact that chest physicians are very good at distinguishing 
IPF from other ILD subsets.  It should be noted that immunoprecipitation may rule 
out a number of CTDs, but does not exclude other mimicking conditions such as 
asbestosis.  However, the working hypothesis for this component of the PhD was that 
chest physicians were potentially missing subtle features of an underlying CTD. 
This, however, does not appear to be the case. 
There are only a very small number of patients who had CTD-associated antibodies 
detected in their sera, and thus suggestive of an underlying CTD.  It is vital that IPF 
and CTD-ILD groups are accurately distinguished as there are treatment differences 
between IPF patients and CTD patients.  Patients with an underlying CTD respond 
well to immunosuppression while such treatment increases mortality in those with 
IPF.  This study therefore provides reassurance that the majority of patients assigned 
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an IPF diagnosis by use of guidelines and HRCT are indeed commencing the correct 
treatment.   
Of the IPF patients uncovered as having an underlying CTD, all 4 were diagnosed in 
secondary care rather than in tertiary ILD centres.  Although the numbers were very 
small, and this should be kept in mind, it does support previous work that IPF 
diagnoses should be made in a specialist setting with a specialised MDT (158). 
Although the number of patients with an underlying autoantibody associated with 
ILD in this cohort is low, it is of interest to discuss whether patients with different 
scan appearances may actually have a higher prevalence of undisclosed CTDs.  For 
example, in a diagnosis such as COP or cellular NSIP would a higher proportion of 
patients have an underlying CTD, as disclosed by serotyping using 
immunoprecipitation?  The HRCT appearances of COP and cellular NSIP are much 
more common in myositis and SSc and it is therefore possible that there are more 
covert CTD cases in this group of patients.   
This work has also shown the importance of Hep-2 ANA testing.  Many of the 
autoantibodies recognised in this cohort show particular patterns by Hep-2 screening 
and therefore this specialised test may be helpful to clinicians who do not have 
access to immunoprecipitation which can be costly and labour intensive.   
The work undertaken here has shown that IPF is a distinct disease and gives a group 
of patients, that have actively had the presence of an underlying CTD excluded, to do 
further studies.  It has given confidence that respiratory physicians are good at 
clinically distinguishing between IPF and other causes of ILD.   
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4 Developing an in vitro Model of Fibrosis to 
Investigate Underlying Pathogenesis 
 
In this chapter the development of an in vitro model of fibrosis, to investigate the 
underlying pathological mechanisms relating to the fibrotic process is presented. This 
model was used to assess for biomarkers of disease.  Two cell types, implicated in 
the development of pulmonary fibrosis, were cultured and treated with TGF-β, a pro-
inflammatory cytokine that is known to induce fibrosis.  This preparatory work was 
undertaken to recreate the basic in vitro response of different cell types driven by 
TGF-β, and to develop methods by which to measure changes in cellular pathways 
and inflammatory cytokines in an accurate and reproducible way.  Perfecting this 
model will allow investigation into the mechanisms driving fibrosis in two cell types, 
the MRC5 fibroblasts and the A549 epithelial cells. 
Fibroblasts and epithelial cells were chosen for this work as they are two cell types 
implicated in processes of fibrosis, which are discussed in more detail in the initial 
introduction.  The MRC5 cell line are normal human lung fibroblasts developed from 
the lung tissue of a human foetus in 1966, the cells are therefore of a normal 
phenotype (159).  MRC5 fibroblasts are therefore an established cell line, which has 
been used in a variety of studies.  These cells are present in the normal pulmonary 
interstitium and it was previously thought that an external trigger activates the 
fibroblast leading to its transformation into a myofibroblast, cells that are more 
contractile than fibroblasts with an increase in the presence of α-SMA.  
Myofibroblasts produce and secrete excess ECM proteins including collagen and 
FN-EDA.  However, the hypothesis that myofibroblasts are activated fibroblasts 
which are solely responsible for excessive ECM production is no longer accepted 
and it has been suggested that myofibroblasts are derived from a variety of cell types.  
Hence work has also been undertaken on epithelial cells. 
The A549 alveolar epithelial cell line was derived from an adenocarcinoma of the 
lung in 1972 (160).  They are type II alveolar epithelial cells, and they are also an 
established cell line that has been used in multiple studies.  It has been noted that, 
despite being from a cancerous cell lineage, these cells retain the phenotype and 
metabolic properties of type II alveolar epithelial cells (108).  Unfortunately, there 
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are obvious drawbacks to using a cancerous cell line as cells will not be truly 
“normal” in phenotype.  There is evidence to suggest that EMT occurs in fibrosis, 
described in detail in the initial introduction, and this causes transition of epithelial 
cells into a myofibroblast.  This process likely contributes to a small percentage of 
the myofibroblast pool.  
The aim of this chapter is to assess what effects a pro-inflammatory cytokine will 
have when used at different concentrations to treat these two different cell types.  
The chapter will investigate whether these effects are measurable using a variety of 
techniques, including qPCR, immunocytochemistry and western blot, to assess 
changes in fibrosis associated genes and proteins.  It will also assess the 
reproducibility of the TGF-β driven changes. 
  
4.1 Validation of qPCR Primer Sets 
 
To create accurate primers for qPCR a literature search was undertaken to assess if 
primers had been used previously for investigating the gene of interest.  If such work 
had been undertaken, the sequence was transferred to the National Centre for 
Biotechnology Information (NCBI) primer-BLAST page to assess primer specificity 
(161).  If the primer pair was designed the same website was used to ensure specific 
targets.  The ideal primer should give an amplified region between 60-150 base pairs 
(bp) and should be separated by an exon-exon boundary to reduce the risk of 
amplification from genomic DNA contamination.  The produced primer pair was 
then tested by using a four-fold serial dilution to produce a standard curve to assess 
for the assay efficiency.  Efficiency was calculated from the slope of the standard 
curve, with a value of -3.32 indicating 100% efficiency.  A melt curve was checked 
to ensure that a single product was formed (Figure 4-1).  As a final check, the PCR 
product was run on a gel to ensure that only a single product had been produced 
(Figure 4-2). 
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Figure 4-1 Melt curve to show only a single product had been formed.  At the end of 
the qPCR cycles, SYBR green fluoresces as it is incorporated into the double-
stranded DNA product.  The reaction mixture is then heated in increments, until this 
strand denatures into single-stranded DNA, releasing the SYBR green and reducing 
the measured fluorescence.  If only a single product has been formed, a single peak 
should be produced, occurring at the same temperature for all samples. The melt 
curve for RPLPO is given as a representative example above, and shows a single 
peak occurring at 83°C. 
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Figure 4-2  Agarose gel showing single product formation for qPCR products.  
Products for the housekeeping gene RPLPO, MRTFa, TGF-β receptor (not used), 
PDGFR-α, CCN4, CCN1, COL1A1, COL3A1, Fibronectin-EDA, CCN2, slug and 
snail are represented in the above figure. 
 
4.2 The Effect of TGF-β Treatment on Fibroblast (MRC5) 
Cells  
  
Preliminary work was undertaken to assess if treating MRC5 fibroblasts with 
increasing concentrations of the pro-inflammatory cytokine TGF-β would cause a 
change in the morphology of the cells.  This was initially assessed visually, with a 
representative example of changes observed after 48 hours given in Figure 4-3.   
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4.2.1 The Effect of TGF-β Treatment on the Morphology of MRC5 
Fibroblasts  
 
 
Figure 4-3  Change in morphology of MRC5 cells treated with TGF-β.  (a) Control 
cells maintained in baseline conditions without TGF-β, (b) MRC5 cells treated with 
0.5ng/ml TGF-β for 48 hours, (c) MRC5 cells treated with 1ng/ml TGF-β for 48 
hours; (d) MRC5 cells treated with 2ng/ml TGF-β for 48 hours.  Fibroblasts treated 
with increased concentrations of TGF-β appeared enlarged with a possible increase 
in proliferation.  Magnification x10 objective lens, scale bar 10µm. 
 
Figure 4-3 shows that treatment with TGF-β led to enlarged cells with the possibility 
of increased proliferation (discussed in further detail later in the chapter).  Previous 
literature has suggested that these cells are a “myofibroblast”, activated fibroblasts 
that produce αSMA.   
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4.2.2 Immunolocalisation of Fibroblast Markers in MRC5 cells 
Treated with TGF-β 
 
Immunocytochemistry was undertaken to assess if myofibroblast transformation had 
occurred, and whether the treated cells were producing more of this contractile 
protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
Figure 4-4  MRC5 cells stained for phalloidin (green) and α-SMA (red).  (a) Staining 
for αSMA in untreated control cells after 48 hours showed no red colour, (b) cells 
under same conditions but treated with TGF-β 2ng/ml for 48 hours.  MRC5 cells 
treated with TGF-β showed increased red staining to confirm production of more α-
SMA in the treated cells.  Magnification x10 objective lens, scale bar 200μm. 
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Figure 4-5  MRC5 cells stained for phalloidin (green) and α-SMA (red) after 48 hours 
shown at higher magnification.  (a) control cells stained for phalloidin and α-SMA, (b) 
same image with phalloidin staining removed, (c) cells treated with TGF-β 2ng/ml for 48 
hours and stained for phalloidin and α-SMA, (d) same image with phalloidin staining 
removed.  The image shows that more α-SMA is produced by cells treated with TGF-β, 
again suggesting that cells were becoming more “myofibroblast-like”.  Magnification x20 
objective lens, scale bar 100μm. 
(c) (d) 
(a) (b) 
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Figure 4-4 and Figure 4-5 show the results of immunocytochemistry performed on 
MRC5 cells to assess for changes in α-SMA production.  The images show very little 
production of α-SMA in the untreated, control cells.  After treatment with TGF-β, 
there was an increase in expression of α-SMA within the cell.  This association has 
been shown in previous literature (162).  This result suggests that the cells are 
responding to TGF-β by increasing production of α-SMA to become more 
“myofibroblast-like”. 
 
Cells were also stained for COL1A1, the results of which are shown in Figure 4-6 
and Figure 4-7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6   MRC5 cells stained for phalloidin (green) and COL1A1 (red).  (a) 
Untreated control cells in baseline conditions, (b) cells under same conditions but 
treated with TGF-β 2ng/ml for 48 hours.  It is difficult to establish any differences in 
the production of COL1A1 from these images given the abundance of COL1A1 in 
baseline conditions.  Magnification x20 objective lens, scale bar 100µm. 
(a) (b) 
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The images above show that the MRC5 fibroblasts already produced a lot of 
COL1A1 before treatment with TGF-β.  It was unclear from the 
immunocytochemistry images whether more COL1A1 was produced after treatment 
as such a large amount is produced before treatment with TGF-β.  The COL1A1 is 
found in the cytoplasm of the cell, surrounding the nucleus. 
 
 
 
 
 
 
(a) (b) 
Figure 4-7 MRC5 cells stained for phalloidin (green) and COL1A1 (red).  (a) 
Untreated control cells in baseline conditions, (b) cells under same conditions but 
treated with TGF-β 2ng/ml for 48 hours.  It remains difficult to assess for any 
increase in COL1A1 production.  Magnification x40 objective lens, scale bar 
100µm. 
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4.2.3 The Effect of TGF-β Treatment on the Proliferation of MRC5 
Fibroblasts 
 
It was unclear whether the MRC5 fibroblasts were proliferating in response to 
treatment with TGF-β, or whether the cells were becoming larger to give the 
impression of an increase in cell number.  For this reason, a number of experiments 
were performed to assess if this treatment induces an increase in cell number at 24, 
48, 72 and 96 hour time points respectively. 
Initially a fluorescence assay was used, the trade name being alamar blue.  This 
contains a weakly fluorescent indicator dye called Resazurin, which permeates 
through the cell where it is affected by cell metabolism and on being reduced to 
Resorufin becomes strongly fluorescent.  The fluorescence emitted is then measured 
with results being directly proportional to the number of metabolically active cells.  
 
 
Figure 4-8  MRC5 cells treated with increasing concentrations of TGF-β and then 
fluorescence measured with alamar blue.  These results show that treatment with 
TGF-β reduces proliferation of MRC5 fibroblasts in a dose-dependent response.  
Results are expressed as mean values (n= 4) with error bars +/- SD.  Two-way anova 
with Bonferroni post-test was performed, ***p<0.001. 
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The only significant difference in this experiment was shown between control cells 
and cells treated with TGF-β 2ng/ml where there was a significant reduction in cell 
proliferation at the 72 hour time point.  Surprisingly, although not significant, there 
appeared to be a general reduction in proliferation of cells treated with TGF-β, with a 
dose-response trend.  However, these results seem to oppose the findings in the cell 
morphology experiment.  It may be that fibroblasts stimulated with TGF-β enlarge 
which gives the appearance of apparently increased proliferation.  It may also cause 
changes in the cell, which prevents them from remaining healthy and metabolically 
active, thus leading to the differences seen in the alamar blue assay at 72 hours. 
As a further experiment, MRC5 cells were stained for Proliferating Cell Nuclear 
Antigen (PCNA) antibody.  This molecule has an essential role in DNA replication 
and is thus expressed in proliferating cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
Figure 4-9  MRC5 proliferation assessed by PCNA staining. (a) Untreated, control 
cells under baseline conditions, (b) Cells treated with TGF-β 2ng/ml for 48 hours.    
There appears to be a reduction in proliferation of MRC5 fibroblasts in cells treated 
with TGF-β shown by a reduction in cell number above.  Magnification x10 objective 
lens, scale bar 100μm. 
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Figure 4-9 shows that cells appeared to be proliferating well at 48 hours, whether 
untreated or treated with TGF-β 2ng/ml.  There did appear to be a reduction in the 
number of proliferating cells present after 48 hours when they were treated with 
TGF-β.  Although this difference was not significant until 96 hours in the alamar 
blue assay, this result did suggest a definite reduction in cellular proliferation.  
 
4.2.4 The Effect of TGF-β on Gene Expression in MRC5 Fibroblasts 
  
It was then investigated whether treatment with TGF-β could induce changes in 
fibroblasts that could be measured at an mRNA level, with changes in transcription 
of genes for proteins that form the ECM.  The mRNA levels were assessed by qPCR 
at 24 hour intervals over a 96 hour treatment period.  The levels of COL1A1, 
COL3A1 and FN-EDA expression in treated cells were compared with untreated 
control cells, the results are shown in the figures Figure 4-10 – Figure 4-12 below.  
   
 
Figure 4-10  Fold change in COL1A1 in MRC5 cells after treatment with TGF-β 
over 96 hours.  The results show there was a significant increase in gene expression 
of COL1A1 after 24 hours, however the results were not sustained at the later time 
points.  Results are mean values (n=4) with error bars +/- SEM.  Two-way anova 
with Bonferroni post-test performed, *p<0.05, **p<0.01. 
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Figure 4-11  Fold change in COL3A1 in MRC5 cells after treatment with TGF-β 
over 96 hours.  There were no significant changes in COL3A1 gene expression at any 
TGF-β concentration or at any length of treatment.  Results are mean values (n=4) 
with error bars +/- SEM.  Two-way anova with Bonferroni post-test performed. 
 
Figure 4-12  Fold change in FN-EDA in MRC5 cells after treatment with TGF-β 
over 96 hours.  There was a significant increase in expression of FN-EDA, which 
was sustained at all time points with the highest concentration of TGF-β used (2 
ng/ml).  Results are mean values (n=4) with error bars +/- SEM.  Two-way anova 
with Bonferroni post-test performed, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4-10 showed a 2-fold increase in the transcription of COL1A1 by MRC5 
fibroblasts treated with TGF-β occurring after 24 hours.  This response tapered after 
72 and 96 hours.  There was no significant difference in transcription of COL3A1 
throughout the time course however, at 24 hours there did appear to be a non-
significant increase in transcription of COL3A1.  Again, this response tapered after 
48 hours, represented in Figure 4-11.  For both genes, there was an initial increase in 
transcription which was not sustained throughout the 96 hour time course. 
Figure 4-12 showed a significant increase in FN-EDA present at 24 hours at all doses 
of TGF-β used, and at 48, 72 and 96 hours, at the highest dose of TGF-β.  Unlike 
collagen, this appeared to be a truly dose-dependent effect.   
Although the data presented above has shown that the MRC5 fibroblasts upregulate 
transcription of ECM genes, it is possible that this may not translate into ECM 
protein production.  For example, RNA binding proteins can affect RNA levels and 
then reduce the amount of translated protein produced.  To assess if this occurred, a 
western blot experiment was undertaken on the conditioned medium to assess if the 
treated cells were producing more COL1A1 and FN.   
 
 
 
4.2.5 The Effect of TGF-β on Protein Production by MRC5 
Fibroblasts  
 
Western blots were produced from conditioned medium taken after 96 hours of TGF-
β treatment.  Protein was precipitated and western blot performed as per methods 
described in section 2.9.  The predicted molecular weight of COL1A1 is 139kDa.  
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Figure 4-13 Western blot for COL1A1 from conditioned medium of MRC5 cells 
treated with increasing concentrations of TGF-β over 96 hours.  (a) Annotated 
western blot gel image, (b) analysis of western blot with results normalised for 
protein loading against ponceau S staining.  Although visually there appeared to be 
an increase in COL1A1 protein, when results were normalised there was no 
significant differences found.  Results are mean values (n=2) of the relative band 
intensity with error bars +/- SEM.  One-way anova with Bonferroni’s multiple 
comparison test performed.  
 
Although visually there appeared to be an increase in COL1A1 secretion by MRC5 
fibroblasts, once normalised, there was no significant difference apparent despite the 
results showing an upregulation in COL1A1 at 24 hours at an mRNA level.   
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A western blot was also produced to measure the change in FN secreted by MRC5 
cells after 96 hours.  The predicted molecular weight of FN is 220kDa. 
 
 
 
 
 
Figure 4-14  Western blot for FN secreted by MRC5 cells treated with increasing 
concentrations of TGF-β for 96 hours. (a) Annotated western blot gel image, (b) 
analysis of western blot with results normalised for protein loading against ponceau 
S staining.  There was a significant increase in production of FN with increasing 
concentrations of TGF-β, with a dose-dependent response.  Results are mean values 
(n=2) with error bars +/- SEM.  One-way anova performed with Bonferroni multiple 
comparison test, *p<0.05, **p<0.01. 
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The western blot of FN appeared to show an upregulation in secretion of the protein 
after treatment with increasing concentrations of TGF-β.  This would match the 
upregulation of the FN-EDA splice variant transcription observed and shown earlier 
in the chapter.  It should be noted that the protein assessed using western blot was the 
regular form of FN and not the FN-EDA form in which expression was measured. 
 
 
 
4.3 The Effect of TGF-β Treatment on Epithelial Cells 
(A549) 
 
As previously discussed, alveolar epithelial cells are likely implicated in pulmonary 
fibrosis, potentially undergoing EMT and then becoming mesenchymal cells, and 
becoming capable of producing more ECM.  For this reason, they were chosen as an 
interesting cell type to assess the impact of TGF-β.  In a similar way to the MRC5 
fibroblasts, they were treated with increasing concentrations of TGF-β to assess for 
changes in pro-fibrosis markers. 
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4.3.1 The Effect of TGF-β Treatment on the Morphology of A549 
Epithelial Cells 
 
Initially A549 cells were treated with increasing concentrations of TGF-β and images 
were recorded at 24, 48, 72 and 96 hours respectively.  The Figure below 
demonstrates the changes observed in cell morphology after 48 hours TGF-β 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15  Change in morphology of A549 cells treated with TGF-β for 48 hours.  
(a) Control cells treated in baseline conditions without the addition of TGF-β, (b) 
A549 cells treated with 1.5ng/ml TGF-β, (c) A549 cells treated with 3ng/ml TGF-β 
for 48 hours.  These figures demonstrate the subtle changes in morphology brought 
about by TGF-β treatment, with slightly more elongation of the usually tightly 
packed cuboidal cells.  Magnification x10 objective lens, scale bar 10µm. 
(b) (a) 
(c) 
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A549 cells treated with TGF-β showed a subtle change in appearance.  Figure 4-15 
shows that the epithelial cells have lost their cuboidal shape with tightly adherent 
junctions and have become elongated, spindle-shaped cells.  Further 
immunohistochemistry staining and qPCR was performed to assess if these cells 
were undergoing EMT. 
 
4.3.2 Immunolocalisation of EMT Proteins in A549 cells treated 
with TGF-β 
 
To assess these morphological changes further the epithelial cells were stained for 
both COL1A1 and αSMA.  These proteins may be produced by epithelial cells that 
have undergone EMT and are more mesenchymal in phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
Figure 4-16 A549 cells stained for phalloidin (green) and COL1A1 (red). (a) control 
cells cultured in baseline conditions, (b) cells treated with TGF-β 3ng/ml for 48 hours.   
The phalloidin staining, appreciated better at low magnification, allows the tight, 
cobblestone appearance of the A549 epithelial cells to be assessed.  It is difficult to 
detect the COL1A1 staining in this image so the figure below shows the samples at 
higher magnification.  Magnification x20 objective lens, scale bar 100µm. 
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A549 cells treated with TGF-β showed an increase in production of COL1A1, as 
represented by an increase in red staining in Figure 4-16 and Figure 4-17.  This was 
further quantified using qPCR and western blot, shown later in the chapter. 
 
The A549 cells were then stained for α-SMA to assess if there was an increase in 
production of this protein, suggesting that EMT was occurring in response to TGF-β 
treatment. 
 
 
 
 
 
 
(a) (b) 
Figure 4-17  A549 cells stained for phalloidin (green) and COL1A1 (red). (a) 
control cells cultured in baseline conditions without TGF-β treatment, (b) cells 
treated with TGF-β 3ng/ml for 48 hours.  At this higher magnification it was 
noted that more COL1A1 is produced by treated cells, evidenced by increased 
red staining of the cells.  Magnification x40 objective lens, scale bar 100µm. 
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Figure 4-18 shows that A549 cells produced α-SMA in response to TGF-β.  As can 
be seen from these images control cells produce very little of this protein, which 
stained red, suggesting that the cells were undergoing EMT in response to TGF-β 
treatment. 
 
Figure 4-18 A549 epithelial cells stained for αSMA (red) alongside nuclear DAPI 
staining (blue) for 48 hours. (a) control cells cultured in baseline conditions, (b) cells 
treated with TGF-β 1.5ng/ml, (c) cells treated with TGF-β 3ng/ml.  The images show 
that more α-SMA was produced in response to TGF-β treatment suggesting that 
EMT may be occurring.  Magnification x40 objective lens, scale bar 50µm. 
(a) (b) 
(c) 
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4.3.3 The Effect of TGF-β Treatment on the Proliferation of A549 
Epithelial Cells 
 
It was investigated whether TGF-β induced a proliferative response in A549 
epithelial cells.  An alamar blue assay was performed to measure the number of 
metabolically active cells at different time points and thus give an estimate of the 
proliferation of the A549 cells over a 72 hour time course. 
 
 
Figure 4-19 Alamar blue assay assessing the proliferation of A549 cells treated with 
increasing concentrations of TGF-β over 72 hours.  There were no significant 
differences noted, however A549 cells treated with TGF-β seemed to proliferate less 
than control cells.  Results are mean values (n=4) with error bars +/- SEM.  Two-way 
anova with Bonferroni post-test was performed. 
 
Figure 4-19 shows the growth of A549 epithelial cells over 72 hours after treatment 
with 1.5ng/ml and 3ng/ml TGF-β respectively.  Although the cells grew well over 
the time course, there did not appear to be any significant difference between the 
growth of control cells and those that were treated.  In fact, there was trend for 
proliferation to be less in cells that were treated with TGF-β, although this was non-
significant.   
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4.3.4 The Effect of TGF-β Treatment on Gene Expression in A549 
Epithelial Cells 
 
It was then investigated if treatment with TGF-β could cause a change in 
transcription levels of genes associated with production of the ECM or EMT over the 
time course.   
 
Figure 4-20  Fold change in mRNA levels of COL1A1 in A549 cells treated with 
1.5ng/ml TGF-β and 3ng/ml TGF-β over 96 hours in comparison to untreated, 
control cells.  There was a significant increase in expression of COL1A1 at all 
concentrations of TGF-β used.  This was still present after 72 hours treatment.  
Results are mean values (n=4) with error bars +/- SEM.  Two-way anova with 
Bonferroni post-test was performed, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4-21  Fold change in mRNA levels of COL3A1 in A549 cells treated with 
1.5ng/ml TGF-β and 3ng/ml TGF-β over 96 hours in comparison to untreated, 
control cells.  There were no significant changes in expression of COL3A1 after 
treatment with TGF-β.  Results are mean values (n=4, n=3 at 96 hours) with error 
bars +/- SEM.  Two-way anova with Bonferroni post-test performed.  
 
Figure 4-22  Fold change in mRNA levels of FN-EDA in A549 cells treated with 
increasing concentrations of TGF-β over 96 hours in comparison to untreated, 
control cells.  There was a significant increase in expression of FN-EDA, sustained to 
72 hours treatment.  Results are mean values (n=4) with error bars +/- SEM.  Two-
way anova with Bonferroni post-test performed, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4-23  Fold change in mRNA levels of Slug in A549 cells treated with 
1.5ng/ml TGF-β and 3ng/ml TGF-β over 96 hours in comparison to untreated, 
control cells.  These results showed a significant increase in Slug after TGF-β 
treatment.  Results are mean values (n=4) with error bars +/- SEM.  Two-way anova 
with Bonferroni post-test performed, ***p<0.001. 
 
Figure 4-24 Fold change in mRNA levels of Snail in A549 cells treated with 
1.5ng/ml TGF-β and 3ng/ml TGF-β over 96 hours in comparison to untreated, 
control cells.  This demonstrated a significant increase in expression of Snail with up 
to 72 hours TGF-β treatment.  Results are mean values (n=4) with error bars +/- 
SEM.  Two-way anova with Bonferroni post-test performed, ***p<0.001. 
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Figure 4-20 shows a significant increase in transcription of COL1A1 mRNA in 
response to treatment with TGF-β.  This was a very significant change (45 times 
higher in cells treated with the highest dose of TGF-β at 48 hours) and the response 
was sustained up to 96 hours after initial treatment.  It was also a dose-dependent 
effect with the higher treatment dose of TGF-β having the largest effect.  This may 
be because these cells produce very little COL1A1 under normal, control conditions, 
so once stimulated to produce collagen this effect appears profound.  However, there 
was no significant effect on mRNA levels of COL3A1 after treatment with either 
concentration of TGF-β (as represented in Figure 4-21).  There was also a dose-
dependent upregulation of FN-EDA, again sustained to at least 72 hours treatment 
(see Figure 4-22).   
These changes were associated with a dose-dependent increase in the mRNA level of 
the transcription factors Slug and Snail (represented in Figure 4-23 and Figure 4-24 
respectively).  The changes in ECM genes peaked around 48-72 hours, whereas the 
changes in transcription factors peaked earlier (around 24-48 hours).   
 
 
4.3.5 The Effect of TGF-β on Protein Production by A549 Epithelial 
Cells 
 
Given that TGF-β treatment had such a profound effect in the transcription of 
COL1A1, a western blot was also performed to assess for upregulation of the 
transcribed protein (see Figure 4-25). 
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Figure 4-25  Western blot for COL1A1 secreted by A549 cells treated with 
increasing concentrations of TGF-β for 96 hours. (a) Western blot image, (b) analysis 
of western blot showing relative band intensity.  There was no significant change in 
the production of COL1A1 in epithelial cells treated with TGF-β.  Results are mean 
values (n=2) with error bars +/- SEM.  One-way anova performed with Bonferroni 
multiple comparison test. 
 
Figure 4-25 shows a tendency to an increase in the production of COL1A1 produced 
by A549 cells in response to treatment with TGF-β.  Unfortunately, there was a lot of 
variation within the experiment and this was not found to be significant, although the 
result suggests that more COL1A1 may be produced by A549 cells stimulated with 
TGF-β. 
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4.4 The Use of TCH (A Serum Replacement Product) in 
Experiments Requiring Serum Starvation 
 
4.4.1 MRC5 cells Cultured in TCH Supplemented Medium 
 
Serum starvation is used in multiple types of in vitro studies, but there is no standard 
practice to guide how such studies should be undertaken (163).  For example, cells 
may be starved for anything from 15 minutes to several hours.  As serum contains 
variable amounts of growth factors and cytokines, removing it makes experiments 
more reproducible and ensures that cells are only being stimulated by the 
experimental cytokine being added (in this case, TGF-β).  However, there has been 
evidence to suggest serum starvation impacts upon the growth of cells causing 
environmental stress and perhaps even being an apoptotic trigger (164).  For this 
reason, TCH was used as an alternative to FBS.  This is a serum replacement product 
that lacks steroid hormones, growth factors and cytokines.  The MRC5 and A549 cell 
types are listed by the company as being cultured successfully using this supplement 
(165). 
To improve reproducibility and to ensure that any changes in the cells were not 
imposed due to serum starvation, the cells were cultured using this serum 
replacement (as described in materials and methods chapter, section 642.3.2.2). 
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Figure 4-26 Changes in fibrosis associated genes in MRC5 cells treated with increasing concentrations of TGF-β for 48 hours.  There were 
significant increases in COL1A1, FN-EDA, CCN1 and CCN2 when MRC5 cells were treated with TGF-β for 48 hours.  Results are mean values 
(n=3) with error bars +/- SEM.  A one-way anova was used for each gene with Bonferroni correction for multiple comparisons.
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This experiment, the results of which are shown in Figure 4-26, showed that treating 
cells with TGF-β had similar effects whether cells are serum starved or TCH is used.  
There is an increase in expression of genes associated with the production of ECM, 
including COL1A1 and FN-EDA.  However, when cells were serum starved any 
significant increase in COL1A1 only occurred at 24 hours and had tapered after 48 
hours.  However, this was sustained until 48 hours when cells were given TCH 
suggesting that serum starvation was detrimental to the MRC5 cells.  There was not a 
significant increase in COL3A1, which was similar to previous data when cells were 
serum starved prior to TGF-β treatment.   
Interestingly, CCN1, the role of which is controversial in fibrosis research, was also 
upregulated.  CCN2 was upregulated after TGF-β treatment, which concurs with 
published literature, and this effect appeared dose-dependent.  CCN3, a molecule that 
may have an antifibrotic effect, was attenuated 48 hours after cells were stimulated 
with TGF-β, although this effect was not shown to be significant.  Surprisingly, 
CCN4 was also attenuated after TGF-β treatment, which is in contradiction to 
previous literature that states CCN4 is a pro-fibrotic mediator (137).  However, this 
response was not significant.  The above data was also at a single time point and so 
the results may be different if the mRNA was assessed after 12 hours or 24 hours of 
TGF-β treatment. 
MRTFa, a transcriptional co-activator is translocated to the nucleus when stimulated 
by growth factors such as TGF-β.  Here it can initiate transcription of genes involved 
in fibrosis, including COL1A1 and α-SMA.  This experiment showed a trend to an 
increase in MRTFa in response to TGF-β, although this was not significant at 48 
hours.  It was therefore decided to stain the MRC5 cells for MRTFa, i.e. to assess if 
there was a change in location of the MRTFa protein (i.e. had the protein 
translocated from the cytoplasm of the cell to the nucleus in response to TGF-β), as 
suggested to occur by the current literature.  The results are shown in Figure 4-27 
below.   
Thy-1 is a glycophosphatidylinositol anchored cell surface protein found on the 
surface of fibroblasts.  There is evidence to suggest that mesenchymal cells involved 
in fibrosis lose expression of this protein.  For this reason, change in gene expression 
for this protein was measured after treatment with TGF-β.  There appeared to be a 
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downward trend in Thy-1 expression but this did not meet significance. However, 
given the recent controversial literature surrounding the role of this protein in IPF the 
MRC5 fibroblasts were stained for Thy-1 protein to assess if there was a change in 
expression with TGF-β treatment.  There were no significant changes in PDGFR-α 
when cells were treated with TGF-β, although there was a trend for a reduction in 
gene expression of this receptor. 
 
4.4.2 The Effect of TGF-β Treatment on the Immunolocalisation of 
MRTFa in MRC5 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-27 shows the expression of MRTFa in MRC5 fibroblasts.  It shows that 
only a small amount of MRTFa was expressed in control cells and this did not appear 
to be significantly upregulated after 48 hours of TGF-β treatment, concurring with 
the mRNA data shown in Figure 4-26. 
 
(a) (b) 
Figure 4-27 MRC5 cells showing staining with nuclear DAPI (blue), phalloidin 
(green) and MRTFa (red).  (a) untreated control cells, (b) cells under same 
conditions but treated with TGF-β 2ng/ml for 48 hours.  No significant changes 
were noted in the expression or localisation of MRTFa in the treated MRC5 
fibroblasts.  Magnification x40 objective lens, scale bar 50µm. 
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4.4.3 The Effect of TGF-β Treatment on the Immunolocalisation of 
Thy-1 in MRC5 Cells 
 
As previously discussed Thy-1 is a cell surface protein that belongs to the 
immunoglobulin-like gene family (166).  It is lost from the surface of fibroblasts 
located in fibroblastic foci of patients with IPF (140). 
As can be seen from the qPCR data shown in Figure 4-26, the treatment of 
fibroblasts with TGF-β appeared to down-regulate expression of Thy-1, although this 
change was not statistically significant.  Staining was then undertaken to assess if 
there was any change in Thy-1 expression of the fibroblasts, visible by 
immunocytochemistry.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
Figure 4-28  MRC5 cells stained for phalloidin (green) and Thy-1 (red). (a) control, 
untreated cells, (b) cells treated with TGF-β 2ng/ml for 48 hours. There appeared to 
be little change in expression of Thy-1 in fibroblasts treated with TGF-β.  
Magnification x10 objective lens, scale bar 100µm. 
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Figure 4-28 shows little or no change in the expression of Thy-1 when visualised by 
immunocytochemistry staining, concurring with the qPCR data already shown in 
Figure 4-26. Interestingly, however, very little staining was seen on the cell 
membrane, as would be expected from a cell surface protein and there did not appear 
to be a change in the location of the protein after treatment with TGF-β. 
 
4.4.4 A549 cells Cultured in TCH Serum Supplemented Medium 
 
The experiment, using serum replacement medium instead of serum starvation when 
treating cells with TGF-β, was repeated using the A549 epithelial cells.  These cells 
appeared more sensitive to serum starvation and, unlike the MRC5 fibroblasts, could 
only be starved for 8 hours as they did not survive when starved overnight. It was 
therefore important that they were given serum supplementation to ensure that they 
stayed healthy prior to treatment.
(a) (b) 
Figure 4-29  MRC5 cells stained for phalloidin (green) and Thy-1 (red). (a) control, 
untreated cells, (b) cells treated with TGF-β 2ng/ml for 48 hours. A higher magnification 
showed there was no difference in the localisation of the Thy-1 protein after treatment 
with TGF-β.  Magnification x40 objective lens, scale bar 50µm. 
132 
 
 
Figure 4-30  Changes in fibrosis genes in A549 cells treated with increasing concentrations of TGF-β over 48 hours.  Cells were not serum 
starved prior to treatment but were cultured in serum replacement medium.  There were significant increases in COL1A1, Slug, N-cadherin, 
CCN1 and CCN2 when A549 cells were treated with TGF-β.  Results are expressed as mean values (n=2) with error bars +/- SEM.  (* p<0.05, 
** p<0.01, *** p< 0.001) 
-2
0
2
4
6
8
10
12
14
16
18
F
o
ld
 C
h
a
n
g
e
Gene
The Effect of TGF-β on Gene Expression in A549 Epithelial Cells Treated with TGF-
β over 48 hours
Control
TGF-β 1.5ng/ml
TGF-β 3ng/ml
** 
** 
* 
** 
*** 
** 
133 
 
Figure 4-30 showed an increase in transcription of COL1A1 when A549 cells were 
treated with TGF-β and serum replacement medium for 48 hours, corresponding 
with previous data when cells were serum starved.  FN-EDA and COL3A1 were not 
significantly increased, although FN-EDA did show a trend to upregulation but this 
was not significant.  This may be due to a slight variation in the control wells.  There 
was also a trend for a reduction in E-cadherin, which did not reach significance and 
also an associated upregulation of N-cadherin, both features associated with EMT 
(108, 167).  As expected, the transcription factors Slug and Snail were upregulated 
in a dose-dependent manner.  The CCN family showed a similar pattern of response 
as shown in the MRC5 fibroblasts, with an upregulation of CCN1 and CCN2 seen at 
the higher dose of TGF-β and a corresponding, although non-significant, reduction 
in CCN3 and CCN4 respectively. 
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5 Utilising the in vitro Model to Assess Changes 
Induced by Plasma From Patients with Fibrotic 
Diseases 
 
In chapter 4 it was demonstrated that a cellular model had been produced, in which 
fibrotic change can be measured in cell lines from two cell types previously 
implicated in fibrosis.  This was shown when a cytokine known to induce pro-
fibrotic changes in cells, in this case TGF-β, was added to the cell medium in 
various experimental set-ups.  Changes were shown in cell morphology (using 
immunocytochemistry), proliferation (using alamar blue assays), mRNA (using 
qPCR) and protein production (using western blot and immunocytochemistry).   
In this chapter the same model was used to assess whether treating cell lines with 
plasma from patients with ILD could cause similar changes to those seen when cells 
were treated with a pro-inflammatory cytokine (as described in chapter 4).  Cells 
treated with plasma from healthy subjects were used as a control.  The hypothesis 
was that plasma from ILD patients would induce changes in the cells to suggest that 
systemic factors are present in the plasma, and that such treatment would initiate and 
propagate a pro-fibrotic response.  Despite extensive literature searching it appears 
to be unknown whether treating cell lines directly with plasma from ILD patients 
can induce any such changes in related cell lines.  However, it is wondered if there 
are cytokines present in patient plasma that may propagate the fibrotic pathways.   
There has been some recent literature to suggest that plasma and serum have 
differing properties.  Serum is the liquid part of whole blood obtained after it has 
been coagulated and then separated by centrifugation.  However, this process may 
lead to the release of a number of pro-inflammatory cytokines, making the results 
less reliable.  Plasma is obtained from tubes that have been treated with heparin 
prior to the blood being taken, preventing it from coagulating.  There is some 
evidence to suggest that using plasma instead of serum may improve the 
reproducibility of experiments (168). 
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5.1 The Effects of Plasma from Patients with IPF on 
Different Cell Lines 
 
5.1.1 Patient demographics of IPF patients compared to healthy 
control subjects 
 
The first group of patients assessed were those with IPF.  As discussed in more 
detail in the introduction, this group of patients develop fibrosis in the lungs but not 
in other organs.  The underlying cause is unknown and patients develop fibrosis 
spontaneously and at a rapid pace (median mortality is just 3 years).   
The plasma used was from patients recruited through the UK-BILD study.  The 
demographic profile of these patients was compared to that of the healthy control 
subjects used.  Whereas the UK-BILD proforma was completed for all ILD patients, 
limited data was available regarding healthy control subjects.  However, the table 
below compares the demographic data that was available between the two groups.  
Of note, patients in the healthy control group were younger than those in the IPF 
group.  Finding healthy control subjects can be difficult given the number of elderly 
people with co-morbidities.  All patients used had a diagnosis of definite IPF 
according to ATS / ERS diagnostic guidelines and had a UIP pattern on HRCT 
scanning. 
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 IPF Patients (n=14) Healthy Controls (n=7) Significant 
difference 
between groups 
Gender Male 10 (71.4%) 
Female 4 (28.6%)  
Male 4 (57.1%) 
Female 3 (42.9%) 
ns 
Age (years) Median 68 (55-83) Median 48 (42-58) ***p<0.0001 
Ethnicity Caucasian 14 (100%) Unknown N/A 
 
Table 5-1  Demographic details for IPF patients and healthy controls.  A Fisher’s 
exact test was used to compare gender and an unpaired two-tailed t-test was used to 
calculate significance between age in the two groups.  Healthy control subjects were 
significantly younger than patients with IPF.  ns = no significant difference. 
 
 IPF Patients 
Time from ILD diagnosis (days) Median 533.5 (Range 42 – 1826) 
17.5 months (Range 1.4 – 60 months) 
Smoking History (Pack year smoking 
history) 
Never 3 (21%) 
Ex <20 3 (21%) 
      >20 but <40 5 (36%) 
      >40 3 (21%) 
Current 0 (0%) 
Respiratory features Clubbing 4 (29%) 
Crackles 11 (79%) 
Pulmonary hypertension 0 (0%) 
Malignancy history 0 (0%) 
 
Table 5-2  ILD data regarding plasma from patients with IPF used to treat cells.  
Data collected includes time from ILD diagnosis, smoking history, diagnostic 
category and presence of respiratory features. 
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Interestingly patients had been diagnosed with IPF for a median of 1.5 years.  The 
median time from diagnosis to death is estimated at around 3 years (14).  It is 
therefore clear that the studied patients were well established in the course of their 
illness.  No patients in the cohort were currently smoking but the majority (79%) 
were ex-smokers.  All patients had been diagnosed by HRCT with a definite UIP 
pattern on the HRCT scan and therefore did not require diagnostic lung biopsy.  On 
examination, end-inspiratory crackles were present in 79% and clubbing in 29% of 
cases respectively.  No IPF patients had pulmonary hypertension, which may have 
its own unique cytokine profile. 
 
5.1.2 The Effect of IPF Plasma Treatment on the Morphology of 
MRC5 Fibroblasts 
 
Cells were treated directly with patient and healthy control plasma, as described in 
materials and methods section 2.3.2.3.  Images were taken at 24, 48 and 72 hours to 
assess if there were any morphological changes induced by the patient plasma.  The 
images given in the figures below are representative examples of the changes 
observed. 
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(c) 
(e) (f) 
(a) (b) 
(d) 
Figure 5-1  MRC5 cells treated over time course with 100ul plasma.  (a) Cells treated 
with healthy control plasma for 24 hours, (b) Cells treated with IPF plasma for 24 
hours, (c) Cells treated with healthy control plasma for 48 hours, (d) Cells treated with 
IPF plasma for 48 hours, (e) Cells treated with healthy control plasma for 72 hours, (f) 
Cells treated with IPF plasma for 72 hours.  There were no differences observed in cell 
morphology between cells treated with healthy control plasma and IPF patient plasma.  
Magnification x10 objective lens, scale bar 10µm. 
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The above figures show that MRC5 fibroblasts proliferated well with the addition of 
human plasma.  There did not appear to be any differences in cell morphology 
between MRC5 cells treated with plasma from healthy control subjects or those 
treated with plasma from IPF patients.  However, after 72 hours, the plasma treated 
cells appeared more spindle shaped and less healthy when compared to cells grown 
with TCH or treated with TGF-β, shown in the previous chapter.  The reason for this 
is unclear and immunocytochemistry, shown later in this chapter, was thus 
performed to assess these changes in more detail.  There was the possibility of an 
increase in proliferation of the MRC5 cells treated with IPF plasma, although it was 
difficult to assess whether this was a true effect or based on variable factors when 
plating cells, or from taking pictures in different parts of the 6 well plate.  Changes 
in proliferation may be subtle and it is difficult to assess visually across a few 
images in a 6 well plate.  For this reason, cell proliferation was assessed using an 
alamar blue assay (see later). 
 
5.1.3 The Effect of IPF Plasma Treatment on the Proliferation of 
MRC5 Fibroblasts 
 
As previously described in materials and methods section 2.5, an alamar blue assay 
was used to assess cell viability and cell proliferation.  Cells were treated with 
plasma from healthy controls or from IPF patients, and fluorescence measured at 
different time points to assess if there was an increase in the number of viable, 
proliferating cells.  The results are shown in the figure below; 
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Figure 5-2  Proliferation of MRC5 cells, measured using an alamar blue assay, the 
red line represents wells treated with healthy control plasma (n=7) and the blue line 
represents wells treated with plasma from patients with IPF (n=14).   There was 
increased proliferation of MRC5 cells treated with plasma from patients with IPF 
which was statistically significant after 48 hours.  Results are expressed as mean 
values +/- SD. A two-way anova with Bonferroni post-test was performed for 
analysis, * p<0.05. 
 
Figure 5-2 shows there was a general increase in proliferation of MRC5 fibroblasts 
treated with IPF patient plasma in comparison to healthy control plasma.  However, 
this effect was only significant at 48 hours (p<0.05), although the trend was for an 
increase at all time points. 
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5.1.4 The Effect of 24 hours IPF Plasma Treatment on Gene 
Expression in MRC5 Fibroblasts 
 
After images were obtained, RNA was extracted as described in materials and 
methods section 2.7.  This RNA was then converted to cDNA, and then qPCR 
performed as previously described.  The first genes to be investigated were those 
that build the ECM.  These include COL1A1, COL3A1 and FN-EDA.  All genes 
were examined when cells were treated with TGF-β in the previous chapter and both 
COL1A1 and FN-EDA were significantly upregulated by TGF-β treatment.  
COL3A1 was not upregulated in this model, although it is implicated in fibrosis (77). 
Individual points, representing a single patient result, were plotted as there was a 
large variation between subjects and this would not be fully recognised using a 
standard bar chart.  This variation may be accounted for by variations in patient’s 
ages, differences in their disease severity as well as differences in disease duration.  
For this reason, individual points were plotted to assess if there were not only trends 
between patients and controls but between individual patients as well.  For example, 
if a patient was producing an increased amount of COL1A1, does that patient also 
produce more FN-EDA?  These scatter plots allow for this variation to be 
investigated.  As this study is only exploratory, the statistics were not corrected for 
multiple comparisons, therefore any p value must be interpreted with caution. 
The values were plotted in relation to the mean value of the healthy control group.  
The values are presented in logarithmic base 2 form, this is a delta CT calculation to 
show the baseline of the gene in question, as there are variations in mRNA levels.  
In each of the plots, zero is a mean control and every one unit is a doubling of the 
mRNA levels. The data has been presented as dot plot to show the variation of the 
patient cohort.   
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Figure 5-3  Two log of the fold difference values plotted individually for ECM 
genes showing healthy control values against those with IPF after treatment of cells 
for 24 hours.  (a) COL1A1, (b) COL3A1, (c) FN-EDA.  There were no significant 
differences for any of the ECM genes between cells treated with healthy control 
plasma and those treated with IPF plasma.  Bar shows mean value for IPF patients.  
Unpaired two-tailed t-test performed for analysis. 
 
There were no differences in the amount of COL1A1, COL3A1 and FN-EDA 
produced by the MRC5 cells treated with IPF plasma for 24 hours compared to those 
cells treated with healthy control plasma.  There was variation present between both 
control and patient groups but both produced similar changes in transcription levels 
of genes that form proteins in the ECM.  The CCN genes were then evaluated in a 
(c) 
(a) (b) 
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similar way, to assess if treatment with IPF plasma caused changes in these genes.  
The results are shown in the figure below; 
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Figure 5-4  Two log of the fold difference values showing individual results for 
genes of the CCN family comparing healthy control plasma with IPF patient plasma 
after treatment of cells for 24 hours.  (a) CCN1, (b) CCN2, (c) CCN3, (d) CCN4.  
There were no significant differences between the two groups.  Bar shows mean 
value for IPF patients.  Unpaired two-tailed t-test performed for analysis. 
 
Figure 5-4 shows that there were no differences in transcription of CCN1-4 between 
cells treated with plasma from healthy controls and those treated with plasma from 
IPF patients after 24 hours.  As discussed in the introduction, it is recognised that 
(c) (d) 
(a) (b) 
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these genes interact and may exert opposing effects.  As points were plotted 
individually there were no obvious patterns seen in individual patients.  For 
example, patients producing more CCN2 did not appear to be producing less CCN3.  
As no changes were seen within the genes encoding for the ECM proteins or within 
the CCN family, changes within other genes associated with fibrosis were also 
analysed. 
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Figure 5-5  Two log of the fold difference values plotted individually for other 
genes relevant in fibrosis showing healthy control values against those with IPF after 
treatment of cells for 24 hours.  (a) MRTFa, (b) PDGFR-α, (c) Thy-1.  There were 
no differences between the other genes involved in fibrosis tested in the MRC5 cells.  
Bar shows mean value for IPF patients.  Unpaired two-tailed t-test performed for 
analysis. 
 
(b) 
(c) 
(a) 
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Figure 5-5 shows there was no change in MRTFa, a molecule that drives fibroblasts 
to become myofibroblasts.  There was also no change in PDGFR-α, a receptor on 
the cell surface that may be expected to change as an early response to fibrosis. 
There were also no differences in transcription levels of Thy-1, a molecule that has 
been found to be downregulated in the fibroblastic foci of patients with IPF.  
Given that changes may take longer than 24 hours to develop, this experiment was 
repeated at 48 and 72 hours.  The data is not shown but changes were similar to 
those at 24 hours and no significant differences were present in any of the genes 
associated with fibrosis.  It can therefore be concluded that treatment of MRC5 
fibroblasts with plasma from patients with IPF induced no significant changes in 
transcription of any genes associated with pro-fibrosis, as assessed in this 
experimental model.  It does, however, appear to induce an increase in proliferation 
of fibroblasts which is sustained to 72 hours.  This increase in proliferation does not 
seem to be driven by any of the pro-fibrotic genes assessed above. 
  
 
5.1.5 The Effect of IPF Plasma Treatment on the Morphology of 
A549 Epithelial Cells 
 
A549 epithelial cells were treated with IPF patient plasma in a similar manner to the 
MRC5 fibroblasts above.  Images were taken prior to RNA extraction at 24, 48 and 
72 hours respectively. 
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(a) (b) 
(c) (d) 
(e) (f) 
Figure 5-6  A549 epithelial cells treated over time course with plasma.  (a) Cells 
treated with healthy control plasma for 24 hours, (b) Cells treated with IPF plasma for 
24 hours, (c) Cells treated with healthy control plasma for 48 hours, (d) Cells treated 
with IPF plasma for 48 hours, (e) Cells treated with healthy control plasma for 72 
hours, (f) Cells treated with IPF plasma for 72 hours.  There were no obvious 
differences in the morphology of the epithelial cells between the two groups. 
Magnification x10 objective lens, scale bar 10µm. 
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Figure 5-6 shows that the A549 cells proliferated well with both healthy control 
plasma and IPF plasma.  In most cases the cells were almost confluent after 48 
hours.  There were no obvious phenotypic changes between A549 cells in the 2 
groups at any of the time points.  To assess the possibility of an increase in cellular 
proliferation, cell growth was tested using an alamar blue assay. 
  
5.1.6 The Effect of IPF Plasma Treatment on the Proliferation of 
A549 Epithelial Cells 
 
An alamar blue assay was used to assess for cell proliferation.  It has been shown in 
the previous chapter that the A549 cells do not respond to TGF-β by increasing 
proliferation.  It was felt interesting to assess the effect that IPF patient plasma has 
on the growth rate of cells compared to healthy control plasma. 
 
Figure 5-7  Proliferation of A549 cells, measured using an alamar blue assay.  The 
red line represents wells treated with healthy control plasma (n=7) and the blue line 
represents wells treated with plasma from patients with IPF (n=14).  There were no 
significant differences in proliferation between A549 cells treated with healthy 
control plasma and those treated with IPF plasma.  Results are expressed as mean 
values +/- SD. Two-way anova with Bonferroni post-test was performed for 
analysis. 
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Figure 5-7 showed cellular proliferation of the A549 cells and there was no 
significant difference between cells treated with plasma from IPF patients versus 
that of healthy control subjects.  However, there was a trend to an increase in 
proliferation of the A549 cells treated with patient plasma.  This effect was present 
at 24 hours and sustained to 72 hours.  There was a large amount of variation 
between subjects, so a much larger sample size would be needed to assess if this is a 
real difference.   
 
5.1.7 The Effect of IPF Plasma Treatment on Gene Expression in 
A549 Epithelial Cells 
 
A549 cells were treated with plasma from either IPF patients or from healthy control 
subjects.  Images were taken and RNA extracted at 24 hours.  qPCR was performed 
for genes involved in fibrosis.  The first genes of interest were genes that encode for 
proteins that form the ECM including COL1A1, COL3A1 and FN-EDA. 
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Figure 5-8  Two log of the fold difference values plotted individually for ECM 
genes showing A549 cells treated with healthy control plasma against those treated 
with plasma from IPF patients for 24 hours.  (a) COL1A1, (b) COL3A1, (c) FN-
EDA.  Treatment with IPF plasma led to a significant reduction in expression of 
COL3A1 and FN-EDA.  Bar represents mean value for IPF patients.  Unpaired two-
tailed t-test performed for analysis, * p<0.05, ** p<0.01. 
 
Figure 5-8 shows the individual values for genes that make up the ECM, comparing 
A549 cells treated with healthy control plasma versus cells treated with IPF plasma.  
After 24 hours there was no difference in COL1A1 produced by either group.  
However, there was a reduction in COL3A1 (p<0.01) with a corresponding decrease 
(b) 
(c) 
(a) 
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in FN-EDA (p<0.05) in cells treated with plasma from IPF patients.  This change 
was noted at 24 hours but when these genes were investigated at 48 and 72 hours 
(not shown) there were no significant differences seen, so any changes occurring in 
the genes appear to happen at an early stage, when cells are first treated with IPF 
plasma.  
The transcription factors Snail and Slug, as well as the cell surface markers E-
cadherin and N-cadherin, were thus studied to assess if EMT could explain the 
changes occurring in the cells. 
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Figure 5-9  Two log of the fold difference values plotted individually for the 
transcription factors Snail and Slug and cell surface markers E-cadherin and N-
cadherin showing healthy control values against those with IPF after treatment of 
A549 cells for 24 hours.  (a) Snail, (b) Slug, (c) E-cadherin, (d) N-cadherin.  There 
was a significant downregulation of E-cadherin and N-cadherin when cells were 
treated with IPF patient plasma.  Bar represents mean value for IPF patients.  
Unpaired two-tailed t-test performed for analysis, ** p<0.01. 
 
There were no changes in the transcription factors Slug and Snail between healthy 
controls and IPF patients.  However, there was a significant downregulation 
(p<0.01) in E-cadherin, which is an early change occurring in cells undergoing EMT 
(108).  However, there was also a decrease in N-cadherin (p<0.01) which does not 
usually occur in EMT, but may explain some of the changes seen in the transcription 
of COL3A1 and FN-EDA which were downregulated, again changes that do not 
typically occur in EMT.   
(a) 
(b) 
(d) (c) 
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Figure 5-10  Two log of the fold difference values plotted individually for CCN 
genes showing healthy control values against those with IPF after treatment of A549 
cells for 24 hours.  (a) CCN1, (b) CCN2.  There were no significant differences in 
CCN1 or CCN2 when cells were treated with IPF plasma.  Bar represents mean 
value for IPF patients.  Unpaired two-tailed t-test performed for analysis. 
 
When the CCN family of genes were evaluated, there was no change in the CCN 
genes (CCN1 or CCN2) after 24 hours of plasma treatment.  This suggests that these 
genes were not responsible for any differences seen in the ECM proteins.   
 
Overall, there were a number of significant differences in A549 cells treated with 
IPF plasma after 24 hours of treatment.  This included a significant reduction in 
transcription of COL3A1 (p<0.01) and FN-EDA (p<0.05).  There were no 
corresponding changes in COL1A1 at this time point.  When the CCN family was 
explored, to assess if it was responsible for these changes, no significant differences 
were found.  There was no change after 24 hours in the transcription factors Snail or 
Slug.  There was also a significant reduction in N-cadherin (p<0.01), a marker on 
the surface of the cell that is increased when cells undergo EMT.   
(a) (b) 
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The cells were then examined after 48 and 72 hours to assess the trend at these later 
time points.  The data is not shown but there were no significant differences between 
A549 cells treated with healthy control plasma and those treated with IPF plasma at 
these time points.  The trend, however, was similar to the significant results with 
reductions in the ECM proteins when treated with IPF plasma. 
 
5.2 The Effects of Treatment with Plasma from Patients 
with SSc-ILD on Different Cell Lines 
 
As there were directionally surprising and small degree only changes noted between 
IPF patients and healthy control subjects in mRNA of several genes involved in 
fibrosis, this experiment was repeated using plasma from patients with diffuse SSc.  
The reasons for this choice of patient group included;  
(a) IPF is a disease characterised by a pro-fibrotic response in the lungs only, i.e. no 
other organs are targeted for fibrotic changes.  It could thus be hypothesised that the 
factors triggering and propagating pro-fibrosis are localised solely to the lungs, with 
only very small quantities circulating in the affected patient’s plasma.  On the other 
hand, diffuse SSc is recognised to also cause fibrosis of the skin and other internal 
organs, including the kidneys, lungs and GI tract.  It is therefore possible that higher 
levels of pro-fibrotic cytokines would be circulating in the plasma of SSc patients, to 
have an effect on so many distant organs other than the lungs.  
(b) Results from section 1 show that the IPF population used is likely homogeneous, 
and that a diagnosis of IPF is likely correct and reliable.  Similarly, diffuse SSc is 
likely to be a robust diagnosis as the clinical features are usually clearly apparent, so 
that SSc is unlikely to be misdiagnosed.  
(c) SSc-ILD is usually associated with an NSIP pattern on HRCT (169) but a small 
proportion of patients have a UIP pattern making this a useful comparison group. It 
may explain the differences in mechanisms that may give similar HRCT 
appearances to those of IPF. 
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5.2.1 Patient demographics of SSc patients with ILD 
 
The table below shows the demographic data available for patients with SSc-ILD 
and the healthy controls.  Again, the UK-BILD proforma had been completed for all 
patients with SSc-ILD meaning that there was more data available for these patients.  
Only limited data was available for the healthy control patients. 
 Healthy Controls 
used for qPCR 
experiments (n=2) 
SSc-ILD Patients 
used for qPCR 
experiments (n=4) 
Significant 
difference between 
groups 
Gender Male 1 (50%) 
Female 1 (50%) 
Male 1 (25%) 
Female 3 (75%) 
ns 
Age (years) 34.5 (Range 31-38) 62 (Range 46-76) ns 
Ethnicity Unknown Caucasian 14 (100%) N/A 
 
Table 5-3  Demographic details of SSc patients and healthy controls used to assess 
changes in mRNA transcription.  This compares demographic data available for 
gender, age and ethnicity.  A Fisher’s exact test was used to compare gender and an 
unpaired two-tailed t-test was used to calculate significance between age in the two 
groups.  ns = no significant difference. 
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 Healthy Controls 
used for 
Proliferation 
experiments (n=3) 
SSc-ILD Patients used 
for Proliferation 
experiments (n=10) 
Significant 
difference? 
Gender Male 1 (33%) 
Female 2 (66%) 
Male 1 (10%) 
Female 9 (90%) 
ns 
Age (years) 33 (Range 31-38) 55.5 (Range 46-76) **p<0.01 
Ethnicity Unknown Caucasian 10 (100%) N/A 
 
Table 5-4  Demographic data for SSc patients and healthy controls used in the cell 
proliferation experiment.  This compares demographic data available for gender, age 
and ethnicity.  A Fisher’s exact test was used to compare gender and an unpaired 
two-tailed t-test was used to calculate significance between age in the two groups.  
Healthy controls were significantly younger than the SSc-ILD patients.  ns = no 
significant difference 
 
 SSc-ILD Patients in 
qPCR experiments (n=4) 
SSc-ILD Patients in 
Proliferation 
experiments (n=10) 
Time from ILD diagnosis 
(days) 
Median 766 (Range 430-
1978) 
Median 860.5 (Range 66-
2849) 
Smoking history (Pack 
year smoking history) 
Never 3 (75%) 
Ex <20 0 (0%) 
      >20 but <40 1 (25%) 
      >40 0 (0%) 
Current 0 (0%) 
Never 6 (60%) 
Ex <20 2 (20%) 
      >20 but <40 1 (10%) 
      >40 1 (10%) 
Current 0 (0%) 
SSc Diagnostic Category Diffuse SSc 4 (100%) 
Limited SSc 0 (0%) 
Diffuse SSc 10 (100%) 
Limited SSc 0 (0%) 
CTD features Raynaud’s 3 (75%) 
Arthralgias 2 (50%) 
Sclerodactyly 3 (75%) 
Calcinosis 0 (0%) 
Raynaud’s 8 (80%) 
Arthralgias 5 (50%) 
Sclerodactyly 6 (60%) 
Calcinosis 0 (0%) 
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Raised CK 0 (0%) 
Mechanics hands 0 (0%) 
Myalgias 0 (0%) 
Periungal erythema 1 
(25%) 
Telangiectasia 1 (25%) 
Raised CK 0 (0%) 
Mechanics hands 0 (0%) 
Myalgias 1 (10%) 
Periungal erythema 3 
(30%) 
Telangiectasia 1 (10%) 
Respiratory features Clubbing 0 (0%) 
Crackles 3 (75%) 
Pulmonary hypertension 0 
(0%) 
Malignancy 0 (0%) 
Clubbing 0 (0%) 
Crackles 7 (70%) 
Pulmonary hypertension 0 
(0%)  
Malignancy 1 (10%) 
 
Table 5-5  Collected ILD data regarding the SSc patients.  Data collected includes 
time from ILD diagnosis, smoking history, diagnostic category and presence of CTD 
or respiratory features. 
 
5.2.2 The Effect of Plasma from Patients with SSc-ILD on the 
Morphology of MRC5 Fibroblasts 
 
Using methods described for treating cell lines with plasma, described in section 
2.3.2.3, MRC5 cells were treated with plasma from healthy control subjects or that 
from patients with diffuse SSc-ILD. Images were taken at 24, 48 or 72 hours and are 
shown in the figure below. 
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(a) (b) 
(c) 
(e) 
(d) 
(f) 
Figure 5-11  MRC5 cells treated over time course with healthy control or diffuse SSc 
plasma.  (a) Cells treated with healthy control plasma for 24 hours, (b) Cells treated 
with SSc patient plasma for 24 hours, (c) Cells treated with healthy control plasma for 
48 hours, (d) Cells treated with SSc patient plasma for 48 hours, (e) Cells treated with 
healthy control plasma for 72 hours (f) Cells treated with SSc patient plasma for 72 
hours.  There were no obvious differences in cell morphology between cells treated 
with healthy control plasma and those treated with SSc-ILD plasma at any time point.  
Magnification x10 objective lens, scale bar 10µm. 
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There were no obvious changes in MRC5 cell morphology between cells treated 
with healthy control plasma and those treated with plasma from patients with SSc-
ILD. The cells appeared over-confluent after 72 hours which is similar to the effects 
after treatment with IPF plasma.  It is unclear whether there is a difference in 
proliferation of the cells, and so a further experiment was undertaken to assess for 
proliferation. 
 
5.2.3 The Effect of Plasma from Patients with SSc-ILD on the 
Proliferation of MRC5 Fibroblasts 
 
An alamar blue assay was undertaken to assess for cell health and proliferation of 
MRC5 fibroblasts when treated with plasma from patients with diffuse SSc.  The 
results are shown in the figure below; 
 
Figure 5-12  Proliferation of MRC5 fibroblasts measured with alamar blue, when 
treated with plasma from healthy, control subjects (represented by red line, n=3) in 
comparison to cells treated with SSc patient plasma (represented by blue line, n=10).  
There were no significant differences in proliferation of MRC5 cells when cells 
were treated with healthy control plasma or SSc-ILD patient plasma.  Results are 
expressed as mean values +/- SD. Two-way anova with Bonferroni post-test was 
performed for analysis. 
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There was little or no difference in proliferation between cells treated with healthy 
control plasma and those treated with diffuse SSc patient plasma.  Cells probably 
reached maximum confluency in the 96 well plate by 48 hours, so it was difficult to 
interpret cell proliferation past this point but at 72 hours the cells did remain healthy 
and viable, despite the phenotypic changes shown in more detail in the figures 
below. 
 
5.2.4 Immunolocalisation of Thy-1 produced in MRC5 Fibroblasts 
Treated with Healthy Control Plasma Compared with Plasma 
from Patients with IPF and with SSc-ILD over 48 hours 
 
To assess the morphology of the MRC5 cells treated with plasma in greater detail 
and the localisation of proteins involved in fibrosis, immunocytochemistry was 
performed.  MRC5 cells were plated in 6 well plates and treated with patient plasma 
for 48 hours.  After 48 hours cells were fixed, permeabilised and stained for 
phalloidin, Thy-1 and nuclear DAPI.  This staining is shown in the figure below; 
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The images show that very little Thy-1 (represented by red staining) was produced 
by cells either treated with healthy control plasma, plasma from IPF patients or those 
with SSc-ILD.  However, the phalloidin staining in this image shows the change in 
the morphology of MRC5 cells after treatment with plasma for 48 hours, from 
healthy controls or from patients with ILD, very clearly.  This shows that the 
cytoplasm appeared more spindle shaped.  There were definite changes in the 
cytoplasm of the cell, however, this occurred in the cells treated with healthy control 
plasma or those treated with plasma from patients with ILD, suggesting that it is the 
Figure 5-13  MRC5 cells treated with plasma and stained for Thy-1. Green represents 
phalloidin staining, red is Thy-1 staining and nuclei are stained blue.  (a) Healthy 
control plasma, (b) Plasma from patient with IPF, (c) Plasma from patient with 
diffuse SSc. The images above are given as representative examples.  There was very 
little Thy-1 staining but the images show the changes in the MRC5 fibroblasts that 
have become more spindle-shaped.  Magnification x40 objective lens, scale bar 
50µm. 
(a) (b) 
(c) 
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plasma treatment that changed the cell morphology not a secreted circulating factor 
from patients with a particular systemic disease.   
 
5.2.5 Immunolocalisation of COL1A1 Produced by MRC5 
Fibroblasts Treated with Healthy Control Plasma Compared 
with Plasma from Patients with IPF and with SSc-ILD 
 
In a similar manner MRC5 cells were stained for COL1A1.  The results of this 
staining are shown in the figures below; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-14  MRC5 cells treated with plasma and stained for COL1A1. Green 
represents phalloidin staining, blue is nuclear staining and red is COL1A1.  (a) Healthy 
control plasma, (b) Plasma from patient with IPF, (c) Plasma from patient with SSc-
ILD.  Cells had become more disorganised with plasma treatment but were still 
producing COL1A1.  Magnification x20 objective lens, scale bar 100µm. 
(a) (b) 
(c) 
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Figure 5-14 and Figure 5-15 demonstrate that cells became disorganised after 
treatment with human plasma. Although the cytoplasm becomes more spindle 
shaped, the MRC5 cells treated with healthy plasma or plasma from ILD patients of 
either subgroup continued to produce COL1A1. There did not appear to be an 
appreciable difference in the amount of COL1A1 that was produced, which is 
similar to the changes seen in mRNA transcription. 
 
Figure 5-15  MRC5 cells treated with plasma and stained for COL1A1. (a) 
Healthy control plasma, (b) Plasma from patient with IPF, (c) Plasma from 
patient with diffuse SSc. This figure shows that there was no obvious 
difference in the quantity of COL1A1 produced by the cells when treated with 
different patient plasma.  Magnification x40 objective lens, scale bar 50µm. 
(a) (b) 
(c) 
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5.2.6 Immunolocalisation of α-SMA Produced by MRC5 
Fibroblasts Treated with Healthy Control Plasma Compared 
with Plasma from Patients with IPF and with SSc-ILD 
 
MRC5 cells were stained for α-SMA to assess if treatment with plasma from ILD 
patients caused an increase in production of this protein.  Results are shown in the 
figure below; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(c) 
(b) 
Figure 5-16  MRC5 cells treated with plasma and stained for α-SMA. Green represents 
phalloidin staining, blue is nuclear staining and red is α-SMA.  (a) Healthy control 
plasma, (b) Plasma from patient with IPF, (c) Plasma from patient with SSc-ILD. There 
was no difference in the amount of α-SMA produced by MRC5 cells whether treated with 
healthy control plasma, IPF plasma or SSc-ILD plasma.  Magnification x40 objective lens, 
scale bar 50µm. 
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Again, Figure 5-16 shows that the MRC5 cells remained disorganised after 
treatment with plasma.  There did not appear to be any difference in the amount of 
αSMA produced in either patient group after 48 hours of treatment.    
 
5.2.7 The Effect of SSc-ILD Plasma Treatment on Gene Expression 
in MRC5 Fibroblasts 
 
MRC5 cells were plated in 6 well plates and treated with plasma from healthy 
control subjects or plasma from patients with SSc-ILD.  After images were taken, 
RNA was extracted at 24 and 48 hours.  The figures below show changes in gene 
expression after 24 hours. 
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Figure 5-17  Two log of the fold difference values plotted individually for ECM 
genes showing MRC5 cells treated with healthy control plasma against those treated 
with plasma from patients with SSc-ILD for 24 hours.  (a) COL1A1, (b) COL3A1, 
(c) FN-EDA.  There were no significant differences in any of the ECM genes when 
MRC5 cells were treated with plasma from patients with SSc-ILD.  Bar represents 
mean value for SSc-ILD patients.  Unpaired two-tailed t-test performed for analysis. 
 
There were large variations between the results arising from patient and control 
plasmas.  It was thus difficult to draw conclusions from this data particularly when 
such a small number of subjects were studied.  However, there were no significant 
differences in production of any of the genes for ECM proteins after 24 hours of 
treatment using diffuse SSc-ILD patient plasma in comparison to treatment with 
healthy control plasma. 
 
(b) 
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Figure 5-18  Two log of the fold difference values plotted individually for the CCN 
genes showing MRC5 cells treated with healthy control plasma against those treated 
with plasma from patients with SSc-ILD for 24 hours.  (a) CCN1, (b) CCN2, (c) 
CCN3, (d) CCN4.  There was a significant downregulation in expression of CCN3 in 
cells treated with SSc-ILD plasma.  Bar represents mean value for patients with SSc-
ILD.  Unpaired two-tailed t-test performed for analysis, * p<0.05. 
 
The CCN family of genes was then assessed to see if there were any noticeable 
differences in these proteins after 24 hours treatment.  There appeared to be a slight 
downregulation in CCN1 although this did not meet significance.  This was 
associated with a significant reduction (p<0.05) in CCN3 in cells treated with SSc-
ILD plasma.  There appeared to be a corresponding decrease in CCN4 in cells 
treated with plasma from patients with SSc-ILD although this was non-significant. 
(a) (b) 
(c) (d) 
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Figure 5-19  Two log of the fold difference values plotted individually for other 
genes involved in fibrosis showing MRC5 cells treated with healthy control plasma 
against those treated with plasma from patients with SSc-ILD for 24 hours.  (a) 
MRTFa, (b) Thy-1.  There was no significant difference in either gene in MRC5 
cells treated with SSc-ILD plasma.  Bar represents mean value for patients with 
diffuse SSc.  Unpaired two-tailed t-test performed for analysis. 
 
Figure 5-19 shows no significant difference between the production of MRTFa or 
Thy-1 in those treated with healthy control plasma or SSc-ILD patient plasma.   
 
Overall, treatment of MRC5 cells with plasma from patients with diffuse SSc caused 
a significant down regulation of CCN3 but very little change in the other genes 
associated with fibrosis.  It is difficult to draw strong conclusions from this data as 
only very small numbers of healthy control subjects and patients with diffuse SSc 
were compared.  When the same patients were analysed after 48 or 72 hours there 
were no significant differences found between healthy controls and patients with 
SSc-ILD in any of the fibrosis genes examined, suggesting that no differences are 
occurring at the later time points.   
(a) (b) 
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This corresponds to the changes seen in MRC5 cells treated with IPF patient plasma, 
where very little difference in mRNA production occurred.  The A549 epithelial 
cells were then assessed to see if any changes were induced in this cell type. 
 
5.2.8 The Effect of Plasma from Patient with SSc-ILD on the 
Morphology of A549 Epithelial Cells 
 
In a similar way, A549 cells were plated and treated with plasma from patients with 
SSc-ILD or healthy control plasma for 24, 48 and 72 hours.  The figure below shows 
representative images taken at each time point. 
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(a) 
(c) 
(e) 
(d) 
(f) 
(b) 
Figure 5-20  A549 cells treated over time course with healthy control or SSc-ILD 
plasma.  (a) Cells treated with healthy control plasma for 24 hours, (b) Cells treated with 
SSc patient plasma for 24 hours, (c) Cells treated with healthy control plasma for 48 
hours, (d) Cells treated with SSc patient plasma for 48 hours, (e) Cells treated with 
healthy control plasma for 72 hours (f) Cells treated with SSc patient plasma for 72 
hours.  There were no differences in epithelial cell morphology between cells treated 
with healthy control plasma and those treated with plasma from patients with SSc-ILD.  
Magnification x10 objective lens, scale bar 10µm. 
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There did not appear to be any obvious changes in morphology of A549 cells treated 
with SSc-ILD patient plasma.  Cells appeared most confluent at 48 hours in both 
patient and control wells.  At 72 hours cells appeared less confluent but it was 
unclear whether this was due to cell death or variation within the well.  A 
proliferation assay was undertaken to assess this further. 
 
5.2.9 The Effect of Plasma from Patients with SSc-ILD on the 
Proliferation of A549 Epithelial Cells 
 
 
Figure 5-21  Proliferation of A549 epithelial cells measured with alamar blue, when 
treated with plasma from healthy, control subjects (represented by red line, n=3) in 
comparison to cells treated with plasma from patients with SSc-ILD (represented by 
blue line, n=10).  A549 cells appeared to proliferate at a similar rate whether cells 
were treated with healthy control plasma or SSc-ILD plasma.  Results are expressed 
as mean values +/- SD. Two-way anova with Bonferroni post-test was performed for 
analysis. 
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There were no significant differences in proliferation when A549 cells were treated 
with plasma from patients with SSc-ILD compared to healthy control plasma.  Cells 
appeared to grow consistently throughout the 72 hours, with no appreciable 
difference between the two groups. 
 
5.2.10 Immunolocalisation of α-SMA produced by A549 Epithelial 
Cells Treated with Healthy Control Plasma Compared with 
Plasma from Patients with SSc-ILD 
 
A549 cells were stained for αSMA to assess whether there was an upregulation of 
this protein with plasma treatment, suggesting EMT was occurring. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
Figure 5-22  A549 cells treated with plasma and stained for αSMA. Blue is nuclear 
staining and red is αSMA.  (a) Healthy control plasma, (b) Plasma from patient with SSc-
ILD.  There appeared to be more α-SMA produced in the A549 cells treated with SSc-
ILD plasma, as represented by increased red staining in image (b).  Magnification x40 
objective lens, scale bar 100µm. 
(a) (b) 
172 
 
Figure 5-22 shows that A549 cells produced αSMA when treated with patient 
plasma, and there appeared to be more αSMA produced by A549 cells treated with 
plasma from patients with SSc-ILD compared to those treated with healthy control 
plasma.  This was then compared to qPCR data available for the genes involved in 
production of the ECM, described below. 
 
5.2.11 The Effect of SSc-ILD Plasma Treatment on Gene Expression 
in A549 Epithelial Cells 
 
RNA was extracted after treatment of the A549 cells for 24 and 48 hours.  The 
results at 24 hours are shown in the figure below.  However, they should be 
interpreted with caution as there are noticeable large differences present between 
patients and very small numbers were used for this exploratory experiment.   
 
 
 
 
 
 
 
173 
 
COL1A1
C
on
tr
ol
 
P
at
ie
nt
 
-3
-2
-1
0
1
2
 l
o
g
 f
o
ld
 d
if
fe
r
e
n
c
e
   COL3A1
C
on
tr
ol
Pa
tie
nt
-2
0
2
4
6
***
2
 l
o
g
 f
o
ld
 d
if
fe
r
e
n
c
e
 
 
        FN-EDA
C
on
tr
ol
Pa
tie
nt-1
0
1
2
3
4
**
2
 l
o
g
 f
o
ld
 d
if
fe
r
e
n
c
e
 
Figure 5-23  Two log of the fold difference values plotted individually for ECM 
genes showing A549 cells treated with healthy control plasma against those treated 
with plasma from patients with SSc-ILD for 24 hours.  (a) COL1A1, (b) COL3A1, 
(c) FN-EDA.  There was a significant increase in gene expression for COL3A1 and 
FN-EDA in A549 cells treated with SSc-ILD plasma.  Bar represents mean value for 
SSc-ILD patients.  Unpaired two-tailed t-test performed for analysis, **p<0.01, 
***p<0.001. 
 
Figure 5-23 shows an upregulation of COL3A1 (p<0.001) and FN-EDA (p<0.01) in 
A549 cells treated with plasma from patients with SSc-ILD plasma.  qPCR was then 
performed on the CCN family to assess if these changes could be explained due to 
changes in this family of genes.   
(c) 
(a) (b) 
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Figure 5-24  Two log of the fold difference values plotted individually for CCN 
genes showing healthy control values against those with SSc-ILD after treatment of 
A549 cells for 24 hours.  (a) CCN1, (b) CCN2, (c) CCN3.  There were no significant 
differences in gene expression of any of the CCN genes tested in this experiment 
when cells were treated with SSc-ILD patient plasma.  Bar represents mean value 
for patients with SSc-ILD.  Unpaired two-tailed t-test performed for analysis. 
 
Figure 5-24 shows that there were no significant differences seen in any of the CCN 
family of genes after 24 hours.  It was then assessed if these changes could be 
explained by changes in the transcription factors Slug and Snail, or the markers of 
EMT, E-cadherin and N-cadherin, that occur earlier in the fibrosis pathway. 
 
(c) 
(a) (b) 
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Figure 5-25 Two log of the fold difference values plotted individually for the 
transcription factors Snail and Slug and cell surface markers E-cadherin and N-
cadherin showing healthy control values against those with plasma from patient 
with SSc-ILD after treatment of A549 cells for 24 hours.  (a) Snail, (b) Slug, (c) E-
cadherin, (d) N-cadherin.  There was a significant increase in expression of E-
cadherin in cells treated with SSc-ILD patient plasma when compared with healthy 
control plasma.  Bar represents mean value for SSc-ILD patients.  Unpaired two-
tailed t-test performed for analysis, * p<0.05. 
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There appeared to be an upregulation in both Slug and Snail, although this difference 
did not meet significance, and would need to be confirmed using a larger patient 
group.  There was a significant increase in E-cadherin production, which is 
surprising and would not explain the changes seen in production of ECM proteins.  
There was also a trend to upregulation of N-cadherin although this trend did not 
meet significance.  However, it is recognised that this protein is increased in EMT 
and would be associated with the changes seen in ECM proteins, shown in Figure 
5-23.  RNA was extracted and qPCR performed for cells at 48 hours. Although there 
was a trend for a continued increase in production of COL3A1, this did not meet 
significance.  There was no significant difference between groups for any of these 
genes when they were assessed at 48 hours. 
In conclusion, treatment of A549 epithelial cells with plasma from patients with 
SSc-ILD, caused a significant upregulation in the production of COL3A1 (p<0.001) 
and FN-EDA (p<0.01) mRNA.  Interestingly, there was no significant difference in 
production of COL1A1.   
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6 Adapting the in vitro Model to Assess the Impact 
of Stretch on Fibrotic Pathways 
 
The lungs are not an immobile organ but are constantly moving to allow respiration.  
For this to occur cells in the lung are undergoing constant stress in the form of 
stretch.  Many lung cell studies have tried to replicate this movement both in vitro 
and in vivo and have found that these shear forces alone do impact upon cellular 
responses to wound healing and pro-fibrotic stimulation (170).  It was therefore 
appropriate to investigate what happens to stretched pulmonary cells in the presence 
of TGF-β, and how key pro-fibrotic genes behave under such a stretch regime.  Both 
fibroblasts and epithelial cells have thus been investigated in vitro, the results of 
which are shown in this chapter.   
It is already recognised that lung-derived cells respond differently to stretch 
depending on the density of the cells that are experimentally plated (171).  The 
particular substrate that the cells are grown on, for example a collagen coating or a 
FN coating, will have an impact upon how the cells react, as well as the substrate 
used, e.g. tissue culture plastic (172).  There are also different responses depending 
on the degree of stretch applied and whether the resulting force is unidirectional or 
bidirectional in nature (173).  These variables will thus have an impact upon the 
response of the cells to both stretch and TGF-β treatment.  The conditions used for 
the current experiments were therefore carefully chosen to try to mirror the 
environment pulmonary parenchymal cells are subjected to in vivo. 
Initially MRC5 cells were stretched using the methods described in section 2.3.2.4. 
A higher density of cells was plated than described in previous chapters, and the 
cells were cultured until almost confluent prior to treatment as cell density may 
impact their response and this ensured this variable was standardised.  The plated 
cells were either treated with TGF-β (2ng/ml), stretch, a combination of both TGF-β 
(2ng/ml) and stretch or cultured in the same conditions but left untreated.  Stretch 
was applied using the Flexcell Strain Unit at 6.66% length in pulsed sine wave 
intervals at a frequency of 1 Hz.  
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6.1.1 The Effect of Stretch +/- TGF-β (2ng/ml) on the Morphology 
of MRC5 Cells  
 
The experiments assessed whether stretch forces applied to the MRC5 fibroblast 
cells in culture caused a change in their morphology.  Figure 6-1 (below) shows that 
when stretch was applied to the cells, they became slightly more organised spatially 
and began to follow a single direction.  It should be noted that the stretch applied to 
the fibroblasts was biaxial, with cells grown as a monolayer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
Figure 6-1  Change in morphology of MRC5 cells treated with TGF-β +/- stretch for 24 
hours.  (a) Control cells treated in the same conditions without the addition of TGF-β or 
stretch, (b) MRC5 cells treated with stretch only, (c) MRC5 cells treated with TGF-β 
(2ng/ml), (d) MRC5 cells treated with TGF-β (2ng/ml) and stretch.  Cells became more 
organised and began to follow a similar direction.  Magnification x10 objective lens, 
scale bar 10µm. 
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6.1.2 The Effect of TGF-β (2ng/ml) +/- Stretch Treatment on Gene 
Expression in MRC5 Fibroblasts 
 
Once images had been taken, mRNA was extracted from cells using methods 
previously described in section 2.7.  The first genes to be assessed were those that 
code for ECM proteins, including those for COL1A1 and FN-EDA. 
 
 
Figure 6-2  Fold change in COL1A1 and FN-EDA in MRC5 cells after treatment 
with stretch +/- TGF-β (2ng/ml) over 24 hours.  There was a significant increase in 
FN-EDA when cells were treated with TGF-β, which was attenuated when combined 
with stretch.  Results shown are mean values (n=4) with error bars +/- SEM.  One-
way anova with Bonferroni post-test performed, *p<0.05, **p<0.01. 
 
Figure 6-2 shows that there were no changes in COL1A1 when the MRC5 cells were 
treated with stretch alone.  As shown in chapter 4, there was however an 
upregulation in gene expression of COL1A1 after treatment with TGF-β (2ng/ml) to 
just over twice the baseline levels, which was also shown in this experiment.  When 
stretch was used alongside TGF-β, the transcription of COL1A1 stayed at around 
twice the baseline levels, similar to the changes seen with TGF-β treatment alone. 
Similarly, there was no change in FN-EDA expression when the cells were treated 
with stretch alone.  There was a 3.5-fold increase in transcription of FN-EDA when 
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MRC5 cells were treated with TGF-β (p<0.01), with these results mirroring those 
seen in chapter 4.  Interestingly, when stretch was also deployed alongside TGF-β 
treatment, there was a reduction in the amount of FN-EDA produced (p<0.05).  This 
was surprising as it was expected that these stressed cells may produce more FN-
EDA.  Other genes involved in fibrosis were therefore examined to try to explain 
these changes. 
 
 
Figure 6-3 Fold changes in CCN1, CCN2, CCN3 and CCN4 in MRC5 cells after 
treatment with stretch +/- TGF-β over 24 hours.  There were no significant 
differences in any of the CCN genes regardless of treatment with TGF-β, stretch or a 
combination of the two.  Results are mean values (n=4) with error bars +/- SEM.  
One-way anova with Bonferroni post-test performed.  
 
Figure 6-3 shows there were no significant differences between any members of the 
CCN family when the MRC5 cells were treated with stretch, TGF-β or a 
combination of the two.  There was an upregulation of both CCN1 and CCN2 when 
the cells were treated with TGF-β alone, which occurred simultaneously alongside a 
decrease in the amount of CCN3 and CCN4, but none of these results were 
statistically significant.  These results were similar to those seen in chapter 5, 
although these genes were only checked at the 48 hour time point whereas the above 
results are after 24 hours.  When stretch was applied together with TGF-β treatment, 
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there was a downregulation of both CCN1 and CCN2 to baseline levels.  This may 
explain why there was a corresponding reduction of mRNA transcription of FN-
EDA when the cells are treated with both stretch and TGF-β.  In the case of CCN3 
and CCN4, there appeared to be an increase in transcription of these genes when 
cells were treated with TGF-β and stretch, although this did not meet significance 
due to large error bars. 
 
 
Figure 6-4  Fold change in MRTFa and Thy-1 in MRC5 cells after treatment with 
stretch +/-TGF-β (2ng/ml) over 24 hours.  There was a significant upregulation of 
MRTFa when MRC5 cells were treated with TGF-β and stretch.  Results are mean 
values (n=4) with error bars +/- SEM.  One-way anova with Bonferroni post-test 
performed, *p<0.05. 
 
There were minor changes in MRTFa or Thy-1 gene expression when MRC5 cells 
were treated with stretch for 24 hours.  When the cells were treated with TGF-β 
there was a minor upregulation of MRTFa although this was not significant.  This 
was however significantly upregulated when the cells were treated with both TGF-β 
and stretch together (p<0.05).  There was no substantial change in transcription of 
Thy-1 in cells treated with TGF-β, stretch or both together.   
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6.1.3 The Effect of Treatment with Human Plasma +/- Stretch on 
Gene Expression in MRC5 Fibroblasts 
 
This stretch experiment design was then modified to assess the effect of human 
plasma on the transcription of these proteins.  MRC5 cells were thus plated onto 
bioflex plates as described, and treated with human plasma (100ul per well), with 
one plate receiving either healthy control or IPF patient plasma without stretch and 
the other plate receiving the same plasma but having stretch applied.  RNA was 
extracted after 24 hours of stretch. The results should be interpreted with caution as 
they were generated using small numbers of patients.  This movement added an 
extra dimension to the model established in the previous chapters.   
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Figure 6-5  Two log of the fold difference values plotted individually for 
transcription of COL1A1 showing cells treated with healthy control plasma and not 
subjected to stretch, cells treated with plasma from IPF patients not subjected to 
stretch, healthy control plasma values alongside stretch treatment and IPF plasma 
alongside stretch treatment applied for 24 hours.  There was no significant difference 
in gene expression of COL1A1 whether cells were cultured in static conditions or 
treated alongside stretch.  Bars show mean values.  One-way anova performed for 
statistical analysis.  HC, healthy control; IPF, Idiopathic Pulmonary Fibrosis. 
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There were no significant differences noted in transcription of COL1A1 between 
cells treated with IPF patient plasma or healthy control plasma.  This result applied 
whether cells were static or subjected to stretch.  There did appear to be a slight 
decrease in the amount of COL1A1 produced by the cells in either group when they 
were subjected to stretch although this difference was not significant.  
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Figure 6-6 (overleaf) Two log of the fold difference values plotted individually for 
transcription of the CCN genes showing cells treated with healthy control plasma 
and not subjected to stretch, cells treated with plasma from IPF patients not 
subjected to stretch, healthy control plasma values alongside stretch treatment and 
IPF plasma alongside stretch treatment after 24 hours.  (a) CCN1, (b) CCN2, (c) 
CCN3, (d) CCN4.  There was a significant reduction in expression of CCN4 when 
MRC5 cells were treated with IPF plasma alongside stretch, as shown in (d).  Bars 
show mean values.  One-way anova performed for analysis, ** p<0.01.  HC, healthy 
control; IPF, Idiopathic Pulmonary Fibrosis. 
 
 
There were no differences in transcription of CCN1, CCN2 or CCN3 between cells 
treated with IPF patient plasma or those treated with healthy control subject plasma.  
These results were similar to those shown in chapter 5.  There were also no 
significant differences noted when the cells were stretched. 
CCN4 is also shown in the figure above.  There was no significant difference 
between unstretched cells treated with IPF plasma and healthy control plasma, in 
accordance with the data shown in chapter 5.  However, when cells were stretched 
there was a decrease in transcription of CCN4 that reached significance (p<0.01) in 
cells treated with plasma from IPF patients.  There also appeared to be a decrease in 
CCN4 transcription when the cells were stretched in the presence of healthy control 
plasma, although this did not meet significance. 
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Figure 6-7  Two log of the fold difference values plotted individually for 
transcription of the other genes involved in fibrosis, showing results from MRC5 
cells treated with healthy control plasma and not subjected to stretch, cells treated 
with plasma from IPF patients not subjected to stretch, healthy control plasma 
values with stretch and IPF plasma alongside applied stretch after 24 hours.  (a) 
MRTFa, (b) Thy-1.  There was a significant reduction in expression of Thy-1 when 
MRC5 cells were treated with IPF plasma alongside stretch.  Bars show mean 
values.  One-way anova performed for analysis, ** p<0.01. HC, healthy control; 
IPF, Idiopathic Pulmonary Fibrosis.  
 
 
 
(a) 
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MRC5 cells were also investigated for changes in gene expression of MRTFa and 
Thy-1 in the presence of IPF patient plasma.  There was no difference in 
transcription of MRTFa in cells treated with healthy control plasma or plasma from 
patients with IPF.  When cells were stretched it caused no difference in transcription 
compared to cells that were not stretched and whether cells were treated with IPF 
plasma or healthy control plasma. 
When Thy-1 was similarly tested, there were no differences when cells were treated 
with either IPF plasma or healthy control plasma and cultured under static 
conditions, again mirroring the results shown in chapter 5.  However, when the cells 
were stretched there was a downregulation of Thy-1 which reached significance 
when the cells were treated with IPF plasma.  This may not have met significance in 
cells treated with healthy control plasma due to the small number of patients 
assessed in this group.   
 
6.1.4 The Effect of Treatment with TGF-β (1.5ng/ml) +/- Stretch on 
the Morphology of A549 Epithelial Cells 
 
A549 cells were stretched using the methods described in section 2.3.2.5.  The 
stretch chambers used for this experiment were from a custom-built machine which 
stretches cells in a unidirectional manner, thus differing from the MRC5 experiment 
described above where the cells were stretched in a bidirectional manner. 
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There did not appear to be any obvious change in the morphology of the A549 cells 
when they were subjected to stretch.  It was also difficult to assess whether there 
was any difference in the morphology of the epithelial cells when they were treated 
with TGF-β.  One limitation of using the custom-built stretch machine was that 
chambers needed to be coated prior to each experiment.  This meant that a laminin 
coating was put onto the chambers before they were incubated prior to use.  This 
(a) (b) 
(c) (d) 
Figure 6-8  Change in morphology of A549 cells treated with TGF-β (1.5ng/ml) +/- 
stretch for 24 hours.  (a) Control cells treated in the same conditions without the 
addition of TGF-β or stretch, (b) A549 cells treated with stretch only, (c) A549 cells 
treated with TGF-β (1.5ng/ml), (d) A549 cells treated with TGF-β (1.5ng/ml) and 
stretch.  There were no changes in the morphology of the A549 cells when treated 
with stretch.  In these images it is difficult to appreciate whether there is any change 
when cells were treated with TGF-β, the reasons for this are discussed in more detail 
below.  Magnification x10 objective lens, scale bar 10µm. 
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may mean that the coating of the chamber may not have been uniform leading to 
cells in some areas of the chamber not being confluent.  The material of the chamber 
was also much softer meaning that the cells may behave differently due to the 
change of material that they are plated on. 
 
 
6.1.5 The Effect of TGF-β (1.5ng/ml) +/- Stretch Treatment on 
Gene Expression in A549 Epithelial Cells 
 
 
 
Figure 6-9  Fold change in COL1A1, Snail, Slug and E-cadherin in A549 cells 
following treatment with TGF-β +/- stretch over 24 hours.  Stretch alone did not lead 
to any significant differences in any of the above genes.  When treated with TGF-β 
there was a significant increase in COL1A1 and Slug, which was attenuated when 
cells were treated alongside stretch.  Results are mean values (n=4) with error bars 
+/- SEM.  One-way anova with Bonferroni post-tests were performed, ***p<0.001. 
 
This figure shows there was very little or no change in the transcription of COL1A1 
produced by A549 cells subjected to stretch alone.  However, when these cells were 
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treated with TGF-β there was over a 16-fold increase in COL1A1 mRNA, as 
previously shown in chapter 4.  However, this response was attenuated when the 
cells were treated with TGF-β and subjected to unidirectional stretch for 24 hours.  
Other genes were then explored to assess if this impact could be explained. 
The transcription factors Slug and Snail were therefore assessed.  The result showed 
similar patterns of change to those seen in COL1A1 with a more obvious increase 
observed in Slug.  There was very little change in either Snail or Slug when the 
A549 cells were subjected to stretch alone.  There was however a large increase in in 
transcription of Slug and Snail after treatment with TGF-β, mirroring effects 
previously seen in chapter 4.  This response was attenuated when the cells were 
treated with both TGF-β and stretch for 24 hours, perhaps explaining the trend seen 
for COL1A1.  There was very little difference seen in E-cadherin, whether cells 
were treated with stretch, TGF-β or a combination of both.  This trend followed that 
seen in chapter 4. 
 
 
Figure 6-10  Fold change in CCN1, CCN2, CCN3 and CCN4 in A549 cells after 
treatment with TGF-β (1.5ng/ml) +/- stretch over 24 hours.  There were no 
significant differences in expression of the CCN genes whether exposed to stretch, 
TGF-β or a combination of both.  Results are mean values (n=4) with error bars +/- 
SEM.  One-way anova with Bonferroni post-test performed. 
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Treating the A549 cells with either TGF-β, stretch or a combination of the two did 
not induce any significant changes in the expression of the CCN genes within the 
A549 epithelial cells.  This differed from chapter 4 where treatment with TGF-β 
alone led to a significant increase in CCN1 and CCN2.  However, in chapter 4 these 
changes were measured at 48 hours and the changes above are measured at 24 hours.  
Also, the significant differences in chapter 2 were only seen when cells were treated 
with 3ng/ml TGF-β (p<0.01), but the cells above were treated with a smaller 
concentration (1.5ng/ml) which may also explain the differences observed.  
 
6.1.6 The Effect of Human Plasma +/- Stretch Treatment on Gene 
Expression in A549 Epithelial Cells 
 
This model was then adapted to assess the effects of plasma from patients with IPF 
in combination with stretch. 
 
 
192 
 
COL1A1
N
o 
st
re
tc
h 
/ H
C
N
o 
st
re
tc
h 
/ I
PF
St
re
tc
h 
/ H
C
St
re
tc
h 
/ I
PF
-0.5
0.0
0.5
1.0
1.5
2.0
 
*
2
 l
o
g
 f
o
ld
 d
if
fe
r
e
n
c
e
 
Figure 6-11  Two log of the fold difference values plotted individually for 
transcription of COL1A1 showing cells treated with healthy control plasma and not 
subjected to stretch, cells treated with IPF patient plasma and not subjected to 
stretch, healthy control plasma values alongside stretch treatment and IPF plasma 
alongside stretch treatment after 24 hours.  When cells were treated with IPF plasma 
alongside stretch there was a significant increase in expression of COL1A1.  Bars 
show mean values.  One-way anova performed for analysis, * p<0.05. HC, healthy 
control; IPF, Idiopathic Pulmonary Fibrosis.  
 
In A549 cells there were no significant differences between cells that were treated 
with healthy control plasma or IPF patient plasma and cultured under static 
conditions.  However, there appeared to be upregulation in COL1A1 transcription 
once these cells were subjected to stretch, which did reach significance in the cells 
treated with IPF patient plasma (p<0.05). 
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Figure 6-12  Two log of the fold difference values plotted individually for 
transcription of CCN2 showing cells treated with healthy control plasma and not 
subjected to stretch, cells treated with IPF patient plasma and not subjected to 
stretch, healthy control plasma values alongside stretch treatment and IPF plasma 
alongside stretch treatment after 24 hours.  There was no significant difference in 
CCN2 when A549 epithelial cells were treated with IPF plasma and stretch.  Bars 
show mean values.  One-way anova performed for analysis. HC, healthy control; 
IPF, Idiopathic Pulmonary Fibrosis.  
 
CCN2 was then investigated to assess if this upregulation could be explained 
through regulation of this gene which seems to hold such a crucial role in fibrosis.  
Again, when cells were not subjected to stretch there appeared to be no difference in 
CCN2 transcription whether cells were treated with IPF patient plasma or healthy 
control plasma.  However, once stretch was applied there appeared to be a 
corresponding upregulation of CCN2, mirroring the effects seen in the transcription 
of COL1A1.  However, as there was variation between subjects this effect did not 
meet significance. 
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Figure 6-13  Two log of the fold difference values plotted individually for 
transcription of Slug and Snail showing cells treated with healthy control plasma not 
subjected to stretch, cells treated with plasma from patients with IPF and not 
subjected to stretch, healthy control plasma alongside stretch treatment and IPF 
plasma values alongside stretch treatment after 24 hours.  There were no significant 
differences in either transcription factor when cells were treated with IPF plasma 
when in static conditions or when subjected to stretch.  Bars show mean values.  
One-way anova performed for analysis.  HC, healthy control; IPF, Idiopathic 
Pulmonary Fibrosis. 
 
(a) 
(b) 
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There were no significant differences noted in the transcription factors Slug or Snail 
when cells were treated with healthy control plasma or IPF patient plasma, as 
previously shown in chapter 5.  When these cells were exposed to stretch, there were 
no significant differences noted in either of these genes. 
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Figure 6-14  Two log of the fold difference values plotted individually for E-
cadherin showing cells treated with healthy control plasma not subjected to stretch, 
cells treated with plasma from IPF patients and not subjected to stretch, healthy 
control plasma alongside stretch treatment and IPF plasma values alongside stretch 
treatment after 24 hours.  There were no significant differences in E-cadherin when 
cells were treated with IPF plasma and subjected to stretch.  Bars show mean values.  
One-way anova performed for analysis.  HC, healthy control; IPF, Idiopathic 
Pulmonary Fibrosis. 
 
Finally, E-cadherin expression was assessed to see if its regulation was changed 
when cells were stretched.  There were no significant differences apparent between 
transcription of mRNA for this protein when comparing treatment with healthy 
control plasma and IPF patient plasma or when comparing the effect of stretch. 
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7 Discussion 
 
The results presented in this thesis examine the important molecular processes 
involved in inducing and propagating lung fibrosis in IPF and those occurring in 
CTD-ILD.  A number of techniques were used throughout the thesis to achieve some 
key objectives; 
1) To assess whether the IPF population of the UK-BILD study is truly 
homogeneous or whether there are a number of patients misdiagnosed as IPF 
who have an autoantibody present in their sera associated with an underlying 
CTD. 
2) To develop an in vitro cellular model with which to assess changes in genes 
associated with fibrosis which is both reliable and reproducible. 
3) To utilise this cellular model by treating cells with plasma from patients with 
fibrotic diseases and assess if there are differences in the response of the cells 
when compared to healthy controls and when compared to each other. 
4) To imitate the continued movement of the lungs, and the shear forces that 
cells within the lung are exposed to, by stretching the cells in culture.  This 
model was used to assess whether this has any effect on the cellular 
response, firstly using TGF-β and then when cells were treated with IPF 
plasma.  
The major findings of this work included: 
1) Respiratory physicians are good at diagnosing IPF and an underlying CTD is 
not missed very frequently (less than 2% of patients).  It can be inferred that 
the UK-BILD cohort of patients with IPF are a homogeneous population 
with which to do further work. 
2) A cellular model was produced that was able to identify and measure 
extracellular matrix and other fibrosis associated gene induction by TGF-β. 
3) The model was utilised using plasma from patients with fibrotic diseases.  
This appears a novel way to investigate fibrotic pathways. 
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The results of each chapter, with their strengths and limitations, will now be 
discussed in more detail below. 
7.1 Immunoprecipitation Results 
 
The results presented in chapter 3 used immunoprecipitation to identify 
autoantibodies in the sera of patients with IPF.  It was hypothesised that patients 
were being misdiagnosed and actually had an underlying CTD, which would hinder 
any comparisons between IPF and CTD-ILD undertaken in later chapters.  More 
importantly, it also has considerable clinical implications for patients as the 
treatments for the two conditions is different.  CTD-ILD usually responds to steroids 
and immunosuppression, however this is harmful in IPF and actually increases 
mortality (15), perhaps due to side effects such as increased rates of infection.  
Conversely, if patients are misdiagnosed with IPF they may miss out on therapeutic 
options in the form of steroids.  It was therefore of vital importance that the 
diagnostic error in IPF in a UK population was measured.  Although this has been 
investigated previously in Japanese and Korean populations it was unknown in the 
UK population with IPF (69, 70).  Serum samples from 249 patients with IPF were 
screened for autoantibodies using the gold-standard test of immunoprecipitation.  
The results of the UK-BILD population revealed that just 4 patients (1.6%) had an 
underlying MSA / MAA in their sera.  These included anti-OJ, anti-Ku, anti-PM-Scl 
and anti-RNA Pol II.  Each antibody and their associated features are discussed in 
more detail in chapter 3.   
When analysed these patients did not have any overt features suggestive of an 
underlying CTD according to the UK-BILD proforma.  For this reason, it may be 
argued that although a patient has the presence of an autoantibody it cannot be 
concluded that they have the associated disease.  For example, it is known that 
patients may be anti-CCP antibody positive for several years prior to the 
development of Rheumatoid Arthritis (174). However, it is also recognised that a 
patient can have ILD as a lone feature of an underlying CTD and that other features 
such as mechanic’s hands may be subtle or may develop later during the course of 
the disease (175).  One limitation of this study is that these subtle features are 
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assessed by clinicians at each centre and depends upon the expertise of the 
individual physician. 
Overall, the results give confidence that respiratory physicians are accurate when 
making a diagnosis of IPF and the reassurance that patients are likely receiving the 
correct treatment. The 4 patients who had a CTD-associated autoantibody present in 
their sera were diagnosed in non-specialist ILD centres.  It does suggest that an IPF 
diagnosis is more certain when made in a specialist ILD setting, however this is a 
very small number of patients and overall the diagnosis of IPF is secure.  
Interestingly, there appeared to be more patients with IPF with strong bands found 
on immunoprecipitation (36.5% rather than less than 10% in a healthy population, 
data according to expert opinion at the University of Bath).  There did not appear to 
be any obvious demographic differences between patients with strong bands and 
those with no bands present. The significance of these bands is unclear, it may be 
that these patients run a different disease course but as this is a cross-sectional study 
this cannot be investigated and any future longitudinal studies may be able to assess 
the relevance of this finding. 
There was also a novel band noted, present at 54 kDa, with examples given in 
Figure 3-2 and consistent with an associated autoantibody, found in 7 patients 
diagnosed with IPF.  Unfortunately, experiments to classify this antibody have been 
unsuccessful so far.  It did not appear to be consistent with any overt CTD features 
in this population.  Again, longitudinal studies, with collection of Pulmonary 
Function Test (PFT) data, may be helpful to assess if these patients respond 
differently to treatment or have a different disease course than the antibody negative 
population. 
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7.2 The Development of an in vitro Model in MRC5 
Fibroblasts 
 
As chapter 3 has shown that the IPF population from the UK-BILD study is 
homogeneous, the samples collected were then used in further chapters to assess 
differences in the fibrotic pathways between IPF and CTD-ILD.  Firstly, an in vitro 
assay was established to ensure that a reliable and reproducible model was produced.  
Cells were cultured and treated with TGF-β, a pro-inflammatory cytokine that 
promotes fibrosis.  It was chosen as it is a key molecule in the pathway of fibrosis 
and may cause effects similar to those when cells are treated with human plasma 
from patients with fibrotic diseases.  Two cell types, fibroblasts and epithelial cells, 
were chosen as they are key cells associated with fibrosis in the lungs. They both 
have the ability to become a “myofibroblast”, a cell with contractile properties with 
current literature suggesting it is the key cell responsible for fibrotic processes.  
Another cell type with the ability to transition into a cell with mesenchymal 
properties are the endothelial cells, they do this via a process called endothelial-
mesenchymal transition, discussed in more detail in the introduction.  It is 
recognised that they are a key cell to study, particularly in SSc where endothelial 
dysfunction is part of the disease pathogenesis, but unfortunately due to time 
constraints endothelial cells were not used in this experiment.  Future work may be 
important to assess changes in this cell type also.  Initially, for this thesis and to 
assess the viability of this experimental method, the MRC5 fibroblasts and A549 
epithelial cells were treated with increasing concentrations of TGF-β to assess the 
changes that occur.   
When treated with increasing concentrations of TGF-β there appeared to be a 
corresponding increase in proliferation of MRC5 cells when they were visually 
assessed at different time points.  However, an alamar blue assay performed to 
measure proliferation of the cells found that as cells were treated with increasing 
concentrations of TGF-β, there was actually a decrease in the proliferation of the 
fibroblasts.  This became significant at the highest concentration of TGF-β (2 ng/ml) 
when cells were treated for 96 hours.  The response appeared dose-dependent.  This 
was an unexpected result given the photomicrographs of the cell plates, however it 
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may be that when cells were treated with TGF-β they underwent morphological 
changes, becoming larger and giving the impression of being more numerous.  At 
higher TGF-β treatment concentrations they were also producing more fibrotic 
proteins, but this may occur at the expense of cell proliferation.  Early literature 
published on TGF-β suggests that it has very little effect on the proliferation of 
fibroblasts, and actually has inhibitory effects on epithelial cells and endothelial 
cells (discussed later in this chapter) (176-178).   
Given the morphological changes described above, immunocytochemistry was 
performed to assess for changes in the ECM proteins to show if treatment with TGF-
β was leading to increased expression of these molecules. This showed an increase 
in the amount of α-SMA protein present within the fibroblasts treated with TGF-β.  
This protein is a hallmark of the myofibroblast, suggesting that cells were changing 
in response to the TGF-β treatment.  Fibroblasts were also stained for COL1A1 
however as this protein was so abundant prior to treatment with TGF-β it was 
difficult to assess whether more of this protein was being produced after treatment.  
Quantitative PCR and western blot techniques were therefore used to assess for 
changes in gene expression and protein secretion from these treated cells. 
There was a significant increase in gene expression of COL1A1 in MRC5 cells 
treated with TGF-β (1ng/ml and 2ng/ml) after 24 hours.  This effect was to twice the 
control level and was not sustained at the later time points.  This was associated with 
a significant increase in FN-EDA at all concentrations of TGF-β used after 24 hours.  
This effect was sustained at 48, 72 and 96 hours at the highest concentration of 
TGF-β (2ng/ml).  Although COL3A1 has been described as an important molecule in 
fibrosis and the production of ECM, there was no significant increase in this gene at 
any time point tested throughout the experiment. However, the first time point used 
was 24 hours and significant changes in COL3A1 expression may be seen at earlier 
time points than this.  These results are in line with many previous experiments that 
showed TGF-β involvement in matrix deposition by fibroblast cells (176, 179). 
There may be several reasons for this reduction in response of COL1A1 and FN-
EDA over 96 hours.  Binding of TGF-β to its receptor leads to a downstream 
response in the phosphorylation of Smad within 5 minutes (108).  Therefore, the 
transcription of genes affected by TGF-β signalling will occur quickly and may be 
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seen at 24 hours rather than 96 hours when feedback mechanisms may downregulate 
this transcription.   
It was then assessed whether this increase in gene transcription led to an increase in 
the production of protein secreted by fibroblasts by undertaking a western blot.  
Visually, by assessing the blot image, it appeared there was more COL1A1 
produced by MRC5 fibroblasts after 96 hours with increasing concentrations of 
TGF-β.  However, once this was normalised using a ponceau stain to compare 
protein loading between lanes, the increase was not significant.  This technique was 
repeated for FN which produced a dose-dependent increase in FN protein and 
showed significant effects at 1ng/ml and 2ng/ml (p<0.01) which would complement 
the qPCR data previously discussed.  These changes agree with previous literature 
that has shown that fibroblasts exposed to TGF-β increase mRNA production and 
protein synthesis of both collagen and FN, providing further evidence that this was a 
reliable model (179, 180). 
This experiment was modified by using TCH instead of serum starving the 
fibroblasts.  TCH is a serum replacement product, containing nutrients for cells 
without hormones and growth factors which may have an impact upon their growth.  
The ideal length of time to starve cells prior to an experiment is unknown and it may 
have an impact upon the health of the cell (163).  The changes in gene expression of 
these cells was assessed at a single 48-hour time point.  Although this produced no 
changes in COL3A1, there was a dose dependent increase in expression of COL1A1 
and FN-EDA as shown previously, however, when cells were serum starved these 
changes were only present at 24 hours but when cells were treated with TCH they 
remained significant at 48 hours.  There was over a 3-fold increase in COL1A1 and 
over 6-fold increase in FN-EDA.  It may be that serum starvation had a detrimental 
effect on the cells and therefore cells that were not stressed prior to the experiment 
were able to respond to TGF-β stimulation for longer.  It would also remove any 
variation that serum starvation may add to the experiment, thus it was used for 
future experiments. 
During this adaptation of the original experiment several extra genes that have an 
effect in fibrosis were evaluated.  Initially CCN genes were assessed.  The CCN 
family of proteins share a similar structure of five domains.  They have extensive 
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biological effects on cell adhesion, proliferation, migration, signalling and appear to 
play a key role in fibrosis and wound healing (117).  They are secreted into the ECM 
where they interact with a variety of proteins to have such variable effects.  They 
have been investigated in multiple studies and their role is not fully understood.  For 
this reason, it was assessed what impact they had when an inflammatory cytokine 
(TGF-β) was added to each cell type (both MRC5 fibroblasts and A549 epithelial 
cells) and this could be compared with changes induced by human plasma.  There 
was a significant increase in expression of CCN1, to almost twice the baseline levels 
occurring at all concentrations of TGF-β treatment.  CCN1 has been shown in 
wound healing models to have a role in cellular senescence and attenuating the 
fibrotic response (118).  Conversely, it is upregulated in models of lung fibrosis 
where it has a pro-inflammatory effect (122).  At 48 hours, when MRC5 fibroblasts 
are treated with TGF-β, it appears to be upregulated, this may be either driving the 
pro-fibrotic response or as a negative feedback mechanism to attenuate the fibrotic 
response. 
There was also a significant increase in CCN2.  This has been shown to upregulate 
in previous work when fibroblasts were treated with TGF-β (181) where it acts as a 
downstream mediator and allows for a sustained fibrotic response (182).  It is 
upregulated in murine models of fibrosis, such as the inhaled bleomycin model (95).  
When drugs are given that directly inhibit this molecule, for example FG-3019 (an 
anti-CCN2 antibody), there is less of a fibrotic response in the lungs (95).   
In this experiment, there appeared to be a corresponding reduction in CCN3, 
although this did not meet significance.  A recent study published by Liu et al 
suggests that TGF-β treatment reduces the expression of CCN3 in human mesangial 
cells. By pre-treating the cells with CCN3 prior to TGF-β exposure there was a 
reduction of ECM proteins produced by the cells in response to TGF-β (183).  
However, this protein is similar to CCN1 and its role in fibrosis does not seem 
completely established with contradictory literature published, with other studies 
suggesting a pro-fibrotic role (132).  
The expression of CCN4 was also reduced in fibroblasts treated with TGF-β, 
although this change was not significant.  This is an interesting change, as when 
CCN4 was blocked in a mouse model of liver fibrosis, there was a reduction in 
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collagen production suggesting that it acts as a pro-fibrotic marker (137).  Reasons 
for this response may be that this protein acts differently depending on the cell type 
that it is expressed in.  It may also be that by 48-hours it is downregulated due to 
negative feedback mechanisms in place that are attenuating the fibrotic response.  
Further work to establish the role that these key molecules play might include 
assessing the pattern of expression across the 96-hour time point, to assess for 
negative feedback mechanisms that may occur.  It may be that blocking the 
molecule of interest with a specific CCN antibody and then assessing the response 
that occurs in ECM protein markers such as COL1A1 could also give interesting 
results that may show some of the complex interplay between these molecules. 
Other molecules assessed but that did not show significant changes included 
MRTFa, PDGFR-α and Thy-1.  These molecules were chosen as there is evidence 
that they play a key role in fibrosis.  MRTFa is a transcriptional co-activator that is 
formed in the cytoplasm and translocates to the nucleus where it binds to the serum 
response factor and causes the transcription of genes such as α-SMA.  Crider et al 
have shown that MRTFa is a key regulator of myofibroblast formation in response 
to TGF-β stimulation.  However, it should be noted that in this study there was only 
a small increase in message levels of MRTFa when fibroblasts (REF-52 cells) were 
treated with 0.25ng/ml TGF-β for 96 hours (less than twice baseline levels).  The 
protein was shown to be a key part of the fibrosis pathway as knockdown of the 
molecule reduced the expression of key markers of the myofibroblast including α-
SMA (184).  The data shown in this experiment, using MRC5 fibroblasts, did appear 
to correspond showing just under a 2-fold increase in MRTFa expression in cells 
treated with TGF-β, however this small change was not found to be statistically 
significant. 
There was no significant difference in PDGFR-α when fibroblasts were treated with 
TGF-β.  Previous work showed that treatment of fibroblasts with TGF-β in vitro 
leads to a reduction in PDGFR-α, which corresponds with the results in this 
experiment, although this experiment was not statistically significant (185).  PDGF 
is an important signalling molecule found in the ECM that appears to have effects in 
fibrosis.  When mice were exposed to asbestos, inducing pulmonary fibrosis, there 
was an increase in gene expression of PDGFR-α.  The molecule also appears to act 
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synergistically with TGF-β as when corneal fibroblasts were treated with TGF-β and 
PDGF-A there was a significant increase in myofibroblast transition, which was a 
much bigger effect than when they were treated with each molecule alone (186). 
The gene expression of Thy-1 was also assessed in this experiment.  Thy-1 is a cell 
surface protein, found on the surface of a number of cell types including fibroblasts.  
In healthy lung specimens the majority of fibroblasts express Thy-1 on their surface.  
However, the lung biopsy specimens from patients with IPF lack Thy-1 expression.  
Gene expression of this marker was therefore measured to see if expression was 
downregulated when cells were treated with a pro-inflammatory cytokine and later 
with IPF and SSc patient plasma.  The results showed that there was no significant 
change in this protein when fibroblasts were treated with TGF-β. 
 
7.3 The Development of an in vitro Model in A549 
Epithelial Cells 
 
A similar experiment was performed in the A549 epithelial cells.  This was an 
important cell type to investigate as type II alveolar epithelial cells have been 
implicated as playing a key role in the onset of IPF.  There is a theory that IPF is 
caused by repeated subclinical injury of the lung with damage occurring to the 
alveolar epithelial cells and affecting the integrity of the basement membrane (187).  
This damaging process leads to a chain of events that permits the formation of the 
myofibroblast, a contractile cell which produces excess ECM (188).  There is also 
evidence for EMT occurring, with type II alveolar epithelial cells transitioning into 
mesenchymal cells, adding to the myofibroblast pool (110).  Epithelial cells are 
therefore an interesting target to investigate further.  Cells were treated with TGF-β 
(1.5ng/ml and 3ng/ml) for 24, 48, 72 or 96 hours.  Images were taken and RNA 
extracted at these time points.  There appeared to be changes observed in the 
morphology of the cells with squamous epithelial cells changing from the typical 
tight-spaced, cobblestoned appearance to slightly more elongated cells.  Proliferation 
of the cells was measured using an alamar blue assay and showed no significant 
difference in proliferation between control cells and A549 cells treated with TGF-β.  
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Interestingly, the A549 cells were very fast growing and reached peak confluence by 
24 hours.  At 72 hours the number of healthy, viable cells had reduced.  Similar 
findings were also shown by Shipley et al, where mouse embryonic epithelial cells 
(AKR-2B cells) were treated with TGF-β.  This caused a prolonged pre-replicative 
phase of the cells and did not induce proliferation.  There was however a definite 
early change in morphology with an early increase in protein synthesis.  The authors 
also hypothesised that cells were not replicating while there were such drastic 
changes in morphology occurring (189). 
Immunofluorescence staining was undertaken to assess if cells were undergoing 
EMT in response to TGF-β.  It showed that cells were producing more COL1A1 and 
α-SMA after 48 hours treatment and suggests that cells were undergoing EMT, 
producing fibrosis associated proteins in response to TGF-β treatment. These results 
are in accordance with previous literature that showed that when epithelial cells 
were treated with TGF-β in vitro they became more mesenchymal in phenotype, and 
eventually produced more collagen and fibronectin (assessed further by qPCR and 
western blot in the next few sections) (108).  However, even when directly 
stimulated by TGF-β, epithelial cells did not produce as much COL1A1 as the 
MRC5 fibroblasts did even at baseline levels, without TGF-β stimulation, 
questioning the amount that EMT contributes to fibrosis (109). 
Initial genes assessed were those coding for proteins that form the ECM and would 
expect to be increased if cells were undergoing EMT, and becoming more 
mesenchymal in phenotype.  Changes in gene expression were measured using 
qPCR, with up to a 45-fold increase in gene expression of COL1A1 after treatment 
with the highest concentration of TGF-β (3ng/ml).  This was repeated on several 
occasions when A549 epithelial cells were treated with TGF-β in later chapters, 
confirming it was a true response.  The reason for such a significant increase with 
TGF-β may be that these cells usually produce such small amounts of COL1A1, that 
when stimulated with TGF-β the fold change appears very large.  This effect peaked 
after 48 hours but was sustained up to 96 hours in the experiment.  There was a 
significant increase in FN-EDA, which peaked at 72 hours.  Again, although 
COL3A1 is implicated in fibrosis there was no significant change noted in 
expression of this gene.   
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These changes in ECM genes were associated with over 6-fold changes in the 
transcription factors Slug and Snail.  Although there was overlap, these changes 
occurred prior to the peak changes in the ECM genes, suggesting that cells are first 
stimulated to increase production of transcription factors, which in turn drives the 
cells to produce more ECM proteins, thereby becoming more mesenchymal in 
phenotype.  Previous literature has also shown that Slug and Snail are increased in 
response to TGF-β in vitro. By using small interfering RNA sequences to reduce the 
mRNA level of Slug and Snail the same authors showed there was a corresponding 
reduction in EMT associated proteins, providing evidence they are key to driving the 
TGF-β response (190).  
Figure 4-16, 4-17 and 4-18 show that when treated with TGF-β the A549 cells were 
producing more COL1A1 and α-SMA using immunocytochemistry techniques.    
Western blot of the conditioned cell medium was used to compare how much 
COL1A1 was secreted by the epithelial cells but unfortunately there was a wide 
variation in the experiment making measurement difficult and no significant 
differences were observed.  A recent publication has suggested that although there is 
a definite increase in gene expression of ECM markers in epithelial cells that have 
undergone EMT, this does not correlate with an increase in COL1A1 protein, 
suggesting its contribution to the production of ECM is limited (109). 
Epithelial cells did not survive with prolonged serum starvation.  When it was 
attempted to starve them overnight (16 hours) apoptosis and cell death occurred.  
For the above experiments, cells were starved for 8 hours.  However, similarly to the 
experiment in MRC5 cells described above, the serum replacement product TCH 
was used instead of serum starvation to stimulate cells. 
Again, the ECM genes were assessed first to see if the changes were similar to those 
observed when cells were serum starved.  There was a significant increase in the 
gene expression of COL1A1 to over 16-fold its baseline expression.  This was not 
associated with a significant difference in COL3A1, in agreement with the data 
shown in the previous experiment.  Although there was an increase in expression of 
FN-EDA, this did not meet significance, however this may be due to the small 
number of replicates and some variation in the control samples.  
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These changes appear to be driven by the transcription factors Slug and Snail, with a 
significant increase in Slug at this 48-hour time point.  There appeared to be a 
decrease in E-cadherin, which is a protein required for the tight junctions seen 
between epithelial cells, giving the epithelium its typical cobblestone appearance.  
This protein was assessed as downregulation is recognised as an early response in 
EMT, allowing cells to lose their tight junctions and become more invasive (108).  
This was associated with a significant increase in N-cadherin (p<0.05), another 
recognised feature of EMT (167).  N-cadherin is a cell adhesion molecule, expressed 
by mesenchymal cells, and its expression is increased in EMT.  It is expressed in 
biopsy specimens of patients with IPF suggesting that alveolar EMT may be 
occurring, and making it a good molecule to assess if plasma treatment changes 
expression of this protein (191). 
Again, the CCN family was assessed due to the crucial role it appears to play in 
ECM regulation.  Interestingly in this experiment the CCN family showed a similar 
response to the changes occurring in the MRC5 fibroblasts.  There was a significant 
increase in CCN1 (5-fold with TGF-β 3ng/ml) and CCN2 (8-fold with TGF-β 
3ng/ml).  CCN1 is increased in lung specimens of patients with IPF and correlated 
with increased expression of the ECM proteins, collagen and FN (123).  Previous 
work has shown an increase in CCN2 in response to TGF-β stimulation, where it has 
been shown as a downstream, pro-fibrotic mediator of this pathway.  There were no 
significant differences in CCN3 or CCN4, although the trend appeared that there was 
a reduction in expression of these genes.  The role of these CCN genes in fibrosis is 
less understood and previous literature is controversial. 
The results in this chapter therefore show the establishment of a model with which 
to assess changes involved in fibrosis.  Treatment of MRC5 fibroblasts with TGF-β 
reduced the proliferation of the cells which became larger in size.  There is an 
increase in gene expression of COL1A1 and FN-EDA.  There was an increase in 
production of FN protein secreted by these cells.  Treatment of A549 cells with 
TGF-β caused an increase in gene expression of COL1A1, FN-EDA, Slug, Snail, 
CCN1, CCN2 and N-cadherin.  There was an associated significant decrease in the 
expression of E-cadherin.  Immunocytochemistry showed an increase in expression 
of COL1A1 and α-SMA.  The changes discussed above occurred consistently and 
were those expected when a pro-inflammatory cytokine is placed on the cells, 
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suggesting that this was a reliable model with which to do further work.  As shown, 
a number of factors influenced the changes that occurred, including the 
concentration of TGF-β used as well as the time points that the RNA was extracted.  
It was therefore hypothesised that if the same cell lines were treated with plasma 
from patients with a fibrotic disease this would cause changes similar to those seen 
in this chapter when cells were treated with TGF-β and it may reveal important 
proteins involved in the fibrotic pathways of lung fibrosis. 
 
7.4 Using the in vitro Model to Assess Changes Induced in 
MRC5 Fibroblasts by Plasma from Patients with 
Fibrotic Diseases 
 
The results in chapter 5 show the outcome when this model was used to compare 
changes in fibrotic markers when cells were treated with plasma from two different 
groups of patients.  The first group were patients with IPF, these patients develop 
fibrosis affecting the lungs only but do not develop fibrosis of systemic organs.  We 
also know from the results in chapter 3 that this is a homogeneous population.  
Although the cause is unknown, the disease does not appear to be preceded by 
inflammation but patients develop progressive fibrosis of the lungs, with a median 
mortality of just 3 years (14).  Diffuse SSc-ILD was used as a contrasting disease.  
HRCT scans in this disease often show inflammation and patients generally respond 
to steroids and immunosuppression.  Features of the disease are often overt and 
unlikely to be misdiagnosed.  The disease leads to fibrosis in multiple organs, and 
patients from this cohort are known to suffer fibrosis affecting at least the skin and 
lungs.  It is therefore a contrasting disease and allows comparison of the fibrotic 
pathways and key molecules involved in the fibrotic response.   
Initially MRC5 fibroblasts were treated with 100ul per well of plasma from patients 
with IPF.  As there were so few changes at 96 hours in the previous experiment with 
TGF-β it was decided to reduce the number of time points and so this last time point 
was removed.  Treatment with human plasma appeared to have obvious 
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morphological effects on the cells, with fibroblasts appearing more spindle-shaped.  
This occurred whether cells were treated with plasma from healthy controls or from 
patients with fibrosis, suggesting it was a direct effect of the plasma not the 
underlying disease process.  The cells appeared less healthy and to assess if they 
were still proliferating well an alamar blue assay was performed. This showed that 
MRC5 cells treated with plasma from patients with IPF were more proliferative 
throughout the 72 hours than those treated with plasma from healthy controls.  
Although this was only significant at the 48-hour time point, the trend extended 
throughout the entire 72-hour time course (Figure 5-2).  This trend was not shown 
when MRC5 cells were treated with plasma from patients with SSc, where there 
were no significant differences in cell proliferation regardless of treatment group. 
Given the obvious morphological effects induced by plasma treatment 
immunocytochemistry was performed to assess the cytoskeletal changes.  Phalloidin 
staining revealed that the cells had become more spindle-shaped in response to 
human plasma treatment irrespective of whether the plasma was from a healthy 
control subject, IPF or SSc-ILD patient.  When MRC5 cells were stained for 
COL1A1 there was continued production of the protein but there was no significant 
increase whether patients were treated with healthy control plasma, IPF plasma or 
SSc-ILD plasma.  It is unclear whether these effects were anticipated as these 
methods appear novel and there is very little literature regarding the expected 
changes to cell lines when treated with human plasma. 
RNA was extracted at 24, 48 and 72 hours respectively.  It should be noted that no 
significant differences in any of the genes assessed for fibrosis were noted at 48 or 
72 hours and so the data presented and discussed are changes occurring at 24 hours.  
There were no significant changes noted between healthy control and IPF patient 
plasma for any ECM protein genes, CCN genes or other proteins involved in 
fibrosis.  When the same cell lines were treated with plasma from patients with SSc-
ILD there were no significant differences noted in gene expression for any of the 
ECM associated proteins.  The CCN genes were then explored, showing a 
significant downregulation in expression of CCN3 (p<0.05).  As previously 
described CCN3 is part of the CCN family and has a role in inflammation and tissue 
repair (132).  Its impact upon the fibrotic response has been contradictory, with 
some literature suggesting that it has an anti-fibrotic role and other studies showing 
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evidence that it is pro-fibrotic (132, 135).  As shown in chapter 4, CCN3 appeared to 
be reduced when MRC5 cells were treated with TGF-β for 48 hours although this 
change was not statistically significant and this appeared to be in the same direction 
when cells were treated with SSc-ILD plasma.  There was no difference in CCN2, 
although CCN2 has increased expression from skin fibroblasts isolated from lesions 
in patients with SSc (128).  There were no differences in expression of MRTFa or 
Thy-1 between cells treated with healthy plasma and those treated with SSc-ILD. 
 
7.5 Using the in vitro Model to Assess Changes Induced in 
A549 Epithelial Cells by Plasma from Patients with 
Fibrotic Diseases 
 
In a similar manner the A549 cells were treated with human plasma.  Images were 
recorded at different time points and the cells appeared to grow well, reaching 
maximum confluence at around 48 hours.  There did not appear to be any obvious 
morphological changes in the cells but this was assessed further using 
immunocytochemistry.  When the A549 epithelial cells were stained for α-SMA, a 
protein expressed by myofibroblasts, there appeared to be a minor increase in 
production of this protein from patients with IPF or SSc-ILD compared to cells that 
were treated with healthy control plasma.  This would be expected if cells were 
undergoing EMT, becoming more mesenchymal in phenotype and expressing more 
α-SMA. 
Epithelial cells were also assessed for whether treatment with plasma from patients 
with ILD affected proliferation.  There did not appear to be any significant 
differences in proliferation of A549 cells that were treated with healthy control 
plasma and IPF plasma or when healthy controls were compared with SSc-ILD.  
However, when A549 cells were treated with TGF-β of varying concentrations, 
shown in chapter 4, there was no change in the proliferation of cells.  It was 
hypothesised that the cells were not replicating while undergoing such drastic 
changes in morphology. 
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Changes in gene expression were also assessed in the A549 epithelial cells treated 
with plasma for 24, 48 and 72 hours.  Again, there were no significant differences 
between any of the genes explored at 48 or 72 hours when cells were treated with 
IPF plasma or SSc-ILD plasma and so this data was not shown.  When A549 cells 
were treated with plasma from patients with IPF, there was very little change in 
COL1A1.  There was a significant reduction in COL3A1 (p<0.01) and FN-EDA 
(p<0.05).  These changes are difficult to explain as they are unexpected.  It would be 
hypothesised that in patients with IPF there would be a driving factor present in the 
plasma that would upregulate transcription of genes that code for proteins that build 
the ECM, given the disease leads to excess secretion of ECM.  Interestingly, when 
A549 epithelial cells were treated with TGF-β there was a significant increase in 
COL1A1 and FN-EDA, and although there was a trend for upregulation of COL3A1 
this was not significant.  The changes seen with IPF patient plasma occur in the 
opposite direction, perhaps suggesting that changes are not TGF-β driven.  
Other genes involved in fibrosis and EMT were then explored to see if these changes 
could be explained.  There were no significant differences noted in the transcription 
factors Slug and Snail.  As these transcription factors tend to cause the upregulation 
or downregulation of ECM proteins, any changes in these genes is likely to occur 
prior to any changes noted in ECM genes (i.e., at an earlier time point than 24 
hours).  It may be interesting therefore to assess these genes after 12 hours of IPF 
plasma treatment to see if they are driving these changes.  N-cadherin was assessed 
and this showed a significant downregulation in expression (p<0.01).  This is in the 
opposite direction to that which is expected in cells undergoing EMT, where it is 
upregulated, but may explain the changes noted in the ECM protein genes in this 
experiment.  Interestingly there was a significant decrease in the expression of E-
cadherin (p<0.01).  As discussed previously this is an early change associated with 
EMT, as it is a marker of epithelial cells and reduces when cells are undergoing 
EMT, allowing epithelial cells to lose their tight junctions.  However, this 
downregulation would not explain the changes occurring in gene expression of the 
ECM proteins in the same experiment. If cells were transitioning into a 
mesenchymal phenotype, reducing their expression of E-cadherin as shown, it would 
be expected there would be a corresponding increase in the ECM genes, which there 
was not.  This unexpected effect on gene expression could not be explained by 
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changes in the CCN genes, in which there were no significant differences between 
cells treated with healthy control plasma and those treated with IPF plasma.   
When the same cell line was treated with plasma from patients with SSc-ILD there 
was a significant increase in COL3A1 (p<0.001).  There was a corresponding 
increase in expression of FN-EDA (p<0.01).  This change would be expected if cells 
were undergoing EMT, becoming more mesenchymal in phenotype and producing 
more ECM proteins.  The CCN proteins, including CCN1, CCN2 and CCN3 were 
explored to assess whether these changes could be explained but there were no 
significant differences in expression in any of these genes which would explain the 
changes seen with the ECM proteins. 
However, SSc-ILD plasma treatment was associated with an upregulation in the 
transcription factors Slug and Snail, although this did not meet significance.  These 
markers were increased when cells were treated with TGF-β in the previous chapter, 
where it appeared to be an early change driving cells to increase mRNA production 
of ECM proteins.  Earlier time points were not assessed in this experiment.  
However, these changes may reach significance if assessed after 12 hours, as they 
may be early changes driving the cells to produce more COL3A1 and FN-EDA, and 
therefore when examined at 24 hours levels are starting to decline.  There was a 
significant upregulation of E-cadherin after 24 hours, a marker that is lost from 
epithelial cells when transitioning into mesenchymal cells, and so a downregulation 
would be expected in association with the changes in ECM proteins. One 
explanation for this is whether this early change in the cell is a repair mechanism in 
response to EMT occurring.   
Interestingly, COL3A1 and FN-EDA were significantly downregulated when treated 
with IPF patient plasma, which is in the opposite direction to when cells were 
treated with plasma from patients with SSc-ILD.  They were then associated with a 
significant decrease in E-cadherin, again in the opposite direction to when A549 
epithelial cells were treated with SSc-ILD plasma.  It is known that changes in 
cadherin are seen in cells that are undergoing EMT and may suggest that plasma is 
causing a change in the morphology of the epithelial cells.  It is interesting that these 
changes are in the same genes in patients with different underlying fibrotic diseases 
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and perhaps indicates that they act via different fibrotic pathways.  The fact that it is 
the same genes that show significance may suggest that this is a true interaction. 
The changes expected in the cells when treated with plasma from patients with 
fibrotic diseases were based on the changes induced by TGF-β, a pro-inflammatory 
cytokine.  Interestingly, in SSc there is good evidence that there are increased 
circulating levels of TGF-β in patient plasma and that higher levels correlate with 
increasing disease severity (192).  Alhamad et al measured levels of circulating 
TGF-β in patients with IPF and there was no increase in plasma levels.  There was 
however, an increase in active TGF-β locally in the lungs of patients and this may 
explain why it does not show clinical systemic effects like SSc as well as not 
causing the same changes observed in fibrosis associated genes in this experiment 
(193).  As there is no increase in TGF-β levels in the plasma of patients with IPF it 
may explain why there is no increase in production of ECM genes when this plasma 
was used to treat cells.  In contrast, SSc-ILD plasma, which has more active TGF-β 
than healthy plasma, does induce these changes.  This may also explain some of the 
very different clinical presentations of these two distinct fibrotic diseases. 
 
7.6 Using the in vitro Model to Assess Changes Induced by 
Plasma Treatment from Patients with Fibrotic Diseases 
Alongside Stretch  
 
The final chapter of this thesis explored the stretch model, which was used to assess 
the effect of stretch alongside the plasma treatment.  As understood, the lung is not a 
static organ but is constantly moving, creating shear forces within the cells.  It was 
unknown how these cells would respond to stretch alone and respond to stretch 
alongside treatment with TGF-β or human plasma from patients with IPF. 
In summary, 6.66% biaxial stretch treatment alone in MRC5 cells caused no 
significant differences in any of the genes associated with fibrosis and assessed in 
previous chapters.  This included COL1A1 and FN-EDA, genes that code for ECM 
proteins that are excessively produced and secreted into the extracellular space in 
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fibrosis.  There was no change in the CCN family, MRTFa or Thy-1 from baseline 
levels, other molecules involved in the fibrotic response.  Treatment with TGF-β 
caused an increase in FN-EDA as previously shown in chapter 4.  It also caused an 
increase in COL1A1, alongside an increase in CCN1 and CCN2 although these 
results did not reach significance in this experiment, although the same 
concentration of TGF-β was used (2ng/ml).  The reason for this lack of response, as 
previously seen in COL1A1, CCN1 and CCN2 when MRC5 cells were treated with 
TGF-β, may be due to some key differences with this experiment.  The first 
difference is that in chapter 4 qPCR was performed after the MRC5 cells were 
treated for 48 hours, whereas the stretched cells were assessed after just 24 hours.  
Also, there may be a difference in response when the cells were plated on a softer, 
collagen-lined base rather than tissue culture plastic.   
When the fibroblasts were treated with both TGF-β (2ng/ml) and stretch the FN-
EDA response was attenuated.  This occurred alongside a reduction in CCN1 and 
CCN2 back to baseline levels, although these changes were not significant they may 
explain the reduction seen in FN-EDA.  It should be noted that a reduction in FN-
EDA with stretch treatment is surprising, as it would be expected that cells 
undergoing stretch would upregulate the production of ECM proteins, to counteract 
the shear forces produced by the movement.  However, these effects have been 
shown in previous published literature. In a study conducted by Blaauboer et al 
primary human lung fibroblasts were subjected to 10ng/ml TGF-β.  They were then 
either left to grow for 48 hours or subjected to mechanical stretch and qPCR 
undertaken.  In this experiment, the use of stretch reduced the mRNA production of 
α-SMA and type-I, type-III and type-V collagen (194).   
On the other hand, MRTFa was further increased when TGF-β and stretch were 
combined reaching a significant change when compared to baseline levels.  The 
exact effect of MRTFa in fibrosis is unknown but it appears to target serum response 
factors, which then impact upon cell growth, proliferation and cytoskeleton 
organisation.  It may be that in this situation, expression of MRTFa is required for 
other pathways. 
The same cells were treated with human plasma and stretch using the same stretch 
protocol as previously tested. In agreement with the results in chapter 5 there were 
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no significant differences between cells treated with healthy control plasma and cells 
treated with plasma from IPF patients in static conditions. When cells were stretched 
there were no changes noted in the expression of COL1A1.  There was a significant 
downregulation of CCN4 (p<0.01) in cells that were treated with stretch and IPF 
patient plasma compared to cells treated with IPF plasma in static conditions.  CCN4 
has been considered part of the pro-fibrotic response, with a reduction in fibrosis if 
mice are treated with a CCN4 antibody prior to being exposed to inhaled bleomycin 
which induces lung fibrosis (136).  There was also a significant decrease in Thy-1 
(p<0.01) in cells that were stretched in the presence of IPF patient plasma compared 
to cells treated with IPF plasma without stretch.  It may be possible that treatment 
with patient plasma alongside stretch is leading to a reduction in Thy-1, a change 
that occurs in IPF patient tissue. 
In the A549 epithelial cells 6.66% unidirectional stretch alone caused no significant 
differences in any of the genes tested including COL1A1, Snail, Slug, E-cadherin 
and the CCN family.  As expected, treatment of the cells with TGF-β (1.5ng/ml) 
caused a significant increase in COL1A1 and the transcription factor Slug.  There 
was also an increase in the transcription factor Snail but this did not meet 
significance.  There were no significant changes in the CCN family when the cells 
were treated with TGF-β alone.  This differed to the results presented in chapter 4 
where there was an increase in CCN1 and CCN2 with TGF-β treatment.  It is unclear 
why there was this discrepancy.  The results presented in chapter 4 were after 48 
hours whereas the results from this work were after 24 hours and it is recognised 
that changes in gene expression can vary at different time points.  It should also be 
noted that the results in chapter 4 only reached significance at the higher 
concentrations of TGF-β used (3ng/ml) and although there was upregulation at the 
smaller concentration (1.5ng/ml), this was not a significant change.  More 
importantly it should be noted that there were differences in the material of the 
chamber that the cells were plated on (the cells that were used in the stretch 
experiment were plated in silicone chambers coated with laminin rather than cell 
culture plastic) potentially leading to a change in the way the cells responded to 
TGF-β.   
When A549 epithelial cells were treated with TGF-β and stretch there was a 
significant attenuation of COL1A1.  This is surprising, as it would be expected that 
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cells that are undergoing more shear forces would upregulate their expression of 
collagen. This change occurs alongside a significant reduction in the transcription 
factor Slug in the same cells treated with TGF-β and stretch.   
When the A549 epithelial cells in this experiment were treated with human plasma 
and stretch there was a downregulation of COL1A1 (p<0.05) in the group treated 
with stretch and IPF patient plasma compared to cells that were not stretched.  There 
appeared to be a corresponding reduction in the transcription factors Slug and Snail, 
as well as CCN2, potentially leading to these effects but these changes did not meet 
significance.  As discussed previously Slug and Snail appear to drive the fibrotic 
response, leading to changes in expression of the ECM proteins.  These changes 
appear to mirror those effects seen when cells were treated with TGF-β and stretch. 
It is interesting that the addition of stretch to TGF-β treatment attenuates any fibrotic 
response.  It is unclear why stretch would have this effect in both fibroblasts and 
epithelial cells.  The possibility is that this is a mechanism that has been adapted 
during natural breathing to prevent the lung becoming fibrotic when it is continually 
undergoing shear forces.  
It should be noted that there have been other studies published that show conflicting 
evidence for an attenuated response.  Heise et al isolated type II alveolar epithelial 
cells from mice and applied mechanical stretch (195).  They noted that mechanical 
stretch reduced the amount of E-cadherin, and increased the amount of vimentin and 
α-SMA, changes associated with EMT (195).  However, these changes occurred 
after 15% stretch was applied to the cells for 4 days.  This may explain the 
differences seen, as 6% stretch mirrors the force that the epithelial cells undergo on a 
daily basis during natural breathing, a process in which a fibrotic response should 
not occur.  An in vivo study injured the lungs of mice using acid aspiration to assess 
the effect of mechanical ventilation after injury.  The mice that underwent 
ventilation, associated with increased stretch and shear forces, showed increased 
expression of TGF-β and α-SMA.  There was also an increase in hydroxyproline 
content of the lung (a surrogate marker for excess collagen deposition) as well as 
histological specimens showing more evidence of fibrosis (196).  It should be noted 
that this study is difficult to compare as it is an in vivo study rather than in a single 
cell line.  These changes also occurred after 15 days, a much longer time point than 
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assessed in the above model.  The amount of stretch force applied was also 
significantly greater as the authors were trying to replicate the excessive stress that 
occurs during mechanical ventilation.  Again, these differences may explain the 
conflicting results.  A further study took normal human lung tissue and tissue from 
patients with IPF and applied stretch to both specimens. There was a significant 
increase in the stiffness present in the IPF tissue.  There was also an increase in 
active TGF-β and the amount of phosphorylated Smad 2 and 3 secreted by the 
fibrotic tissue when stretched in comparison to control tissue (197).  However, the 
patients used in this study had established IPF and it could be argued that once the 
tissue has fibrosed the changes continue in a positive feedback cycle. 
 
7.7 Conclusion and Proposed Further Work 
 
In conclusion, the results from thesis have shown that respiratory physicians rarely 
misdiagnose IPF using currently available serology alongside HRCT scan 
appearances.  This gives confidence that the majority of patients are receiving the 
best available treatment for their conditions.  Further work would assess patients 
with other patterns found in ILD such as NSIP and organising pneumonia to assess 
if there is a higher prevalence of antibodies in these patients.  It is recognised that 
these HRCT patterns are more commonly associated with a CTD-ILD, and so there 
may be more patients diagnosed with “idiopathic” disease in these subgroups that 
actually have an underlying CTD.  
A cellular model has been produced which is capable of measuring changes in 
fibroblasts and epithelial cells when treated with increasing concentrations of TGF-β 
in a reliable and reproducible way.  Evidence to suggest this was reliable includes 
the consistency with which the changes occurred throughout the experiments. 
This model was then used to assess for changes in those cell lines occurring when 
they were treated with plasma from patients with ILD.  The main difficulty with this 
experiment is a large variability between individuals and so it is difficult to 
undertake the experiment using sufficient numbers of patients to ensure that 
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significant findings are a true difference.  Given the variation present it would be 
important to repeat this experiment and re-assess the genes that showed significant 
changes and ensure that these changes were reproducible.  Given there were no 
changes at 48 and 72 hours but any significant differences found were at 24 hours it 
may be more important to assess earlier time points such as 12 hours, when changes 
in transcription factors may be more apparent. 
The final chapter added the dimension of stretch to the cellular model.  Cells in the 
lungs are continually moving to allow respiration and the aim of adapting this model 
was to replicate this movement to assess the effects.  There appeared to be an 
attenuation in any response to TGF-β when stretch was added.  It is hypothesised 
that this may be an adaptation of pulmonary cells to prevent fibrosis occurring 
during normal breathing.  It would be interesting to assess the effects of stretch in 
the same cell lines at different time points, using different concentrations of TGF-β 
and using different stretch forces.   
Although this is very preliminary work, there are trends in key genes that should be 
explored further to understand the pathways involved in IPF and SSc-ILD, to 
understand why individual patients may respond to certain therapeutic options 
allowing for a more personalised therapeutic choice. 
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Appendix 1 
38 Recruitment Centres for the UK-BILD Study 
Aintree University Hospitals NHS Foundation Trust 
Basildon and Thurrock University Hospital NHS Trust 
Blackpool Teaching Hospitals NHS Foundation Trust 
Calderdale & Huddersfield NHS Foundation Trust (Calderdale Royal Hospital) 
Calderdale & Huddersfield NHS Foundation Trust (Huddersfield Royal 
Infirmary) 
City Hospital Sunderland NHS Foundation Trust 
Croydon Health Services NHS Trust 
East Sussex Healthcare NHS Trust 
Gateshead Health NHS Foundation Trust 
Harrogate and District NHS Foundation Trust 
King's College Hospital NHS Foundation Trust 
Medway NHS Foundation Trust 
Mid Yorkshire Hospitals NHS Trust 
NHS Fourth Valley 
North Bristol Trust 
Northern Devon Healthcare NHS Trust 
Pennine Acute Hospital NHS Trust (Fairfield General Hospital) 
Pennine Acute Hospital NHS Trust (North Manchester General) 
Pennine Acute Hospital NHS Trust (Royal Oldham) 
Plymouth Hospitals NHS Trust 
Royal Cornwall Hospital 
Royal Derby NHS Foundation Trust 
Royal Devon and Exeter Hospitals NHS Trust 
Royal Wolverhampton Hospitals NHS Trust 
Salford Royal NHS Foundation Trust 
Sandwells and West Birmingham Hospitals NHS Trust 
Sheffield Teaching Hospitals NHS Foundation Trust 
Sherwood Forest NHS Foundation Trust 
Shrewsbury and Telford Hospital NHS Trust 
St George's University Hospitals NHS Foundation Trust 
Staffordshire and Stoke on Trent Partnership NHS Trust 
Surrey and Sussex Healthcare NHS Trust 
Taunton and Somerset NHS Foundation Trust 
University Hospital South Manchester 
West Middlesex University Hospital NHS Trust 
Western Sussex Hospitals Trust 
Worcestershire Acute Hospitals NHS Trust 
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                                                                                             INSET 
TRUST LOGO                                       
    Patient Information Sheet  
Identification of disease susceptibility genes and antibodies associated with 
development and clinical characteristics of Interstitial Lung Disease (ILD). 
We would like to invite you to take part in a research study examining the underlying causes 
of interstitial lung disease (ILD). Before deciding whether or not you want to participate, you 
will need to understand why the research is being done and what it will involve for you. 
Please take time to read the following information carefully and if there is anything you are 
unclear about or if you would like more information, please do not hesitate to ask.  
 
What is the purpose of this study? 
The purpose of this study is to gain a better understanding of what causes ILD, so that we 
can use this information to help design more effective drug treatments in the future.  This is 
important because ILD causes progressive scarring of the lung tissue with a subsequent 
reduction in lung function. This can lead to symptoms such as shortness of breath and 
fatigue, and in more serious cases pulmonary hypertension (- high blood pressure within the 
vessels supplying the lung with blood) and right heart failure (- the inability of the right hand 
side of the heart to pump sufficient blood around the body to meet its needs). Current 
treatments are not always as effective as we would like and their usefulness can be limited 
by potentially damaging side effects. In order to try and understand what causes ILD, we 
would like to take a blood sample from you to carry out genetic and immunological testing 
(examining your DNA and antibody status). By comparing the test results obtained from 
patients with ILD against ‘healthy controls’ (people who do not have ILD), we hope to 
identify genetic and immunological differences between the two. This should indicate if there 
are any specific genes or antibodies involved in the development of ILD, and hopefully lead 
to better drug treatments in the future. We also wish to see if there are any substances in 
the blood (referred to as biomarkers) that could be used for the future diagnose ILD in the 
very early stages so that early treatment could be given. 
 
Why have I been invited?  
You have been invited to take part in this study because you have been diagnosed with 
interstitial lung disease. We want to examine this condition in more detail to determine 
whether or not there are any genetic or immunological factors involved in its development.  
 
Do I have to take part?  
It is up to you to decide whether or not you want to take part. You will be given a full 
explanation of the study, and what it would involve for you if you were to participate. You will 
also be given a copy of the patient information sheet to read and to keep, and the 
opportunity to ask any questions you may have. If having had sufficient time to consider 
your decision you want to take part, we would then ask you to sign a consent form to 
confirm you have agreed to take part. You would be free to withdraw from the study at any 
time, without giving a reason, and this would not affect your rights or the standard of care 
you receive. 
 
What will happen to me if I take part?  
If you decide to take part your consultant will fill in some basic details about yourself and 
your condition. The information requested is similar to the questions he/she would ask you 
at a normal consultation. A single sample of blood (20mls or 4 tea spoons) will be taken for 
genetic (DNA) and immunological (antibody) testing. This research blood sample will be 
taken at the same time as your usual routine blood samples, and therefore no additional 
needle insertion or clinic visits would be required. Additionally, we would like to ask your 
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permission to flag your details with the Medical Research Information Service (MRIS) so 
that we can eventually determine whether ILD patients are at a slightly increased risk of 
developing cancer as a result of their condition. If it is established that there is no increased 
risk, we could potentially avoid future unnecessary and unpleasant investigations to look for 
cancers in such patients. Please be aware that the increased risk of cancer is likely only 
very slight, if at all. This is something your consultant will be checking for, and will be happy 
to discuss with you, so don’t be alarmed. In order to match up information we receive from 
the MRIS with your correct blood sample and clinical details, it is necessary for us to record 
and store some ‘personal identifiers. Therefore we also ask your permission to store your 
name, hospital number, NHS number and date of birth in a centralised database. This 
database will be maintained on a password protected, NHS Trust Network computer, with 
limited access. This database will be kept in compliance with the Data Protection Act 1998 
and NHS code of confidentiality. 
 
What are the possible disadvantages and risks of taking part?  
The only risk associated with this study is the needle insertion into a vein in your arm or 
wrist, in order to get a blood sample. This might cause you some slight discomfort and you 
might be bruised for a few days around the area of the needle insertion.  
                                                                              
What are the possible benefits of taking part?                       
We cannot promise the study will directly benefit you, but the information we get from it will 
help improve the treatment of people with ILD in the future.  
 
What will happen if I don’t want to carry on with the study?  
You can withdraw from the study at any time, without giving a reason, and this will not affect 
the quality of care you receive. If your stored blood sample or clinical details have not yet 
been used for research purposes, they can be destroyed if you wish.  
 
Will my taking part in the study be kept confidential?  
Clinical details about your condition will be stored in a centralised database, along will some 
‘patient identifiers’ including your name, hospital number, NHS number and date of birth. 
This database will be maintained on a password protected, NHS computer at Salford Royal 
in compliance with the Data Protection Act 1998. Our procedures for handling, processing, 
storage and destruction of data are also fully compliant. If you join the study, your clinical 
details may be looked at by the doctors and researchers performing the genetic and 
immunological studies. Representatives of the sponsor, regulatory authorities and the NHS 
Trust will have access to your medical and research records for monitoring and auditing 
purposes. Data collected during the study could be sent to collaborating researchers in 
other countries including Europe and the USA where the laws may not protect your privacy 
to the same extent as the Data Protection Act in the UK. However, the results of your 
genetic and antibody testing, along with your clinical details would be sent in anonymised 
form, with no patient identifiers leaving the UK. 
 
What will happen to any samples I give? 
The blood samples will be sent to the Centre for Integrated Genomic Medical Research 
(CIGMR), within The University of Manchester, where they will be securely stored. Samples 
will be kept for future analyses as outlined above (genetic / immunological). Any details that 
directly identify you to your blood sample or clinical data (eg name, date of birth, hospital 
number) will be securely stored on the password protected NHS computer at Salford Royal. 
You are making a donation of your blood sample for use in research and we will assume 
formal responsibility for custodianship of your donated sample, as per the Nuffield Council 
on Bioethics Report ‘Human Tissue: Ethical and Legal Issues’ (1995).  
 
What will happen to the results of the research study?  
Broad scientific results will be published in peer reviewed medical journals. You will not be 
personally identifiable by any details given in any report or publication thus generated. 
Results with relevance to the individual will include the antibody result which your consultant 
may otherwise not have access to in your own hospital. This antibody result may provide 
some useful information about the clinical progression of your ILD. 
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Who is organising and funding the research? 
The research is being organised by Professor Robert G Cooper (University of Liverpool) and 
Professor William Ollier (University of Manchester). 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given a favourable opinion by the North West Research Ethics Committee. It 
has also been reviewed by the study sponsor University of Liverpool. You will be given a 
copy of the patient information sheet and a signed consent form to keep. 
  
Further information and contact details  
 
INSERT LOCAL CONTACT DETAILS 
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INSERT TRUST LOGO 
CONSENT FORM  
(TO BE RETAINED AT SITE) 
 
Title of project: Identification of disease susceptibility genes and 
antibodies associated with development and 
clinical characteristics of Interstitial Lung 
Disease.   
 
Name of Researchers:  Prof R. G. Cooper & Prof W. Ollier. 
       Please initial box 
 
1. I confirm that I have read and understand the patient information sheet dated       
    29/05/2014 version 4.0 for the above study. I have had the opportunity to 
    consider the information, ask questions and have had these answered   
    satisfactorily. 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without any reason, without my medical care or legal rights being 
affected.         
 
 
 
3. I understand that sections of any of my medical notes may be looked at by the 
ILD research group or from regulatory authorities, the study sponsor and NHS 
trusts where it is relevant to my taking part in research. I give permission for 
these individuals to have access to my records. 
 
 
 
4.   I agree to have my details flagged with the Medical Research Information 
   Service and to have my name, hospital number, NHS number and DOB   
   recorded on a centralised database and stored on a password protected. 
   NHS computer    
 
 
 
5. I agree that my blood sample and clinical & laboratory data can be used in 
    future ILD research projects. All samples and data provided to other researcher,  
    either in the UK or Europe, will be done so in anonymised form   
     
 
 
6. I agree to take part in the above study 
 
 
_______________________ ________________
 ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________
 ____________________ 
Name of Person    Date     Signature  
taking consent.                                                                                                                                                                                     
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REC Approval Form 
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Appendix 4 
Buffers and Reagents Used in Experiments 
 
Phosphate Buffered Saline (PBS) Solution for immunocytochemistry 
PBS tablet (Sigma-Aldrich, Dorset, UK) dissolved in 200ml deionized water 
 
0.01% Phosphate Buffered Saline with Tween for immunocytochemistry 
10ml PBS solution as described above, 1ul Tween 20 solution (Sigma-Aldrich, 
Dorset, UK) 
 
Tris-Acetate-EDTA (TAE) Buffer 
A 50 x TAE buffer solution was produced consisting of;  
242g Tris base (Sigma-Aldrich, Dorset, UK) 
57.1ml glacial acetic acid (Sigma-Aldrich, Dorset, UK) 
100ml 0.5M EDTA (pH 8.0) 
Made up to 1L with distilled water 
 
Once produced the solution was diluted to 1x using distilled water 
 
2% Agarose Gel 
100ml TAE, made according to protocol described above 
2 gram agarose (Sigma-Aldrich, Dorset, UK) 
2-3ul Safe View Nucleic Acid Stain (NBS Biologicals, Cambridgeshire, UK) 
 
Solution mixed in a flask and heated in a microwave until fully dissolved.  Poured 
into a gel casing and allowed to set. 
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Urea-Lysis Buffer 
Solution prepared by mixing;  
40.08g Urea (Sigma-Aldrich, Dorset, UK) 
1M Tris / HCl (pH 6.8) - 1ml – Prepared using 121.1g Tris base, adjusted to pH 6.8 
using HCl, and made to a volume of 1L using distilled water  
10ml Glycerol 
5ml, 20% sodium dodecyl sulphate (SDS) 
0.01g Bromophenol blue 
 
Transfer Buffer for Western Blot 
10 x Transfer buffer (stock)  
This was prepared by mixing;  
30.28g Tris (Sigma-Aldrich, Dorset, UK) 
144.1g glycine (Sigma-Aldrich, Dorset, UK) 
 
Solution was made up to 1L with water and ensured pH was 6.05 
 
1 x Transfer buffer  
This was prepared by mixing; 
100ml 10 x transfer buffer (as described above) 
200ml analytical reagent grade methanol (Fisher Chemical, Fisher Scientific, 
Leicestershire, UK) 
690ml distilled water 
10ml Sodium Dodecyl Sulphate (SDS) 10x solution (Sigma-Aldrich, Dorset, UK)   
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Tris Buffered Saline (TBS) 10% 
This solution was prepared using; 
24.23g Trizma HCl (Sigma-Aldrich, Dorset, UK) 
80.06g NaCl (Sigma-Aldrich, Dorset, UK) 
 
Solution was mixed with 800ml distilled water and the pH adjusted to 7.6 with pure 
HCl, it was then made up to 1L with distilled water 
 
Tris Buffered Saline with Tween, 0.1% Tween 20 (TBST) 
100ml 10x TBS (prepared as described above) 
890 ml distilled water 
250ul tween 20 (Sigma Aldrich, Dorset, UK) 
 
Solution was prepared by mixing the reagents above 
 
3% milk blocking solution 
1.2g Marvel dried skimmed milk powder (Premier Foods, St Albans, UK) 
40ml TBST (prepared as described above) 
 
Solution was prepared by mixing the reagents described above 
 
  
246 
 
Appendix 5 
Papers and Abstracts Published From this Work 
Review Article 
 
 
Abstracts 
Cotton CV, Betteridge ZE, Spencer LG, New RP, Lamb J, McHugh NJ, Cooper RG, 
UK-BILD Collaboration.  Low level detection of CTD-associated autoantibodies in 
patients with idiopathic pulmonary fibrosis confirms this as a robust phenotype 
when diagnosed on clinical grounds alone.  Rheumatology 2018, 57 (suppl_3), 
https://doi.org/10.1093/rheumatology/key075.206 
 
Cotton CV, Spencer LG, New RP, Cooper RG. Comprehensive connective tissue 
disease serology could prevent unnecessary lung biopsies in amyopathic interstitial 
lung disease patients with anti-synthetases other than anti-Jo-1: An illustrative case 
series.  Rheumatology 2017,56 (suppl 2), 
https://doi.org/10.1093/rheumatology/kex062.277 
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Cotton CV, Spencer LG, New RP, Cooper RG.  When interstitial lung disease 
represents the major clinical feature in antisynthetase syndrome cases which are 
clearly amyopathic, is it justifiable to still regard detected antisynthetases as 
myositis-specific antibodies?  Rheumatology 2016; 55 (suppl_1), Pages i133, 
https://doi.org/10.1093/rheumatology/kew135.003 
 
